Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 1of 134Clinical Study Protocol 
Study Intervention MEDI3506
Study Code D9181C00001
Amendment 4.0
Date 08 March 2022
A Phase II, Randomised, Double -blind, Placebo -controlled Study 
to Assess the Efficacy and Safety of MEDI3506 in Adult 
Participants with Uncontrolled Moderate -to-severe Asthma
Sponsor Name: AstraZeneca
Legal Registered Address: AstraZeneca AB, 151 85 Södertälje, Sweden
Regulatory Agency Identifier Numbers:
IND number 140910
EudraCT number 2020 -000789 -40
This Clinical Study  Protocol  has been subject to a peer review according to AstraZeneca 
Standard procedures. The Clinical Study  Protocol  is publicly  registered and the results are 
disclosed and/or published according to the AstraZeneca Glo bal Policy  on Bi oethics and in 
compliance wi th prevailing laws and regulat ions. 
Redacted for Public Disclosure 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 2of 134Protocol Number: D9181C00001
Amendment Numbe r: 4.0
Study  Intervent ion: MEDI3506 and placebo
Study  Phase: II
Short Title: Study  to Assess the Efficacy and Safety  of Subcutaneously Injected MEDI3506 
in Adult s with Uncontrolled Moderate -to-severe Asthma
Acronym :FRONTIER -3
Medical Monitor Name and Contact Information will be provided separately
International co- ordinating investigator
PPD
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 3of 134PROTOCOL AMENDMENT S UMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document Date
Amendment 4.0 08 March 2022
Amendment 3.0 25 May  2021
Amendment 2.0 23 February 2021
Amendment 1.0 19 October 2020
Original Protocol 21 May  2020
Amend ment 4.0 ( 08 March 2022)
Overall Rationale for the Amendment:
Changes from Global Protocol Amendment 3.0
The principal reason for this amendment is to remove Part B, the airway  hyperresponsiveness 
and remodelling study .
Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
ThroughoutRem oval of references to and text 
regarding Part B, including SV3 
which only applied to Part BGiven the challenges of 
conducting this study 
the sponsor has, prior to
any participant 
participating in Part B, 
decided to defer 
assessment of the 
effects of MEDI3506 
on airway 
hyperresponsiveness 
and remodelling until 
later in development of 
MEDI3506Substantial
ThroughoutRem oval of occurrences of 
‘Part A’As Part B has been 
removed, Part A is the 
entirety of the studySubstantial
Section 1.3 Schedule of 
Activities 
 
 
 
  Substantial
Section 2.3.1 Risk 
AssessmentUpdated rationale for risk of 
progression of heart failureTo provide information 
based on current dataNon-substantial
CCI
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 4of 134Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
Section 4.1 Overall 
Design; Section 9.2 
Sample Size 
DeterminationChange to permit not capping 
randomisation of participants not 
included in exploratory cough 
sub-study  solely  to achieve target 
sample size of the sub -studyTo avoid completion of 
explorator y sub-study  
delay ing completio n of 
study overallNon-substantial
Section 5.1 Inclusion 
CriteriaCriterio n 11: Increased the 
maximum permitted BMI to 
40kg/m2To maintain 
consistency with other 
MEDI3506 studies in 
context of other 
exclusion criteriaSubstantial
Section 5.1 Inclusion 
Criteria Criterio n 19: Changed historic 
exacerbation requirement from 
one in 12 months to one in 
24monthsTo adapt to sustained 
fall in real world 
exacerbation rates 
secondary to the 
ongoing COVID -19 
pandemicSubstantia l
Section 5.2 Exclusion 
CriteriaCriterio n1: Removed the 
exclusion of all participants who 
test positive for SARS -CoV -2 at 
SV1. All participants who test 
positive at SV2 continue to be 
excluded.To permit participants 
who test positive for 
SARS -CoV -2 at SV1, 
but negative at SV2 and 
who do not have 
symptoms meeting any 
other exclusion 
criterion to be 
randomised.Substantial
Section 5.2 Exclusion 
CriteriaCriterio n 3: RewrittenRevised text to be 
clearer and consistent 
with other AstraZeneca 
studiesSubsta ntial
Section 5.2 Exclusion 
Criteria ; Section 1.3 
Schedule of Activities, 
Table 1 Footnote iCriterio n 5: Removal of entire 
criterion w hich excluded 
participants with an NT -proBNP 
above the upper limit of normal.Not considered to 
provide additional 
benefit to participant 
safety given other 
mitigatio ns, including 
screening 
echocardiogramsSubstantial
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI35 06 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 5of 134Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
Section 5.2 Exclusion 
CriteriaCriterio n13: Removed the 
reference to HbA1cTo permit investigator 
judgement as to 
whether Type 2 
diabetes is well 
contr olled (and hence 
not exclusionary) and to 
maintain consistency 
with other MEDI3506 
studiesSubstantial
Section 6.5.5 COVID -19 
Vaccinatio nRem oved dose from list of 
information to be recordedInformation is generally 
not availableNon-substantial
Section 8.1.5 Asthma 
ExacerbationsAdjustment of requirements of 
acceptable documentation of 
historical exacerbations. Response to changes in 
practical management 
of real world asthma 
exacerbations in context 
of COVID -19 pandemicNon-substantial
Section 8.5.1 Human 
Biological Samples, 
Appendix D 1 
Use/Analysis of DNA, 
Appendix D 2 Genetic 
Research Plan and 
ProceduresSpecified samples will be retained 
for 15 years after the end of the 
studyTo align with EU 
guidelines for data 
storageNon-substantial
Section 8.5.2 
PharmacokineticsRem oved text specifying how 
many  PK samples would be 
collectedInformation is available 
in the Schedule of 
AssessmentsNon-substantial
Section 8.5.5 Collection 
of Mandatory Samples for 
Biomarker AnalysisChanged IL -33 isoform s ample 
from nasal epithelium to nasal 
lining fluid and mRNA 
transcriptome sample from nasal 
to nasal mucosal sample.Clarification Non-substantial
Appendix A6 Data 
Quality  AssuranceChanged the length of time 
records and documents are stored 
from 15 to 25 years after study 
completionTo align with EU 
guidelines for data 
storageNon-substantial
BMI =body mass index; COVID -19=coronavirus disease 2019; EU=European Union; 
HbA1c =haemoglobin A1c; IL-33 = interleukin -33; NT-proBNP = Nterminal prohormone of B type natriuretic 
peptide; PK=pharmacokinetics; SARS -CoV -2 = severe acute respiratory syndrome coronavirus 2; SV =study 
visit.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 6of 134TABLE OF CONTENTS
TITLE PAGE ........................................................................................................................ 1
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE .................................... 3
TABLE OF CONTENTS ...................................................................................................... 6
1 PROTOCOL SUMMA RY................................................................................ 11
1.1 Synopsis ........................................................................................................... 11
1.2 Schema ............................................................................................................. 13
1.3 Schedule of Act ivities....................................................................................... 15
2 INTRODUCTION ............................................................................................ 23
2.1 Study  Rati onale ................................................................................................ 23
2.2 Background ...................................................................................................... 23
2.3 Benefit/Risk Assessment ................................................................................... 24
2.3.1 Risk Assessment ............................................................................................... 24
2.3.1.1 Study  Conduct During COVID -19 Pandemic .................................................... 28
2.3.1.2 COVID -19 Mi tigations..................................................................................... 28
2.3.1.3 Vaccinat ion Against COVID -19....................................................................... 30
2.3.2 Benefit Assessment ........................................................................................... 31
2.3.3 Overall Benefit: Risk Conclusio n...................................................................... 31
3 OBJECTIVES AND ENDPOINTS ................................................................... 32
4 STUD Y DESIGN ............................................................................................. 35
4.1 Overall Design .................................................................................................. 35
4.2 Scientific Rationale for Study  Design ............................................................... 37
4.2.1 Rationale for Endpoints .................................................................................... 38
4.2.1.1 Primary Endpo ints............................................................................................ 38
4.2.1.2 Secondary  and Safet y Endpo ints....................................................................... 38
4.2.1.3 Exploratory  Endpo ints...................................................................................... 38
4.2.2 Rationale for Study  Popul ation......................................................................... 38
4.2.3 Parti cipant Input into Desi gn............................................................................. 39
4.3 Justification for Dose ........................................................................................ 39
4.4 End of Study  Definit ion.................................................................................... 40
4.4.1 Study  Stopping Cri teria..................................................................................... 40
5 STUDY POPULATION ................................................................................... 41
5.1 Inclusio n Cri teria.............................................................................................. 41
5.2 Exclus ion Cri teria............................................................................................. 44
5.3 Lifest yle Considerat ions................................................................................... 48
5.3.1 Meals, Dietary  Restri ctions, and Caffeine ......................................................... 48
5.3.2 Activity............................................................................................................. 49
5.4 Screen Failure s................................................................................................. 49
6 STUDY INTERVENTION ............................................................................... 49
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 7of 1346.1 Study  Intervent ions Administered ..................................................................... 50
6.2 Preparati on/Handling/Storage/Accountabilit y of Intervent ions.......................... 50
6.2.1 Study  Intervent ion Inspect ion........................................................................... 51
6.2.2 Dose Preparation Steps ..................................................................................... 51
6.2.2.1 Treatment Administration ................................................................................. 52
6.2.2.2 Moni toring Dose Administration ....................................................................... 53
6.2.3 Accountabilit y.................................................................................................. 53
6.3 Measures to Minimise Bias: Rando misat ion and Blinding ................................. 53
6.3.1 Methods for Assigning Treatment Groups ......................................................... 53
6.3.2 Methods to Ensure Blinding .............................................................................. 54
6.3.3 Methods for Unblinding .................................................................................... 54
6.4 Study  Intervent ion Compliance ......................................................................... 55
6.5 Concomitant Therapy ........................................................................................ 55
6.5.1 Resc ue Medicine ............................................................................................... 56
6.5.2 Requi red Medicati ons ....................................................................................... 56
6.5.3 Medicat ion Wit hhold Periods ............................................................................ 56
6.5.4 Prohibited Medications ..................................................................................... 57
6.5.5 COVID -19 Vaccinat ion.................................................................................... 58
6.6 Dose Modificat ion............................................................................................ 58
6.7 Intervention after the End of the Study .............................................................. 58
7 DISCONTINUATION OF S TUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL .......................................................... 58
7.1 Discontinuati on of  Study  Intervent ion............................................................... 58
7.1.1 Missed doses ..................................................................................................... 59
7.2 Parti cipant Wi thdrawal from  the Study ............................................................. 59
7.3 Lost to Follow -up............................................................................................. 60
8 STUDY ASSESSMENTS AN D PROCEDURES ............................................. 60
8.1 Efficacy Assessments ........................................................................................ 61
8.1.1 In-clinic Spiro metry.......................................................................................... 61
8.1.1.1 General requirements ........................................................................................ 61
8.1.2 At-home Spirometry ......................................................................................... 63
8.1.3 Airwave Oscillo metry ....................................................................................... 63
8.1.4 Fract ional Exhaled Nitric Oxide ........................................................................ 64
8.1.5 Asthma Exacerbat ions...................................................................................... 64
8.1.6 Com pEx ........................................................................................................... 66
8.1.7 VitaloJAK Coug h Monitor ( Exploratory  Cough Sub -study  Only )..................... 67
8.1.8 Parti cipant Reported Outcom e Quest ionnaires .................................................. 67
8.1.8.1 Daily eDiary ..................................................................................................... 68
8.1.8.2 Coug h Visual Analogue Scale (Exploratory  Cough Sub -study  Only )................ 68
8.1.8.3 Asthma Control Quest ionnaire -6....................................................................... 68
8.1.8.4 St George’s Respiratory  Quest ionnaire ............................................................. 69
8.1.8.5 Sino-nasal Outcome Test -22............................................................................. 69
8.1.8.6 Patient Gl obal Impressi on of Benefi t/Risk ........................................................ 70
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 8of 1348.1.8.7 Study  Parti cipant Feedback Quest ionnaire ........................................................ 70
8.2 Safety Assessments ........................................................................................... 70
8.2.1 Medical, Surgical, and Asthma History ............................................................. 70
8.2.2 Physical Examinat ions, Weight, and Height ...................................................... 70
8.2.3 Vital Signs........................................................................................................ 71
8.2.4 Electrocardiograms ........................................................................................... 71
8.2.5 Echocardi ograms .............................................................................................. 72
8.2.6 SARS -CoV-2 Serol ogy Testing ........................................................................ 72
8.2.7 Clinical Safety  Laboratory  Assessments ............................................................ 72
8.3 Adverse Events and Serious Adverse Events ..................................................... 74
8.3.1 Time Period and Frequency  for Collect ing AE and SAE Informat ion................ 74
8.3.2 Follow-up of  AEs and SAEs ............................................................................. 74
8.3.3 Causalit y Collection.......................................................................................... 75
8.3.4 Disease Under st udy ......................................................................................... 75
8.3.5 Adverse Events Based on Signs and Symptoms ................................................ 75
8.3.6 Adverse Events Based on Examinat ions and Tests ............................................ 76
8.3.7 Adverse Events of Special Interest .................................................................... 76
8.3.8 Hy’s Law .......................................................................................................... 77
8.3.9 Reporting of Serious Adverse Events ................................................................ 77
8.3.10 Pregnancy ......................................................................................................... 77
8.3.10.1 Materna l Exposure ............................................................................................ 78
8.3.10.2 Paternal  Exposure ............................................................................................. 78
8.3.11 Medicat ion Error ............................................................................................... 78
8.4 Overdose .......................................................................................................... 79
8.5 Hum an Bi ological Sample Bi omarkers ............................................................. 79
8.5.1 Hum an Bi ological  Samples ............................................................................... 79
8.5.2 Pharmacokinet ics.............................................................................................. 80
8.5.2.1 Determinat ion of Drug Concentration ............................................................... 80
8.5.3 Immunogenicit y Assessments ........................................................................... 80
8.5.4 Pharmacodynamics ........................................................................................... 81
8.5.5 Collect ion of Mandatory  Samples for Bi omarker Analysis ................................ 81
8.5.6 Other study  related bi omarker research ............................................................. 82
8.6 Optional Genomics Ini tiative Sample ................................................................ 82
8.7 Health Economics ............................................................................................. 83
8.8 Impact of COVID -19 Pandemic ........................................................................ 83
9 STATISTICAL CONSIDER ATIONS ............................................................... 83
9.1 Statistical Hypotheses ....................................................................................... 83
9.2 Sample Si ze Determinat ion............................................................................... 83
9.3 Popul ations for Analyses .................................................................................. 84
9.4 Statistical Analyses ........................................................................................... 84
9.4.1 General Considerations ..................................................................................... 85
9.4.2 Efficacy ............................................................................................................ 85
9.4.2.1 Primary Endpo int.............................................................................................. 85
9.4.2.2 Secondary  and Expl oratory  Endpo ints............................................................... 85
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 9of 1349.4.3 Subgroup Analyses ........................................................................................... 86
9.4.4 Safety............................................................................................................... 86
9.4.5 Other Analyses ................................................................................................. 86
9.4.5.1 Immunogenicit y and PK ................................................................................... 86
9.4.5.2 Exploratory  Biomarker Outcom es..................................................................... 87
9.4.5.3 Exploratory  Analyses ........................................................................................ 87
9.5 Interim Analyses ............................................................................................... 87
9.6 Data Mon itoring Committee ............................................................................. 87
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ........................................................................................ 88
11 REFERENCES ............................................................................................... 131
LIST OF FIGURES
Figure 1 Study  Flow Diagram ................................................................................ 14
Figure 2 Reversibilit y algorithm ............................................................................ 62
LIST OF TABLES
Table 1 Schedule of Act ivities: Screening Period ................................................. 15
Table 2 Schedule of Act ivities: Study  Intervent ion and Fo llow-up Periods ........... 18
Table 3 Risk Assessment ...................................................................................... 25
Table 4 Object ives and Endpo ints......................................................................... 32
Table 5 Study  Intervent ions.................................................................................. 50
Table 6 Study  Intervent ion Dose Preparation ........................................................ 52
Table 7 Laboratory  Safety Variables ..................................................................... 73
Table 8 Popul ations for Analysis .......................................................................... 84
Table I9 Highly Effective Methods of Contraception ........................................... 113
LIST OF APPENDICES
Appendix A Regulatory , Ethical, and Study  Oversight Consi derati ons......................... 89
Appendix B Adverse Events: Definit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ........................................................................ 93
Appendix C Handling of Human Bio logical  Samples .................................................. 98
Appendix D Optional Genomics Ini tiative Sample ..................................................... 100
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 10of 134Appendix E Actions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ......................................................................... 103
Appendix F Maint enance Therapy Equivalence Table ............................................... 108
Appendix G National Inst itute of Allergy and Infectious Diseases and Food Allergy 
and Anaphylaxi s Network Gui dance for Anaphylaxis Diagnosis ............ 109
Appendix H Signs, Symptom s, and Management of Acute Anaphylaxis .................... 110
Appendix I Contraception Guide .............................................................................. 113
Appendix J Abbreviat ions........................................................................................ 114
Appendix K Protocol  Amendment Hi story................................................................. 118
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 11of 1341 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Phase II, Randomised, Double -blind, Placebo -controlled Study  to Assess 
the Efficacy and Safet y of MEDI3506 in Adult Participants with Uncontrolled 
Moderate -to-severe Asthma
Short Title: Study  to Assess the Efficacy and Safety  of Subcutaneously Injected MEDI3506 
in Adult s with Uncontrolled Moderate -to-severe Asthma
Rationale:
The MEDI3506 pre -clinical profile suggests that MEDI3506 can reduce asthmat ic airway  
inflammat ion, improve epithelial integrit y, reduce mucus production, and improve 
muco -ciliary  transport. As such, MEDI3506 is hypothesised to impact asthma disease status 
by increasing forced expiratory  volume in the first second (FEV 1, and other physio logical 
measures of lung funct ion) and reducing frequency and severit y of asthma exacerbat ions, 
thereby improving qualit y of life. This Phase II study  aims to assess the efficacy  and safet y of 
MEDI3506 in adult participants with uncontrolled moderate -to-severe asthma.
Objectives and Endpoints
Objective Endpoint
Primary
To assess the effect of MEDI3506 compared with 
placebo on lung function, in adult participants with 
uncontrolled moderate -to-severe asthma.As measured in clinic, change from baseline to 
Week 16 in pre -BD FEV 1(L).
Secondary
To further assess the effect of MEDI3506 compared 
with placebo on lung function, in adult participants 
with uncontrolled moderate -to-severe asthma.As measured in clinic, change from baseline to 
Weeks 8 and 16 in post-BD FEV 1(L).
To assess the PK of MEDI3506 in adult participants 
with uncontrolled moderate -to-severe asthma.Serum MEDI3506 concentration -time profiles during 
the intervention and follow -up periods.
To assess the immunogenicity of MEDI3506 in adult
participants with uncontrolled moderate -to-severe 
asthma.ADA during the intervention and follow -up periods.
To assess the effect of MEDI3506 compared with 
placebo on asthma control in adult participants with 
uncontrolled moderate -to-severe asthma.Chang e from baseline to Week 16 in ACQ -6 score.
Proportio n of participants with a decrease in ACQ -6 
score of ≥0.5 from baseline to Week 16.
Proportio n of participants achieving ACQ -6 well 
controlled status (defined as ACQ -6 score ≤0.75 at 
Week 16).
Clinical Study Proto col–Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 12of 134Objective Endpoint
To assess the effect of MEDI3506 compared with 
placebo on health status in adult participants with 
uncontrolled moderate -to-severe asthma.Change f rom baseline to Week 16 in SGRQ score.
Proportio n of participants with a decrease in SGRQ 
total score of ≥4 points f rom baseline to Week 16.
To assess the effect of MEDI3506 compared with 
placebo on CompEx in adult participants with 
uncontrolled moderate -to-severe asthma. Time to first CompEx event based on the period from 
baseline to Week 16.
CompEx annualised event rate.
To assess the effect of MEDI3506 compared with 
placebo on concentration of FeNO in adult 
participants with uncontrolled moderate -to-severe 
asthma.Percent change from baseline to Week 16 in 
concentration of FeNO in exhaled breath.
ACQ -6 = asthma control questionnaire -6; ADA =anti-drug antibody(ies); BD =bronchodilator; 
CompEx =composite endpoint for severe exacerbations of asthma; FeNO =fractio nal exhaled nitric oxide; 
FEV 1=forced expiratory volume in the first second; L =litre(s); PK =pharmacokinetics; SGRQ =St George’s 
respiratory  questionnaire.
For safet y and expl oratory  objectives and endpo ints, see Section 3of the protocol.
Overall Design
Study D9181C00001 is a Phase II, randomised, double -blind, placebo -controlled, 
parallel- group, proof -of-concept study  to eval uate the efficacy , safet y, pharmacokinet ics (PK) 
and immunogenicit y of MEDI3506 in adult participants with uncontrolle d moderate -to-severe 
asthma on standard of care (SOC). The study  has 3 treatm ent-arms. Parti cipants who fail 
screening can be re -screened.
Disclosure Statement : Thi s is a parallel group treatment study  that i s parti cipant -, 
investigator -, and sponsor -blind ed.
Number of Participants:
Approximately  228 participants will be randomised to achieve 216evaluable participants.
Intervention Groups and Duration:
Parti cipants will be randomised in a 1:1:1 ratio to receive mg MEDI3506, mg 
MEDI3506, or placebo every  by subcutaneous (SC) inject ion for a total  of 
doses.
Parti cipants will be enrolled in this study  for up to 29 weeks. The study  com prises of 3 periods 
including the screening period of up to 5 weeks, an intervent ion peri od of  16 weeks, and a 
follow-up period of 8 weeks. 
CCI
CCI
CCI
C
C
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 13of 134Data Monitoring Committee:
A Data Safet y Moni toring Board (DSMB) has been established to oversee the MEDI3506 
clinical development programme. In addit ion to a full DSMB 6- month peri odic review of 
safet y data, the DSMB c hair will review unblinded safet y data summaries every  3months; the 
DSMB can meet on an ad hoc basis.
Statistical Methods
A sample size o f 216 participants (72 participants per treatment group), randomised 1:1:1 to 
MEDI3506 mg: MEDI3506  mg: placebo, will provide at least 80% power to detect a 
statist ically significant difference in change from baseline to Week 16 in pre -bronchodilator 
(BD) FEV 1, assuming a difference of 150 mL between placebo and MEDI3506, a 
between -participant standard devia tion (SD) of 420 mL and a one -sided-10% al pha level . To 
allow for 5% participants being ineligible for the primary analysis, a total of approximately 
228 participants will be rando mised (approximately 76/arm).
Efficacy analyses will be performed using the ITT populat ion. The primary  estimand is a 
‘Treatm ent Policy’ est imand, as fo llows: the difference in mean change from baseline in FEV 1
at Week 16 (MEDI3506 –placebo) will be estimated using a repeated measures mixed effects 
analysis of covariance model, f or the ITT popul ation. This will include all available data fro m 
all visits up to and including Week 16, irrespective of whether the participant discontinued 
study  interventi on or received rescue therapy .
A similar approach will be taken for the analysis o f asthma control  quest ionnaire -6 (ACQ- 6), 
St George’s respiratory  questi onnai re (SGRQ), and fract ional exhaled nitric oxide (FeNO). 
The difference in mean change fro m baseline in post -BD FEV 1at Weeks 8 and 16 will be 
estimated using a repeated measures mi xed effects analysis of covariance model, similar to 
that described for the primary efficacy  analysis. Data m ay be log-transform ed pri or to analysis 
where appropriate. Time to first composite endpo int for severe exacerbat ions of asthma 
(Com pEx) event will be analysed using a Cox proportional hazard model, with treatment 
fitted as a covari ate.
MEDI3506 serum concentrations will be tabulated along with descript ive statist ics. Mean and 
individual serum MEDI3506 concentration -time profiles will be plotted. Popu lation PK 
modelling m ay be performed if data allow. Posit ive ant ibodies to MEDI3506 will be reported 
by treatment group. If there is a high incidence of ant i-drug ant ibody  (ADA), the associ ation 
of ADA wit h MEDI3506 concentration will be assessed.
1.2 Schema
The general study  design is summarised in Figure 1.
CCI
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 15of 1341.3 Schedule of Activities
Once informed consent has been obtained, eDiary provisio n and training for site and ho me 
visits should occur first during SV1, fo llowed by  patient reported outcom e (PRO) 
assessments. PRO assessments should be conducted first at all other visits. For all participants, 
in-clinic spiro metry testi ng must be init iated between 6:00 AM and 11:00 AM during the 
screening or re -screening period, and random isation visit (SV4). Whenever 
electrocardi ogram s (ECGs), vi tal signs, and blood draws are scheduled for the same no minal 
time, the order should be as fo llows: ECG, vital signs (vital signs can occur immediately  after 
ECG using the same rest period), then blood draws. The timing of the first 2 assessments 
shoul d be such that i t allows the bl ood draw (eg, PK blood sample) to occur at the assigned 
nominal t ime. Whenever FeNO, airwave oscillo metry  (AO), and spiro metry are scheduled for 
the sam e nominal  time, the order should be as fo llows: FeNO, AO, then spiro metry. Nasal 
sampling should be performed last, with nasal lining fluid collect ion performed before nasal 
epithelium  collecti on (when both are scheduled). Urine samples may  be collected at any  time 
during the study  visit (when scheduled). On days when invest igational product is 
administered, all assessments should be performed pre -dose unless otherwise specified in the 
Schedule of Act ivities. Refer to Section 8for addi tional information on assessment orderi ng 
(eg, pre -, post -dose or mult iple timepoints within a visit). In the event that a clinical laboratory  
test result is not available fro m central  laboratori es during the screening period, see 
Secti on8.2.7 .
Table 1 Schedule of Activities: Screening Period
Visit Number SV1 SV2 SV3
Procedure/Study Day -35 to -28 -14 to -6 Visit no 
longer 
neededStudy Week-4 -1
Written ICF /assignment 
of SID numberXa
Written informed consent for future use and/or DNA analysis 
(optional)X
Verify  eligibility criteria X X
Demographics X
Baseline asthma assessments
Provision of, and training on use of, home spirometry 
device and eDiaryX
ACQ -6 X X
SGRQ X
SNOT -22 (comorbid CRS participants only) X
At-home eDiary completion and spirometry useTwice daily throughout 
screening period
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 16of 134Table 1 Schedule of Activities: Screening Period
Visit Number SV1 SV2 SV3
Procedure/Study Day -35 to -28 -14 to -6 Visit no 
longer 
neededStudy Week-4 -1
Assess adherence to at -home eDiary completion, 
spirometry , and SOC medication useX
Assessment of asthma exacerbations X
FeNO X X
Airwave oscillometry X
In-clinic spirometry (pre -BD) X X
In-clinic spirometry (post -BD) XbXc
Safety assessments
Concomitant medications X X
Medical, surgical, and asthma history X
Physical examination (complete) X
Weight and height X
Vital signs X
ECG X
Echocardiogram Xd
SARS -CoV -2 PCR test X eX f
Assessment of AEs/SAEs X X
Collect blood for:
Haematology X
Coagulation parameters X
Serum chemistry X
Serum pregnancy testgX
FSH (if needed to confirm post -menopausal status in female 
participants aged < 50 years and not on HRT)X
HbA1c X
Hepatitis B (HBsAg, anti -HBs, anti -HBc), and C; HIV -1 
and HIV -2X
IGRA (TB test)hX
NT-proBNP X
Explo ratory  biomarkers (serum) X
Total IgE (serum) X
EDN (plasma) X
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 17of 134Table 1 Schedule of Activities: Screening Period
Visit Number SV1 SV2 SV3
Procedure/Study Day -35 to -28 -14 to -6 Visit no 
longer 
neededStudy Week-4 -1
Collect urine for:
Urinaly sis X
Urine pregnancy testgX
Pandemic impact assessment X
Exploratory cough sub -study only
At-home cough monitoring (for the 24 hours post -clinic 
visit)X
Cough VAS X
aICF may be signed prior to SV1, providing all screening visits are scheduled to take place within a 28 to 
35day timeframe.
bPost-BD spirometry  should be performed at SV1 if documented evidence of asthma (see Section 5.1) is 
not already available.
cPost-BD spirometry  should be performed at SV2 if documented evidence of asthma (see Section 5.1) is 
not already available.
dMay be perfor med any  time  after signing of informed consent, so that results are available prior to SV4 
(randomisation).
eParticipants are permitted to continue screening if the result from the SARS -CoV -2 PCR test performed 
at SV1 has not been returned by SV2.
fTest may be performed at either visit or anytime on or after Day -7 such that the results are available 
prior to SV4 (see Exclusion Criterion 1).
gFemale participants of childbearing potential only.
hSee Exclusion Criterion 4.
ACQ -6 = asthma control questionnaire -6; AE =adverse event; anti -HBc =hepatitis B core antibody; 
anti-HBs =hepatitis B surface antibody; BD =bronchodilator; CRS =chronic rhinosinusitis;
ECG=electrocardiogram; EDN =eosinophil derived neurotoxin; FeNO =fractional exhaled nitric oxide; 
FSH =follicle -stimulating hormone; HbA1c =haemoglobin A1c; HBsAg =hepatitis B surface antigen; 
HIV =human immunodeficiency virus; HRT =hormone replace ment therapy; ICF =informed consent form; 
IgE=immunoglobulin E; IGRA =interferon gamma release assay; NT -proBNP = N-terminal prohormone of 
B-type natriuretic peptide; SAE =serious adverse event; SARS -CoV -2 = severe acute respiratory syndrome 
coronavir us 2; SGRQ =St George’s respiratory questionnaire; SID =subject identification; 
SNOT -22 = sino-nasal outcome test -22;  SOC =standard of care; 
SV=study visit; TB =tuberculosis; VAS =visual analogue scale.
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 18of 134Table 2 Schedule of Activities: Study Intervention and Follow -up Periods
Period Study Intervention Follow -up
Visit NumberSV4 
(Random -
isation)SV5 
(TC)SV6 SV7 SV8 SV9 SV10 SV11 SV12
E/D
Study Day 1 2 8 (± 3) 29 (±3) 57 (± 3) 85 (± 3) 113 (± 3) 141 (± 3) 169 (± 3)
Study Week 0 0 1 4 8 12 16 20 24
Efficacy assessments
ACQ -6 X X X X X X X X
SGRQ X X X X X X
SNOT -22 (comorbid CRS 
participants only)X X X X X X
At-home eDiary completion and 
spirometry  useTwice daily throughout the intervention period.
Assess adherence to at -home eDiary 
completion, spirometry, and SOC 
medication useX X X X X X X X X
Assessment of asthma exacerbations X X X X X X X X X X
PGI-BR X
Study participant feedback 
questionnaire (optional)X X X X
FeNO X X X X X X X X X
Airwave oscillometry 
(pre-administration of study 
interventio n)X X X X X X
Airwave oscillometry (4 hours 
post-administration of study 
interventio n)X a
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 19of 134Table 2 Schedule of Activities: Study Intervention and Follow -up Periods
Period Study Intervention Follow -up
Visit NumberSV4 
(Random -
isation)SV5 
(TC)SV6 SV7 SV8 SV9 SV10 SV11 SV12
E/D
Study Day 1 2 8 (± 3) 29 (±3) 57 (± 3) 85 (± 3) 113 (± 3) 141 (± 3) 169 (± 3)
Study Week 0 0 1 4 8 12 16 20 24
In-clinic spirometry (pre -BD) (pre -
administration of study intervention)X X X X X X X X X
In-clinic spirometry (4 hours post -
administration of study intervention)Xa
In-clinic spirometry (post -BD) X X X
Safety assessments
Concomitant medications X X X X X X X X X X
Physical examination XbXb Xb Xb Xb Xb Xb Xc Xc 
Weight X X X X
Vital signs X X X X X X X X X
ECG XdX X X
EchocardiogrameXf
Assessment of AEs/SAEs X X X X X X X X X X
Injection site reactions X X X X X X X
SARS -CoV -2 PCR test gX X X X X X X X X
Collect bloodhfor:
Haematology X X X X X X X X
Coagulation parameters X X X X X X X X
Serum chemistry X X X X X X X X
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 21of 134Table 2 Schedule of Activities: Study Intervention and Follow -up Periods
Period Study Intervention Follow -up
Visit NumberSV4 
(Random -
isation)SV5 
(TC)SV6 SV7 SV8 SV9 SV10 SV11 SV12
E/D
Study Day 1 2 8 (± 3) 29 (±3) 57 (± 3) 85 (± 3) 113 (± 3) 141 (± 3) 169 (± 3)
Study Week 0 0 1 4 8 12 16 20 24
Collect nasal sample for:
Nasal mucosal sampling (lining 
fluid)X X X X X X X
Nasal mucosal sampling (mRNA)kX X
Verify eligibility criteria X
Randomisation X
Study intervention administrationl
Pandemic impact assessment mX X X X X X X X X X
Exploratory cough sub -study only
At-home cough monitoring (for the 24 
hours post -clinic visit)X
Cough VAS X
aAirway  oscillometry  and spirometry performed 4 hours (± 15 minutes) post administration of study intervention will require 4 hours withhold of 
bronchodilator (see Section 6.5.3 ).
bBrief phy sical examination.
cComplete physical examination.
dTriplicate ECG. The mean value of each parameter from the triplicate will be used as the baseline value.
eEchocardiogram and NT -proBNP assessments also to be performed as required, for participants who might be experiencing heart failure, or as soon as 
possible after heart failure might have occurred.
fMay be performed at any time at or between SV9 (Week 12) and SV10 (Week 16) inclusive.
gTesting may be performed at any point for a participant suspected of having COVID -19. 
hPrior to administration of study intervention on days when study intervention is administered.
C
C
C
C
C
C
C
C
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 22of 134Table 2 Schedule of Activities: Study Intervention and Follow -up Periods
Period Study Intervention Follow -up
Visit NumberSV4 
(Random -
isation)SV5 
(TC)SV6 SV7 SV8 SV9 SV10 SV11 SV12
E/D
Study Day 1 2 8 (± 3) 29 (±3) 57 (± 3) 85 (± 3) 113 (± 3) 141 (± 3) 169 (± 3)
Study Week 0 0 1 4 8 12 16 20 24
iIf not performed at SV4, can be performed at any subsequent visit. As a la st resort if the participant has completed the study (and not withdrawn consent) 
but the sample has not been received by the analysing laborator y, the site should ask the participant if he/she would be will ing to attend an additional 
optional visit to prov ide this sample.
jFemale participants of childbearing potential only.
kIf deemed by investigator to be intolerable for individual participant at SV4 (eg, due to nasal polyps), subsequent assessmen ts may be omitted. If this 
assessment is not performed at SV4 for any reason, it should not be repeated at SV10.
lParticipants should be monitored for a minimum of one to 2 hours after administration of study intervention (see Section 8.2.3 ). If a suspected 
anaphy lactic reaction occurs during or within a 24 -hour period after administration of study intervention, blood samples for serum tryptase will be 
collected as soon as possible after the event, at 60 ± 30 minutes after the event, at discharge, and between 2 and 4 weeks post -discharge. Immediate care 
of the participant and treatment of the reaction must take priority over collecting blood samples. Additional details on anap hylactic reactio ns are prov ided 
in Appendix Gand Appendix H.
mFor COV ID-19 mitigation, please see Section 2.3.1.2 .
ACQ -6 = asthma control questionnaire -6; AE =adverse event; BD =bronchodilator; COVID -19=coronavirus disease 2019; CRS =chronic rhinosinusitis; 
E/D=early  study  intervention discontinuation; ECG =electrocardiogram; EDN =eosinophil derived neurotoxin; FeNO =fractional exhaled nitric oxide; 
IgE=immunoglobulin E; IL =interleukin; mRNA =messenger RN A; NT -proBNP = N-terminal prohormone of B -type natriuretic peptide; PGI -BR =patient 
global impression of benefit/risk; PK =pharmacokinetic(s); SAE =serious adverse event; SARS -CoV -2 = severe acute respiratory syndrome coronavirus 2; 
SGRQ =St George’s r espiratory questionnaire; SNOT -22 = sino-nasal outcome test -22;   SOC =standard of care; 
sST2 =soluble ST2; SV =study visit; TC =telepho ne contact; VAS =visual analogue scale.
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 23of 1342 INTRODUCTION
MEDI3506 is a human IgG1 mAb that binds to human IL- 33. MEDI3506 binds full length 
and mature forms of human IL -33 wi th except ionally  high affini ty and prevents IL -33 binding 
to sol uble (sST2) and membrane -bound form s of ST2 (al so known as IL -1RL1) receptor. 
Several clinical and non -clinical studies point to the IL -33/ST2 signalling axis playing a key  
role in the pathogenesis o f asthma. Thus, blocking this signalling pathway could be of 
therapeuti c benefit in asthma. MEDI3506 is currently  in devel opment f or th e treatm ent of 
asthma, AD, COPD, and DKD.
2.1 Study Rationale
The MEDI3506 pre -clinical profile suggests that MEDI3506 can reduce asthmat ic airway 
inflammat ion, improve epithelial integrit y, reduce mucus production, and improve 
muco -ciliary  transport. As such, MEDI3506 is hypothesised to impact on asthma disease 
status by  increasing FEV 1(and other phy siological measures of l ung f unction) and reducing 
frequency  and severi ty of asthma exacerbations, thereby improving qualit y of life.
One Phase I clinical study  of MEDI3506 (Study  D9180C00001) was com pleted in 
December 2019. Study  D9180C00001 was a first in human, rando mized, placebo controlled, 
blinded (investigator and participant blinded; sponsor unblinded) clinical study  in 
88participants to evaluate the safe ty, tolerabilit y, PK, and immunogenicit y of single and 
repeated doses of MEDI3506. MEDI3506 was generally found to be safe and well tolerated. 
For further details, refer to the IB.
This Phase II study  aims to assess the efficacy and safet y of MEDI3506 in a dult parti cipants 
with uncontrolled moderate -to-severe asthma.
2.2 Background
Asthma i s a chronic inflammatory  disease of the airway s characteri sed by bronchial 
hyperreact ivity and reversible airflow limitat ion. Internat ional treatment guidelines for asthma 
recommend ICS as first line therapy  (GINA 2020 ). For individuals who are symptomatic on 
medium dose ICS monotherapy , step -up therapy wit h LABA is the recom mended next 
treatm ent opti on followed by  other controller therapies including leukotriene receptor 
antagonists, theophylline, and oral corticosteroids. ‘Bio logic agents’ (eg, omalizumab and 
benralizumab) that inhibit specific mo lecular targets such as IgE or Th2 cy tokines and their 
respective receptors are reserved for those with severe uncontrolled asthma. Furthermore, all 
currently approved asthma controller therapies have little or no impact on the natural history 
of the di sease (i e, most peopl e with moderate -severe asthma need life -long therapy ). There is 
a clear unmet need for asthma therapies that not only  better control  symptom s, but l ead to 
disease m odificati on.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 24of 134Num erous studi es have shown a key  role for IL -33 in asthma. The genes encoding IL -33 and 
ST2/IL1RL1 have been identified as major susceptibilit y loci for human asthma in several 
geno me wide associat ion studies  ( Bonnelykke etal2014 ; Gudbjartsson etal2009 ; 
Hirotaetal2011 ; Moffatetal2010 ; Shrine et al 2019 ; Torgerson etal2011 ; Wan et al 2012 ) 
and were among the few gene s reproducibly  found to be associ ated wi th asthm a across diverse 
ethnic groups. In addit ion, a rare IL -33 loss-of-function m utation has been recent ly described 
that reduces blood eosinophil counts and protects from asthma ( Smit hetal2017 ). The 
protective effect remained, although weaker, after correcting for eosinophil counts, suggesting 
that IL -33 m ay influence asthma risk in part by  controlling bl ood eosinophil count, and also 
through addit ional biological pathways ( Mousas etal2017 ).
Two Phase II studi es support a rol e for anti -IL-33 therapy in asth ma treatment. In a 
proof -of-concept study  involving adult patients with moderate -to-severe asthma, 
REGN3500 monotherapy  (ICS and LABA maintenance therapy  were wi thdrawn during the 
trial) met the primary  endpoint of improvement in loss of asthma control and significant ly 
improved lung funct ion compared to placebo, meeting a key secondary endpo int 
([STUDY_ID_REMOVED]). In a separate Phase II clinical study , a single IV dose of etokimab was 
administered to patients with uncontrolled moderate -to-severe asthma despite being on 
treatm ent wi th high dose combinat ion ICS pl us LABA therapy . Com pared wi th a placebo 
group, asthmat ics treated wi th etokimab had a significant improvement in lung funct ion 
(FEV 1) and a reduction in blood eosinophils ([STUDY_ID_REMOVED]).
A detailed descri ption of  the chemistry , pharmaco logy, mechanism  of action, and safety  of 
MEDI3506 is provided in the IB.
2.3 Benefit/Risk Assessment
More detailed informat ion about the known and expected benefit, potential risks, and 
mitigation strategies of MEDI3506 may be f ound in the IB.
2.3.1 Risk Assessment
Potenti al risks f or thi s study  populati on, study  procedures, and MEDI3506 administration and 
mitigation strategies are listed in Table 3. A blinded review of the safet y data for AEs will be 
perform ed regularly and any potential emerging risks highlighted to the DSMB for further 
consideration.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 25of 134Table 3 Risk Assessment
Potential Risk of Clinical 
SignificanceRationale for Risk Mitigation Strategy
Study Population Related
Worsening of asthma control Efficacy of MEDI3506 on asthma not yet determined.• Participants will continue on their current asthma 
controller and reliever treatments as required.
• Participants will be treated for exacerbations of asthma 
if they  occur.
• eDiary  will trigger ‘worsening of asthma alerts’ for 
participants and research sites.
Study Procedure Related
Nasal mucosal sampling (mRN A) Temporary, minor discomfort (similar to drawing blood).• To be performed by appropriately trained staff using 
appropriate personal protective equipment.
• If deemed by investigator to be intolerable for 
individual participant at SV4 (eg, due to nasal polyps), 
subsequent assessments may be omitted (seeTable 2).
MEDI3506/Study Intervention Related
Gastrointestinal adverse reactions.Observation of what was considered an incidental 
finding of ulcerative colitis in a 26 -week toxicity study 
in cy nomolgus monkeys (see IB Section ◦4.3.1.2). The 
gastrointestinal effects of IL -33 blockade in humans are 
currently  unclear. IL -33 is expressed in the 
gastrointestinal tract, where it has multiple downstream 
effects ( Hodzic etal2017 ). Expression of IL -33 is 
elevated in patients with active ulcerative colitis (see IB 
Section 5.5.1.1).Exclusion of individuals with history of ulcerative colitis, 
Crohn’s disease, or microscopic colitis diagnosed by either 
gastroenterologi st or by histopathology (see Section 5.2).
Serious infections (including 
opportunistic infections and viral 
reactivations).Mechanism of action of M EDI3506, in particular, the 
role of IL -33 as an “epithelial alarmin” 
(Martin andMartin 2016 ; see IB Section 5.5.2.1).Exclusion of individuals with acti ve infection and/or latent 
infections or individuals who are 
immunosuppressed/compromised (see Section 5.2).
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 26of 134Table 3 Risk Assessment
Potential Risk of Clinical 
SignificanceRationale for Risk Mitigation Strategy
Progression of heart failure. 
 
 • Exclusion of individuals at risk of developing of heart 
failure (see Section 5.2).
• Exclusion of individuals with LVEF < 45% (see 
Section 5.2).
• Monitoring of study participants with echocardiograms 
and NT -proBNP (see Table 2).
Injection site reactions.This is based on the SC route of administration and the 
nature of MEDI3506 as an exogenous protein substance
(see IB Section 5.5.3.1).• Instructio ns on injection technique including rotation of 
injection sites (see Section 6.2.2.1 ).
• Routine monitoring for injection site reactions will be 
undertaken at each SV (see Table 2).
Serious hypersensitivity 
(including Type I toIV 
hypersensitivity reactions) and 
immune complex disease.As mAb are foreign proteins, they have the potential to 
provoke hypersensitivity reactions. Ba sed on a potential 
risk known to be associated with foreign proteins, 
occurrence of ADA could result in immune complex 
disease (see IB Section 5.5.4.1).• Exclude individuals with a known history of allergy or 
severe reaction to:
 Any component of the study intervention.
 Biologic agents.
 Human gamma globulin therapy formulations (see 
Section 5.2).
• Exclude individuals with hereditary fructose intolerance 
(see Section 5.2).
• Required monitoring of participants for a minimum of 
one to 2 hours after administration of study intervention 
(seeTable 2).
• Sites must be equipped to diagnose and manage 
anaphy laxis and serious allergic reactions until the 
participant can be transferred to a suitable facility 
(seeTable 2and Appendix H).
• Serum try ptase will be determined in the event of 
suspected anaphylactic symptoms (seeTable 2and 
Appendix H).
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 27of 134Table 3 Risk Assessment
Potential Risk of Clinical 
SignificanceRationale for Risk Mitigation Strategy
Reproductive toxicity.Consistent with ICH guidance on the timing of 
nonclinical studies, MEDI3506 has not been evaluated i n 
embryo -foetal development toxicity studies (see IB 
Section 5.5.5.1).• Stipulation of highly effective contraceptive 
requirements for participants (see Appendix I).
• Female participants may only be included if they have a 
negative pregnancy test during screening and prior to 
administration of study intervention, and agree to use a 
highly  effective method of contraception from 
screening until the end of the study (see Section 5.1).
• Male participants may only be included if they agree to 
use a male con dom with (if available) spermicide and 
another highly effective method of contraception during 
the intervention and follow -up periods (see Section 5.1).
ADA =anti-drug antibo dy(ies); IB =Investigator’s Brochure; ICH =International Council for Harmonisation; IL =interleukin; LVEF = left ventricular ejection 
fraction; mAb= monoclonal antibody(ies); mRNA =messenger RNA; NT -proBNP = N-terminal prohor mone of B -type natriuretic peptide; SC =subcutaneous; 
sST2 =soluble ST2; SV =study visit.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 28of 134Serious infect ions (including those with SARS -CoV -2) are also a potential risk of MEDI3506. 
AstraZeneca is not aware of any current evidence of a direct link between IL -33, or IL -33 
suppressio n, and contracting SARS -CoV -2 and early stages of coronavirus disease 2019 
(COVID -19) illness post infect ion.  Moreover, it is hy pothesised that IL -33 suppression might 
be beneficial in the later, hy perinfla mmatory  phase of severe COVID -19 illness; MEDI3506 
will be tested in patients with severe COVID -19 infect ions as part of the ACcelerating 
COVID -19 Research and Development (ACCORD) study  2 (ACCORD -2; EudraCT number 
2020 -001736 -95).
2.3.1.1 Study Conduct During COVID -19 Pandemic
Coronavirus disease 2019 (COVID- 19) has emerged as a worldwide pandemic disease with 
significant implicat ions for public healt h. AstraZeneca accepts that a careful risk -benefit 
analysis should be performed in each region before init iating cl inical  research that im pacts the 
clinical resources needed for the COVID -19 pandemic. Specifically, this study  woul d not be 
initiated in regions where local and/or national authorities have issued stay -in-place or 
lock-down orders. Hence, AstraZeneca will commence this study when local and nat ional 
governments indicate that it is acceptable to perform clinical studies. Furthermore, each study  
site must have appropriate measures to ensure safety  of site staff and parti cipants, and this 
study  woul d be paused if local or nati onal governments or sites determine that they  can no 
longer support safe conduct of clinical research. AstraZeneca will mo nitor countri es and sites, 
and the study  will not begin unt il local and nat ional governments and clinical sites have 
indicated that i t is acceptable to conduct clinical studies and the safet y of site staff and 
participants can be ensured. 
If during study  conduct, l ocal or nati onal governments or si tes determine that the current 
environment can no longer support safe cond uct of clinical research, this study  woul d be 
paused.
2.3.1.2 COVID -19 Mitigations
In order to exclude higher risk participants, the age range is set at 18 to < 65 y ears incl usive at 
time of enrolment.
Severe asthma is a risk- factor for severe COVID -19 illness, an d the foll owing parti cipants will 
not be included in the study  (see Exclusi on Cri teria 1 and 2, Secti on 5.2). 
1Parti cipants wi th active COVID -19 infect ion at screening.  
2Parti cipants wi th a history  of significant COVID -19 illness wit hin 6 months of enrolment.
(a)Parti cipants wi th history  of COVID -19 pneumo nia diagnosed based on 
radiological  assessment.
(b)Parti cipants w ith history  of COVID -19 and significant findings from pulmo nary 
imaging tests.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 29of 134(c)Parti cipants wi th history  of COVID -19 requi ring hospi talisat ion and/or oxy gen 
supplementati on therapy .
Because the run -in period ranges fro m 28-35 days, participants will be te sted for active 
SARS -CoV -2 infect ion using a PCR test targeting SARS -CoV -2 at 2 screening visits (see 
SOA; see Table 1, Secti on 1.3), and those with a posit ive result prior to randomisation will 
beco me screen failures. 
Parti cipants suspected of having contracted COVID -19 shoul d be managed according to local 
and nat ional guidelines to prevent spread of COVID -19 infect ion to staff and pat ients. These 
participants, as well as any who test positive for SARS -CoV -2, should not be automat ically 
discontinued fro m invest igational product or be withdrawn from the study . Invest igators 
shoul d refer to Secti on 7when considering participant discont inuat ion or withdrawal 
decisio ns. Si tes will  be requi red to p rovide documentation of a COVID -19 screening and 
mitigation plan that describes how and where participants would be tested if they are 
suspected to have SARS -CoV -2 infect ion. The plans should also describe mit igation act ivities 
designed to protect site sta ff and others at the site, including other participants and pat ients.
Invest igators should ensure that potential participants with significant risk factors for 
COVID -19 rel ated com plicat ions are not enrolled as per Exclusion Criterion 13 (Section 5.2).
It is recognised that depending on the location and facilit ies of a clinical site, study  visit 
attendance may place participants at risk of exposure to SARS -CoV -2. Furthermore, it is 
recogni sed that m ore general  popul ation-level measures to reduce infect ion rates (eg, travel 
restri ctions) may inhibit the abilit y of participants to attend study  visits. Necessary  heal thcare 
responses at sites to the pandemi c (eg, addi tional infect ion control measures) may  also inhibi t 
the abilit y of a clinical site to effect ively and properly conduct the study . Study  visit 
attendance for dosing and for clinical assessments of treatment response are crit ical for the 
scientifi c value of the study .
Therefore, investigators should not enrol participants unless they have reasonable confidence 
that throughout the duration of the study :
Parti cipants will be able to attend study  visit s, whilst avoi ding contact wi th concentrati ons 
of COVID -19 pati ents (eg, hospi tal entrances used by  such pati ents); and
The site will be able to conduct the study  effect ively and safely , considering rel evant 
national and local factors.
The primary  endpoint will be analysed using a repeated measures mixed effect m odel which, 
in the event of missing data, uses all data that are available. The sponsor will mo nitor the 
number of discont inuat ions, withdrawals, missed visit s and other missing data.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 30of 134AstraZeneca will routinely conduct risk -based enrolment assessm ents on a country  and si te 
level during the pandemic phase of COVID -19, and study  monitoring will focus, in part, on 
AEs associ ated wi th new onset SARS -CoV -2 infection and part icipants wi thdrawn due to 
COVID -19 illness. 
All site staff shoul d wear personal protective equipment in accordance with local or national 
guidelines.  
If, for reasons related to the COVID -19 pandemic, a participant is not able to attend their 
scheduled visit with in the ±3 day  visit window, they  can have their visit rescheduled wit hin 
14days of the ori ginal  scheduled visi t; however, visits that cannot be rescheduled within a 
14day window m ust be skipped and participants should continue at the next scheduled visit.
During the COVID- 19 pandemic, on -site visi ts may be repl aced by  a telemedicine visit if 
allowed by  local/regional gui delines. Having a telemedicine contact with the participants will 
allow co llection of data for AEs, concomitant medicat ions, adherence to the eDiary  and PRO 
measures to be reported and documented. The term telemedicine visit refers to remote contact 
with the parti cipants using teleco mmunicat ions techno logy including phone calls, virtual or 
video visits, and mo bile health devices.
2.3.1.3 Vaccination Against COVID-19
There are no clinical data available to assess the interaction (if any) of MEDI3506 with any 
COVID -19 vaccine.
The sponsor accepts that vaccinat ion against COVID -19, when and where it is available and 
participants are eligible according to applicable guidelines, is in the participant’s best interest. 
Cons equent ly, vaccinat ion during the study  is, in general, permitted and any delays in 
vaccination due to study  partici pation shoul d be minimised.
To hel p ensure the interpretabilit y of safet y data, recei pt of  COVID -19 vaccine (either first or 
subsequent dose) is prohibited within 30 days befo re randomisation or within 7 days before or 
after any  dose of study  interventi on (Sect ion6.5.4 ). Receipt of, at least, the first dose of 
COVID -19 vaccine more than 30 day s before randomisat ion, wi thout si gnificantly delaying 
enrolment, should be preferred but may not be possible, eg, not locally available at the time, 
participant not eligible at the time, express participant decisio n not to be vaccinated. 
Otherwi se, vaccinat ion may be perform ed at any  time outsi de the prohibited 7 -day window 
before or after any  dose of study  intervent ion. If the (approximate) date of a subsequent dose 
of COVID -19 vaccinat ion is known, then enro lment of the parti cipant shoul d be t imed so that 
the dose i s not wi thin 30 days prior to scheduled rando misat ion. If this date is not known then 
enrolment into the study should not be delayed. If an enrolled part icipant does (unexpectedly ) 
receive COVID -19 vacci ne wi thin 30 days pri or to scheduled randomisat ion, the si te shoul d 
contact the AstraZeneca Study  Physician for advice on how the situation should be managed.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 31of 1342.3.2 Benefit Assess ment
The purpose of this Phase II, proof -of-concept clinical study  is to eval uate t he efficacy and 
safet y of MEDI3506 in adult participants with uncontrolled moderate- to-severe asthma. For 
participants randomised to MEDI3506, there is a potential benefit in terms of improvement of 
their asthma status. However, the efficacy  of MEDI3506 in participants wi th asthma is yet to 
be determined. Participants may derive benefit from healt h assessments (eg, ECG, 
echocardiogram, clinical laboratory  safet y measurements, and SOC adherence mo nitoring) 
perform ed as part of the study .
2.3.3 Overall Benefit: Ris k Conclusion
Taking into account the measures to minimise risk to participants in this study , the potenti al 
risks in association wit h MEDI3506 are just ified by the potential benefit in terms of 
improvement of their asthma status.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 32of 1343 OBJECTIVES AND ENDPO INTS
Table 4 Objectives and Endpoints
Objective Endpoint
Primary 
To assess the effect of MEDI3506 compared 
with placebo on lung function, in adult 
participants with uncontrolled 
moderate -to-severe asthma.As measured in clinic, change from baseline to Week 16 
in pre -BD FEV 1(L).
Secondary 
To further assess the effect of MEDI3506 
compared with placebo on lung function, in adult 
participants with uncontrolled 
moderate -to-severe asthma.As measured in clinic, change from baseline to Weeks 8 
and16 in post -BD FEV 1(L).
To assess the PK of MEDI3506 in adult 
participants with uncontrolled 
moderate -to-severe asthma.Serum MEDI3506 concentration -time profiles during the 
interventio n and follow -up periods.
To assess the immunogenicity of MEDI3506 in 
adult participants with uncontrolled 
moderate -to-severe asthma.ADA during the intervention and follow -up periods.
To assess the effect of MEDI3506 compared 
with placebo on asthma control in adult 
participants with uncontrolled 
moderate -to-severe asthma.Change f rom baseline to Week 16 in ACQ -6 score.
Proportio n of participants with a decrease in ACQ -6 score 
of ≥0.5 from baseline to Week 16.
Proportio n of participants achieving ACQ -6 well 
controlled status (defined as ACQ -6 score ≤0.75 at 
Week 16).
To assess the effect of MEDI3506 compared 
with placebo on health status in adult 
participants with uncontrolled 
moderate -to-severe asthma.Change f rom baseline to Week 16 in SGRQ score.
Proportio n of participants with a decrease in SGRQ total 
score of ≥ 4points from baseline to Week 16.
To assess the effect of MEDI3506 compared 
with placebo on CompEx in adult participants 
with uncontrolled moderate -to-severe asthma. Time to first CompEx event based on the period from 
baseline to Week 16. 
CompEx annualised event rate.
To assess the effect of MEDI3506 compared 
with placebo on concentration of FeNO in adult 
participants with uncontrolled 
moderate -to-severe asthma.Percent change from baseline to Week 16 in concentration 
of FeNO in exhaled breath.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 33of 134Table 4 Objectives and Endpoints
Objective Endpoint
Safety
To assess the safety and tolerability of 
MEDI3506 compared with placebo, in adult 
participants with uncontrolled 
moderate -to-severe asthma.During the intervention and follow -up periods:
• AEs, SAEs, AESIs
• Vital signs
• Clinical chemistry, haematology, and urinalysis
• ECGs
• LVEF as measured by echocardiogram
• NT-proBNP
• Number of participants seropositive for 
SARS -CoV -2 at end of study who were seronegative 
at randomisation visit
• For participants testing positive for SARS -CoV -2 (by  
PCR or serology test), du ring the intervention and 
follow -up periods, the number and proportion of 
patients with COVID -19 AEs/SAEs and the 
proportion asymptomatic .
Exploratory
To further assess the longitudinal effect of 
MEDI3506 compared with placebo on lung 
function in adult participants with uncontrolled 
moderate -to-severe asthma.As measured at home, change from baseline up to 
Week 24 in 2 -weekly mean PEF and FEV 1
To assess the effect of MEDI3506 compared 
with placebo on airway hyperresponsiveness in 
adult participants wit h uncontrolled 
moderate -to-severe asthma.Change f rom baseline to Weeks 8 and 16 in FEV 1% 
reversibility.
To assess the effect of MEDI3506 compared 
with placebo on asthma related inflammatory 
blood biomarkers in adult participants with 
uncontrolled moderate -to-severe asthma.Change f rom baseline to Weeks 1,4, 8, 12,16, 20 and 24 
in inflammatory blood biomarker levels, including but not 
limited to:
•
• Serum IL -5.
• Serum IL -13.
• Serum TSLP.
Change f rom baseline to Weeks 4,16, and24 in plasma 
EDN.
Change f rom baseline to Weeks 16 and 24 in total IgE.
Change f rom baseline to Week 16 in:
• sST2.
• Proinflammatory gene signatures in whole blood.
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 34of 134Table 4 Objectives and Endpoints
Objective Endpoint
To assess the longitudinal effect of MEDI3506 
compared with placebo on small airway funct ion 
in adult participants with uncontrolled 
moderate -to-severe asthma.Change f rom baseline to Weeks 1,4, 8, 12,and16 in 
airway reactance and resistance as assessed by AO 
parameters, including but not limited to:
• R5
• R20
• R5-R20
• AX
To assess the longitudinal effect of MEDI3506 
compared with placebo on lung function in adult 
participants with uncontrolled 
moderate -to-severe asthma.As measured in clinic, change from baseline in pre -BD 
FEV1 to Weeks 1,4, 8, 12,20, and 24.
To assess the acute effe ct of MEDI3506 
compared with placebo on pre -BD FEV1 in 
adult participants with uncontrolled 
moderate -to-severe asthma.As measured in clinic, change in pre -BD FEV1 (L) from 
pre-administration of study intervention to 4 hours 
post-administration of MEDI3506 or placebo at Day 1.
To assess the effect of MEDI3506 compared 
with placebo on asthma control in adult 
participants with uncontrolled 
moderate -to-severe asthma.During the intervention period (baseline to Week 16):
• Annualised rate of asthma exacerbations .
• Annualised rate of hospitalised asthma 
exacerbations.
To assess the longitudinal effect of MEDI3506 
compared with placebo on asthma control and 
health status in adult participants with 
uncontrolled moderate -to-severe asthma.Change f rom baseline to Weeks 1,4, 8, 12, and 24 in 
ACQ -6 score.
Change f rom baseline to Weeks 4,12,and24 in SGRQ 
score.
Change f rom baseline up to Week 24 in 2 -weekly mean 
daily  rescue medication usage (puffs/day).
Change f rom baseline to Weeks 4,8,12, 16, 20, and 24 in:
• A sthma symptom score.
• Mean number of night -time awakenings.
To assess the benefit -risk profile of MEDI3506 
as perceived by adult participants with 
uncontrolled moderate -to-severe asthma.PGI-BR at Week 16.
To evaluate and inflammatory blood 
biomar kers that may predict an efficacy response 
to MEDI3506 in adult participants with 
uncontrolled moderate -to-severe asthma. 
 
Association o f allergen -specific IgE status with primary 
and secondary efficacy endpoints at Week 16.
To assess the effect of MEDI3506 compared 
with placebo on asthma related inflammatory 
airway biomarkers in adult participants with 
uncontrolled moderate -to-severe asthma.Percent change from baseline to Weeks 1, 4, 8, 12, 16, 20, 
and 24 in concentration of FeNO.
Change f rom baseline to Weeks 4, 8, 12, 16, 20, and 24 in 
exploratory biomarkers measured in nasal lining fluid.
Change f rom baseline to Week 16 in mRNA nas al 
transcriptome.
CCI
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 35of 134Table 4 Objectives and Endpoints
Objective Endpoint
To assess the effect of MEDI3506 compared 
with placebo on nasal symptom control in a 
subset of adult participants with uncontrolled 
moderate -to-severe asthma who have comorbid 
CRS.Change f rom baseline to Weeks 1,4, 8, 12, and 16 in 
SNO T-22 score.
Exploratory cough sub -study
To evaluate the effect of MEDI3506 compared 
with placebo on objective cough measures in 
adult participants with uncontrolled 
moderate -to-severe asthmaChange f rom baseline to Week 16 in:
• Daily  (ie, 24 hour) cough frequency.
• Awake time cough frequency.
• Night- time cough frequency.
• Cough VAS.
ACQ -6 = asthma control questionnaire -6; ADA =anti-drug antibody(ies); AE =adverse event; AESI =adverse 
event of special interest; AO =airwave oscillometry; BD=bronchodilator; COVID -19 = coronavirus 
disease 2019; CompEx =composite endpoint for severe exacerbations of asthma; CRS =chronic rhinosinusitis; 
ECG =electrocardiogram; EDN =eosinophil derived neurotoxin; FeNO =fractional exhaled nitric oxide; 
FEV1=forced expiratory volume in the first second; IgE =immunoglobulin E; IL =interleukin; L =litre(s);
LVEF =left ventricular ejection fraction; mRNA =messenger RNA; NT -proBNP = N-terminal prohormone of 
B-type natriuretic hormone; PCR =polymerase ch ain reaction; PEF =peak expiratory flow; PGI -BR =patient 
global impression of benefit/risk; PK =pharmacokinetic(s); SAE =serious adverse event; SARS -CoV -2= severe 
acute respiratory syndrome coronavirus 2; SGRQ =St George’s respiratory questionnaire; SNOT -22 = sino- nasal 
outcome test -22;  sST2 =soluble ST2; TSLP =thymic stromal 
lymphopoietin; VAS =visual analogue scale.
4 STUDY DESIGN
4.1 Overall Design
Study D9181C00001 is a Phase II, randomised, double -blind, placeb o-controlled, 
parallel- group, proof -of-concept study  to eval uate the efficacy , safet y, PK and 
immunogenicit y of MEDI3506 in adult participants with uncontrolled moderate -to-severe 
asthma on SOC.
Approximately  228 parti cipants will be randomised in a 1:1:1 ratio to achieve 216evaluable 
participants. Parti cipants will receive mg MEDI3506, mg MEDI3506, or placebo 
 by SC inject ion for a total  of  doses. The rando misat ion will be stratified according to 
cough sub -study  parti cipat ion. Note that the e xploratory  cough sub -study  may not be activated 
in all countries.
Parti cipants who fail  screening can be re -screened. 
Parti cipants will be enrolled in this study  for up to 29 weeks. The study  com prises of 3 periods 
including the screening period of up to 5 weeks, an intervent ion peri od of  16 weeks, and a 
follow-up period of 8 weeks. 
CCI
CCI
CCI
CCI
C
C
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 37of 1344.2 Scientific Rationale for Study Design
Interl eukin- 33, an ‘alarmin’ cy tokine, is expressed by  epithelial and endothelial cells. Its 
cognate receptor, ST2, is expressed by several cell types including ILC2s, Th2 cells, Th1 
cells, regulatory  T cells, and mast cells. IL -33 release in airways is triggered by airway  
epithelial cell  injury  resul ting from environmental  factors such as airborne aller gens 
(Cayroland Girard 2018 ; Scott et al 2018 ), cigarette sm oke ( Weng et al 2018 ) and respiratory  
tract viruses ( Kearl eyet al 2015 ). 
Interl eukin- 33 st imulates ILC2s, mast cells and other airway cells to generate a variet y of 
soluble pro -inflammatory mediators such as IL -4, IL -5, and IL -13. In turn, these mediators 
amplify the pro -inflammatory effects of IL-33 by  recrui ting immune cells, including 
eosinophils, into airways. In asthma, airway inflammat ion is causat ive in manifestation of 
symptoms and damage to structural cells. This inflammat ion indirect ly also causes 
mal-adaptive epithelial repair and airway  wall re -modelling / thickening of the airway  wall; 
characterist ic features of severe asthma. The functional consequences o f airway wall  
inflammat ion and thi ckening in asthma are reduced lung function (FEV 1) and increased 
sensit ivity to bronchoconstr ictor agents such as methacho line ie, bronchial hyperreact ivity. 
Thus, evidence suggests that IL -33 init iates and drives the cardinal features linked to the 
development and persistence o f asthma. Consequent ly, neutralising IL -33 activit y in asthmat ic 
airways, would be expected to improve lung function, reduce airwall thickening and reduce 
bronchial hyperreact ivity.
Data from large -scale geno me-wide associ ation studi es strongly  associate the IL -33 gene 
locus and the ST2 gene locus with increased risk of asth ma (Bonnelykke etal2014 ; 
Gudbjartsson et al 2009 ; Hirotaetal2011 ; Moffat et al 2010 ; Torgerson et al 2011 ; 
Wan et al2012 ). Furtherm ore, one SNP in the IL -33 gene has been shown to generate a 
truncated, non -functional IL -33 protein. The pleiotropic pro -inflammatory effects of IL -33 in 
airways in conj uncti on wi th the genet ic linkage to asthma risk provide strong evidence that 
neutralisat ion of  IL-33 si gnalling may  have significant therapeutic benefit in asthma. 
However, since asthma is a heterogeneous disease, it is not clear whether all asthmat ics will 
benefit equally fro m anti-IL-33 therapy . In parti cular, individuals whose asthma develo ps 
early  in life (< 25 years of age) are more likely  to have family members with asthma ie, have a 
‘heritable’ form  of asthma, and so m ore likely  to have IL -33 m ediated di sease.
This Phase II proof -of-concept study  will evaluate the efficacy  and safet y of MEDI3506 in 
patients wi th persistent m oderate -to-severe asthma inadequately controlled on ICS plus 
LABAs. To explore whether IL -33 variants predict response to MEDI3506, this study will test 
the effects of anti -IL-33 therapy  in adult s whose asthma develope d before the age of 25 y ears.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI 3506 - D9181C00001
CONFIDENTIAL AND PROPRIETARY 38of 1344.2.1 Rationale for Endpoints
4.2.1.1 Primary Endpoints 
The primary  endpoint is absol ute change in pre -BD FEV 1. Pre-BD FEV 1is a valid and reliable 
quant itative tool to assess changes in airway obstruction in asthma over time.
4.2.1.2 Secondary an d Safety Endpoints 
Safety, PK, and immunogenicit y endpo ints will be evaluated to inform risk -benefit analyses 
and determine optimal dosing regimen for MEDI3506 in asthma. PROs (ACQ -6 and SGRQ) 
reliably  identify part icipants wi th uncontrolled asthma. CompE x is a composite score of 
asthma control composed of data gathered using an eDiary  and asthma exacerbat ion reporting 
that has predictive value in assessing whether an intervent ion reduces asthma exacerbat ions of 
asthma ( Fuhlbrigge et al 2017 ). FeNO i s a reliable quant itative tool to assess changes in 
asthma inflammat ion over time.
4.2.1.3 Exploratory Endpoints
Airwave oscillo metry  (AO) i s a sensi tive, non -invasiv e measure of ai rway functi on that 
concomitant ly assesses peripheral (small) and central (large) airways funct ion. FEV 1% 
reversibilit y allows f or assessment of changes in irreversible airway  obstructi on. Al though not 
statist ically powered, asthma exacerbat ion rates will be captured. Blood samples will be 
collected from participants for the assessment of biomarkers that are relevant to asthma 
disease patho logy and/or the m echanism  of action of MEDI3506. Collect ion of epit helial nasal 
fluid and cells will be p erformed on parti cipants to assess bio markers and the mRNA nasal 
transcri ptom e, as sampling in the upper airway may  provide bi omarker data that are more 
reflect ive of lung patho logy com pared wi th systemic bio markers.  
 
Many  patients with asthma have com orbid CRS. The SNOT -22, a validated questionnaire 
measuring nasal symptoms in participants with CRS, w ill be perform ed and evaluated in 
participants wi th com orbid CRS. Changes in SNOT -22 will be used to assess the impact of 
MEDI3506 on CRS.
In the exploratory  cough sub -study , objective cough monitoring will assess the impact of 
MEDI3506 on this important s ymptom of asthma, related to inflammat ion and airway 
hyperresponsiveness.
4.2.2 Rationale for Study Population
Clinical efficacy  of MEDI3506 has yet to be established in asthma. This study  aims to 
determine the effects of MEDI3506 on airway  functi on in asthmat ics with uncontrolled 
moderate -to-severe disease receiving standard of care (see Section 5.1for inclusio n criteria). 
Asthmatics with early  onset disease will be eligi ble but not those with late onset disease (onset 
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 39of 134after age of 25 years). The early onset populat ion of asthmat ics is more likely  to have IL -33 
driven disease based on geno me wide association study data ( Gorbacheva et al 2018 ).
4.2.3 Participant Input into Design
The AstraZeneca Patient Partnership Program is an internal working group that enables study  
participant feedback on clinical trial study  designs. During study  devel opment, the Pati ent 
Partnership Program influenced the following aspects of the study  design:
Provisio n wri tten into protocol to rotate inject ion sites (Sect ion6.2.2.1 ).
Parti cipant training for the eDiary  and spirometry  devices used at -home will be supported 
by troubl e shooting and technical guidance (does not direct ly affect protocol).
Parti cipants may  be provi ded wi th a single source study  guide provi ding study  rationale 
and guidance in seeking addit ional support from sites (does not direct ly affect protocol).
There m ay be ongoing communicat ions with part icipants such as newsletters and regular 
site contac t (does not direct ly affect protocol).
Site facilities were explored to support participant focused visit s such as out of office or 
telephone contact vi sits (does not di rectly affect protocol).
Reimbursement and travel assistance (including alternat ives to the use of public 
transportation systems) may  be consi dered based on site feedback (does not direct ly affect 
protocol ).
In addit ion, a study  coordinator review of the SOA took place in order to ensure the SOA 
were feasible and realist ic, particularly in terms of visit duration. This consultat ion led to:
Text describing the order that assessments should be performed on SV days added to the 
schedule of act ivities introductory  text (Secti on1.3).
Footnote ‘a’ added to the schedule of act ivities: screening period ( Table 1) to all ow 
flexibilit y for ICF to be signed at a separate, stand -alone visi t in order for the participant 
to have sufficient time to read and absorb the study informat ion.
4.3 Justification for Dose
The highest dose of MEDI3506 administered to participants in this study  will be mg by 
SC inject ion . This dose is predicted to have a lower exposure, in terms of maximum 
concentration at steady -state (C max,ss ; approximately  2.4-fold) and AUC (approximately 
1.1-fold), compared with the highest dose administered (ie, single dose of 300 mg IV 
MEDI3506) in the Phase I clinical study  (Study  D9180C00001; refer to IB for further details).
Exposures (ie, mean C max,ss of 1,276 μg/mL, and AUC 0-4 weeks at steady -state of 
28,012 μg•day/mL) achieved at the 26 -week NOAEL of 150 mg/kg in cyno molgus mo nkeys 
(refer to the IB for further detail) are approximately 38 -and 47 -fold higher than predicted at 
CCI
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 40of 134the proposed highest dose of mg SC  in this Phase II clinical study  (refer to the IB 
for addi tional details).
The optimal serum concentration for ME DI3506 efficacy in asthma is not known. A mouse 
challenge model suggests a target concentration of 20 μg/mL (refer to the IB for addit ional 
details). Analysis of the PK data fro m the Phase I clinical study  of MEDI3506 predicts that 
mg SC  will achie ve an average steady -state concentration of 21 μg/m L, similar to 
the target concentration established in the mouse model. In addit ion, thi s dose i s predicted to 
achieve > 90% suppression of IL -33 in the sputum based on the theoretical PK/PD model. If 
replicated in humans wit h asthma, mg SC  is anticipated to achieve near -maximum 
efficacy  based on the m ouse and PK/PD models, and will be used in this study . The l ower 
dose of mg  SC will be used in this Phase II clinical study  to define the effic acy of 
MEDI3506 at lower dose.
4.4 End of Study Definition
An individual participant will be considered to have completed the study  if the parti cipant was 
followed through their last protocol -specified visit/assessment (including telephone contact) 
regardl ess of the number of doses of study  intervent ion that was received.
Parti cipants will not be considered to have completed the study  if consent was wi thdrawn or 
the participant was lost to fo llow-up (see Secti ons7.2and7.3). The end of study is defined as 
the last expected visit/contact of the last participant undergoing the study.
4.4.1 Study Stopping Criteria
Discontinuati on of  specific sites or of the study  as a who le are handled in accordance with 
Appendix A 8.
The study  may be put on hol d pending a full safet y data review, if any o f the following cri teria 
are met:
Two or more (in different participants) reports of new onset symptomat ic heart failure 
confirmed by echocardiography .
Two or more (in different participants) reports of new onset non -infect ive co litis 
confirmed histopathologically.
Five or m ore (in different participants) reports of ≥Grade 4 severit y infect ion (excluding 
COVID -19 infect ion), not associated with an asthma exacerbat ion.
Two or more (in different participants) other clinically significant ( ≥Grade 4 severit y) 
AEs (excluding those described in any  of the preceding criteria) in the same system organ 
class (excluding COVID -19 infect ion and asthma exacerbations) that preclude continuing 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 41of 134dosing of the participant, unless obviously not related to the study  drug (eg, m otor vehicle 
accident).
Parti cipant enrolment is unsatisfactory .
Non-compliance that might significant ly jeopardise the validit y or integri ty of the tri al, or 
safet y of the par ticipant(s).
Sponsor decisio n to terminate development.
If the sponsor determines that temporary  suspensi on or terminat ion of the study  is requi red, 
the sponsor will discuss the reasons for taking such act ion with all part icipating investigators 
(or head of the m edical  institution, where applicable). When feasible, the sponsor will provide 
advance notice to all participating invest igators (or head of the medical inst itution, where 
applicable) of the impending act ion.
If the study  is suspended or terminated for safet y reasons, the sponsor will promptly inform all 
investigators, heads of the medical inst itutions (where applicable), and/or inst itutions 
conducting the study . The sponsor will also promptly  inform the rel evant regul atory  
authori ties of the suspen sion/terminat ion alo ng with the reasons for such act ion. Where 
requi red by applicable regulat ions, the investigator or head of the medical inst itution m ust 
inform  the IRB/IEC prom ptly and provide the reason(s) for the suspensio n/termination. If the 
study  is suspended for safet y reasons and it is deemed appropriate by  the sponsor to resume 
the study , approval  from the rel evant regul atory  authori ties (and IRBs/IECs when applicable) 
will be obtained prior to resuming the study . The investigator shall also prom ptly inform  the 
participant of the study  suspensio n/terminat ion and should assure appropriate participant 
therapy  and/or follow -up.
5 STUDY POPULATION
Prospective approval o f protocol  deviati ons to recrui tment and enro lment criteria, also known 
as protocol w aivers or exemptions, is not permitted. During the screening period, for any  
clinical laboratory  test where the result is not available from central laboratories prior to 
rando misat ion, a result from a local laboratory  may be an acceptable al ternat ive but the 
medical mo nitor must be consulted fi rst.
5.1 Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply: 
If any criterion cannot be fully assessed at a particular visit (eg, due to await ing informa tion 
from the parti cipant’s usual physician at SV1 or laboratory  resul ts not y et available at SV2), 
the criterion m ust be fully assessed prior to randomisat ion:
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 42of 134Age
1Parti cipant m ust be 18 to < 65 y ears of age inclusive, at the time of signing the ICF.
Type of Participant and Disease Characteristics
2Docum ented physician -diagnosed asthma of early  onset, defined as development of 
asthma before the age of 25 years. Asthma should be diagnosed > 12 m onths pri or to 
SV1. Acceptable documentation includes any of th e following:
(a)Contem poraneous clinical notes, dated > 12 months prior to SV1 and when 
participants were aged < 25 years, showing a diagnosis of asthma.
(b)Contem poraneous clinical notes or pharmacy records, dated > 12 months prior to 
SV1 and when participants were aged < 25 y ears, showing on -going treatm ent 
for asthm a (note: the indication of asthma must be documented).
(c)Invest igator documentation based on communicat ion with the physician who 
treats the participant’s asthma.
3Treated with medium -to-high dose ICS defined as total daily dose of > 250g flut icasone 
dry powder or equivalent (see Appendix Ffor equivalent ICS doses), for at least 
12months pri or to SV1 and on a stable dose for ≥3 months pri or to SV1.
4Stabl e LABA therapy  for ≥3months prior to SV1 (this may be as a fixed -dose 
combinat ion product, or a separate inhaler).
Treatment with addit ional asthma controller therapies eg, LAMA, LTRA, 
theophylline ( ≥1 month at a stable dose) prior to SV1 is allo wed. Individuals on 
theophylline must have normal blood levels documented in the 3 months prior to 
SV1. Treatment with oral corticosteroids is allowed if dose has been stable for 
≥ 3months.
5An ACQ -6 score ≥1.5 at SV1, SV2, and SV4 (randomisat ion).
6Morning pre -BD FEV 1<85% predicted normal at SV1.
7 ≥ 70% adherence (day s) to eDi ary com pletion both between SV1 and SV2 and in the 
14days preceding SV4.
An adherent day  requi res com pletion of evening and subsequent morning diary  
between SV1 (evening assessment) and SV2 (morning assessment).
8 ≥ 70% adherence to background medicat ion as assessed by  eDiary  entries both between 
SV1 and SV2 and in the 14 days preceding SV4.
9Parti cipants must dem onstrate abi lity to perf orm acceptable inhaler and spiro metry 
techniques.
10Able and willing to comply wit h the requirements of the protocol including abilit y to 
read, wri te, be fluent in the translated language of all participants facing quest ionnaires 
used at site, an d use el ectroni c devices eg, eDiary and spirometry .
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 43of 134Weight
11Body weight ≥ 40 kg and BMI <40 kg/m2.
Reproduction
12For female participants of childbearing potential (see Appendix Ifor definit ion of 
childbearing potential):
A negat ive serum pregnancy test at SV1.
A negat ive urine pregnancy test at SV2 and prior to administration of study 
intervent ion at SV4 (randomisat ion).
13Female participants of childbe aring potenti al who are sexually act ive with a male partner 
must agree to use a highly effect ive method of contraception fro m screening unt il the end 
of the fo llow-up peri od at SV12 (Week 24) of the study . See Appendix Ifor definit ions of 
childbearing potential and highly effective methods of contraception.
In countri es where spermicide is available, it is strongly  recommended for the m ale 
partner of a female parti cipant of childbearing potent ial to also use m ale condom  plus 
spermicide throughout this period.
In countri es where spermicide is not available, it is strongly recommended for the 
male partner of a female part icipant of childbearing potential to also use male 
condom  throughout this period.
14There are no contraception requirements for female participants who are not of 
childbearing potential. However, all female participants should refrain fro m egg cell 
donati on and breastfeeding throughout the study .
15In countri es where spermicide is available, male participants who are sexually act ive wit h 
a female partner of childbearing potential must agree to use a male condo m with 
spermicide and another highly  effect ive method of contraception during the int ervent ion 
and fo llow-up peri ods f rom SV4 (Day 1) through to SV12 (Week 24) of the study . In 
countri es where spermicide is not available, male participants who are sexually act ive 
with a female partner of childbearing potential must agree to use a male cond om and 
another highly effective method of contraception during the intervent ion and fo llow-up 
periods fro m SV4 (Day 1) through to SV12 (Week 24) of the study . See Appendix Ifor 
definit ions of childbearing potential and highly  effective methods of contraception. Male 
participants shoul d also refrain from bio logically  fathering a child or donating sperm 
during the same period.
Informed Consent
16Provisio nof signed and dated, written informed consent (and any  locally requi red 
authori sation eg, data privacy) for study  parti cipat ion which includes mandatory 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 44of 134genoty ping (study  object ive). Note: If a participant declines to participate in the 
mandatory  genoty ping com ponent of the study , the parti cipant will  not be included in the 
study .
17Optional : provi sion of signed and dated written Optional Genet ic Research Informat ion 
inform ed consent pri or to collect ion of samples for optional genet ic research that supports 
Geno mic Init iative.
Type of Participant and Disease Characteristics
18Parti cipants wi th docum ented evidence of asthma as demonstrated by  either:
Post-BD reversibilit y of FEV 1≥12% and ≥ 200 mL (15 to 60 min after 
administration of 4 puffs of albuterol /salbutam ol), within 12 months prior to SV1, or 
at SV1 or SV2. Note: if the participant cannot perform post -BD spiro metry at SV1 or 
needs to perform a repeat assessment of post- BD spi rometry , it is also acceptable to 
assess this criterion at SV2, or
Positive methacho line challenge test within the 12 months prior to SV1. A positive 
resul t is defined as a PC 20≤ 8mg/mL.
19Docum ented history  of ≥1 asthm a exacerbati on in 24 m onths pri or to SV1 (see 
Secti on8.1.5 for definit ions of acceptable documentation and asthma exacerbation). 
20Morning pre -BD FEV 1≥40% predicted normal and > 1L at SV1.
Criteria to be Assessed for Exploratory Cough Sub -study
Informed Consent
21Provisio n of written dated separate ICF for the exploratory cough sub -study .
5.2 Exclusion Criteria 
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Criteria to be Assessed at SV1 and SV2
If any criterion canno t be fully assessed at SV1 and SV2 (eg, laboratory  resul ts not y et 
available), the criterion must be fully assessed prior to randomisat ion.
Medical Conditions and Diagnostic Assessments
1Parti cipants wi th a posi tive diagnost ic PCR test for SARS -CoV -2, the v irus responsible 
for COVID -19, at SV2, or any time on or after Day -7 and prior to SV4. 
2Parti cipants wi th a significant COVID -19 illness wit hin 6 mo nths of enrolment:
(a)Parti cipants wi th a diagnosi s of COVID -19 pneumoni a based on radi ological 
assessment. 
Clinical Stud y Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 45of 134(b)Participants wi th diagnosis of COVID -19 wi th significant findings from 
pulmo nary imaging tests.
(c)Parti cipants wi th a diagnosi s of COVID -19 requiring hospitalisat ion and/or 
oxygen supplementation therapy .
3Positive hepat itis C antibody ,hepati tis B virus surfac e ant igen,or hepatit is B virus core 
antibody , at screening; or known to have tested posit ive for human immunodeficiency  
virus. 
4Evidence of act ive or un treated l atent TB infect ion (LTBI):
(a)Positive interferon gamma release assay (IGRA) test and evidence of symptom s 
suggest ive of act ive TB.
(b)Positive IGRA, or repeated indeterminate IGRAs, no evidence of act ive TB and 
untreated for LTBI, unable to be treated for, or declines treatment of LTBI.
(c)Parti cipants newly  diagnosed wi th LTBI on ini tial screening coul d be considered 
for rescreening if they  com plete a full course of treatment for LTBI in accordance 
with recommended treatment guidelines prior to rescreening. In this situat ion, 
repeat IGRA test is not required after completion of treatment for LTBI.
(d)Parti cipants wi th an indeterminate IGRA should undergo a repeat test and if still 
indeterminate may be enrolled only  after being treated for LTBI.
5This criterion has been removed .
6An LVEF < 45% m easured by  echocardi ogram  during screening.
7A family history  of heart failure defined as either of the fo llowing:
(a)≥2 first degree relat ives wit h clinically significant heart failure, or
(b)≥1 first degree relat ive with heart failure known to be heritable (eg, hypertrophic 
cardi omyopathy ), unless inheri tance is exclud ed by  geneti c testing.
8Major surgery  within 8 weeks pri or to screening at SV1, or planned inpat ient surgery  or 
hospi talisat ion during the screening, intervent ion or fo llow-up peri ods.
9Donati on of  blood or bl ood products in excess of 500 mL within 3 months prior to SV1.
Prior/Concurrent Clinical Study Experience
10Parti cipation in a clinical study  for a m edical device wi thin 3 m onths pri or to screening at 
SV1.
Other Exclusions
11Current sm okers or recent ex -smokers i e, have quit  e-cigarettes or other inhaled t obacco 
products ≤6 months prior to SV1.
12Ex-smokers wi th a total  smoking history  of >10 pack y ears (not applicable for 
e-cigarettes). Note: pack -years are calculated as average number of cigarettes per 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 46of 134day×number of years/20. For example, 1 pack y ear=20 cigarettes smoked per day for 
1year or 10 cigarettes per day  for 2 y ears.
Criteria to be Assessed at SV1, SV2, and SV4 (Randomisation)
Medical Conditions and Diagnostic Assessments
13As judged by  the invest igator, any  evidence of any active medical or p sychiatric condit ion 
or other reason (prior to randomisat ion) that in the investigator’s opinion makes it 
undesirable for the participant to participate in the study. This includes but is not limited 
to:
(a)Diabetes m ellitus, except for parti cipants wi th type 2 diabetes mellitus that are 
well controlled.
(b)History  of heart failure.
(c)Clinically significant or unstable ischemic heart disease, arrhyt hmia, or 
cardi omyopathy , including acute coronary  syndrome within the last 6 months; or 
any history  of myocardial infa rction.
(d)Clinically significant aortic stenosis.
(e)Systemic hypertensio n except if well controlled using two or fewer medications 
and stable for at least 6 months.
(f)Known history  of primary  pulm onary arterial  hypertensi on.
(g)History  of an underlying condit ion that predi sposes the participant to infect ions 
(eg, hi story  of splenectomy, known primary  or secondary  immune deficiency  
syndro mes).
(h)History  of ulcerative colit is, Crohn’s disease, or microscopic colit is diagnosed by 
either gastroenterologist or by  histopath ology .
(i)Obstructive sleep apnoea.
(j)History  of treatm ent wi th cardi otoxi c medicat ions (eg, as part of cancer therapy ) 
including thiazo lidinedio nes.
14Any clinically  important pulm onary disease other than asthma eg, active lung infect ion, 
COPD, bronchiectasis, pulmo nary fibrosi s, cyst ic fibrosis, hypovent ilation syndro me 
associ ated wi th obesi ty, lung cancer, history  or pl anned lung l obectomy, al pha-1 
anti-trypsin deficiency, primary  ciliary  dyskinesia, Churg- Strauss syndro me, allergic 
bronchopulmo nary aspergill osis and hyper -eosinophilic syndrome.
15Any other clinically  relevant abnorm al findings on physical examinat ion or laboratory  
testing including haematology , coagul ation, serum chemistry , or urinalysis between SV1 
and SV4 (randomisat ion), that in the opinio n of the invest igator or medical mo nitor mi ght 
compromise the safet y of the parti cipant in the study  or interfere with evaluat ion of the 
study  interventi on. Abnorm al findings include, but are not limited to: 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 47of 134(a)ALT or AST > 2 × ULN.
(b)TBL > 1.5 × ULN (unless due to Gilbert’s disease). 
(c)Evidence of chronic liver disease.
(d)Abnorm al vital signs, after 10 minutes of supine rest (confirmed by one 
controlled measurement), defined as any of the fo llowing:
(i)SBP < 80 mmHg or ≥ 150 mmHg.
(ii)DBP < 50 mmHg or ≥ 95 mmHg.
(iii)Pulse < 45or > 100 beats per minute.
(e)Signs of pulmo nary oedem a or vol ume overl oad.
(f)Any clinically  significant rhy thm, conducti on, or m orphol ogy abnorm alities in 
the ECG including but not limited to QTcF ( Vandenberk etal2016 ) >450ms.
16A known history  of severe reacti on to any  medicati on including bio logic agents or human 
gamma glo bulin therapy.
17History  of, or a reason to believe, a participant has a history  of, drug or alcoho l abuse 
within the past 2 years prior to screening.
18Current diagnosis of cancer.
19History  of cancer, except if treated with apparent success wit h curative therapy  (response 
durati on of  >5 years).
20History  of allogeneic bone m arrow transpl ant.
21 A helmint h parasit ic infection diagnosed within 6 mo nths prior to SV4 (rando misat ion) 
that has not been treated, or has not responded to SOC therapy .
22An asthma exacerbat ion within 8 weeks of SV4 (randomisat ion; see Sect ion8.1.5 for 
definit ions of acceptable documentation and exacerbat ion).
Prior/Concomitant Therapy
23Receiving any prohibited conco mitant medicat ions or therapies as specified in the 
protoc ol, as fo llows:
(a)Ident ified any time fro m SV1 through to SV4 (randomisat ion):
(i)Systemic (oral  or injectable) corticosteroids within 4 weeks of SV1 (except as 
stable m aintenance therapy  for asthm a [see Inclusion Criterion 4]).
(ii)Live or attenuated vaccines wit hin 4 weeks o f SV1. (Note: Vaccines wit h 
adenoviral vectors that are unable to replicate, eg, ChAdOx1, are not considered 
live attenuated).
(iii)Ig or blood products withi n 4 weeks of SV1.
(b)Ident ified at SV4 (randomisation):
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 48of 134(i)Any immunotherapy  within 3 months of SV4 (randomisat ion), except for stable 
maintenance dose allergen -specific immunotherapy  started at l east 4 weeks prior 
to SV1 and expected to continue through to the end of the fo llow-up peri od.
(ii)Interferon gamma wit hin 3 mo nths of SV4 (randomisat ion).
(iii)Invest igational products within 4 months or 5 half -lives o f SV4 (randomisat ion).
(iv)Marketed bio logics including dupilumab, benralizumab, and mepo lizumab 
within 4 m onths or 5 half -lives of SV4 (randomisation), whichever is lo nger.
(v)Vaccinat ion against COVID -19 (either first or subsequent dose) within 30 days 
prior to randomisat ion.
Prior/Concurrent Clinical Study Experience
24Concurrent enrolment in another clinical study  involving a study  interventi on.
25Known history  of allergy  or reacti on to any  com ponent of the study  intervent ion 
formulation, including hereditary  fructose intol erance.
Other Exclusions
26Involvement in the planning and/or conduct of the study (applies to both As traZeneca 
staff and/or staff at the study  site).
27Judgment by  the invest igator that the participant should not participate in the study if the 
participant is unlikely  to com ply with study  procedures, restrict ions and requirements.
28Parti cipant has been committed to an inst itution by vi rtue of  an order issued either by the 
courts or by  a public authorit y.
5.3 Lifestyle Considerations
Parti cipants m ust abstain from  donating blood and plasma from the time of informed consent, 
and for 16 weeks (5 half -lives) after final administ ration of  study  intervent ion.
5.3.1 Meals, Dietary Restrictions, and Caffeine
1Parti cipants shoul d avoi d eat ing a large meal for at least 2 hours prior to all spiro metry, 
AO and FeNO assessments at the site.
2Parti cipants shoul d not eat or drink one hour pri or to having FeNO assessment.
3During each dosing session, participants will abstain fro m ingesting caffeine -or 
xanthine -containing products (eg, coffee, tea, cola drinks, and chocolate) for 4 hours prior 
to in-clinic spiro metry .
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 49of 1345.3.2 Activity
1Parti cipants shoul d avoi d engaging in strenuous exercise for 2 hours prior to all 
spirometry, AO and FeNO assessments , both in clinic and at home. 
2Parti cipants shoul d avoi d showers/bathing and any activit y that will cause heavy  
perspi ration whilst wearing the cough m onitor, as the cough monitor must not come into 
contact wi th water.
5.4 Screen Failures
Note : "Enrolled" means a participant's, or their legally acceptable representative’s, agreement 
to parti cipate in a clinical study  following com pletion of the informed consent process. 
Screen failures are defined as part icipants who consent to participate in the clinical study  but 
are not subsequent ly rando mly assigned to study  intervent ion. A minimal set of screen failure 
inform ation is required to ensure transparent reporting of screen failure participants to meet 
the Consolidated Standards of Reporting Tria ls (CONSORT) publishing requirements and to 
respond to queries from regulatory  authori ties. Minimal information includes demography , 
screen failure details, eligibilit y criteria, and any  SAE.
Individuals who do not meet the criteria for participation in this study (screen failure) m ay be 
rescreened, if there is reason to believe the reason for screen failure was temporary . Only  one 
rescreening per participant is allowed in the study . The timing of the rescreening should be 
determined by the PI, taking into account the init ial reason for screen failure. Prior to 
rescreening, participants must be reconsented and will retain their original SID number.
6 STUDY INTERVENTION
Study  intervent ion is defined as any invest igational intervent ion(s), m arketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study  protocol .
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 51of 1344MEDI3506 does not contain preservatives and therefore, any  unused porti on m ust be 
discarded.
The unblinded study  intervent ion manager will select the appropriate kits allocated by  the 
RTSM to prepare the participant’s dose. The unblinded study  intervent ion manager must 
ensure that only the unblinded team members have access to the areas of the pharmacy  where 
the study  intervent ion is being stored and prepared.
6.2.1 Study Intervention Inspection
Each vial allocated for dose prepara tion shoul d be inspected. MEDI3506 and placebo are 
supplied as a clear to opalescent sterile liquids.
If there are any defects noted with the study  intervent ion, the invest igator and site monitor 
shoul d be notified immediately. Refer to the Product Complaint sect ion in the IMP manual for 
further instructions.
6.2.2 Dose Preparation Steps
No incompat ibilities bet ween MEDI3506 and plastics passing co mpat ibility tests (i e, 
polypropylene and po lycarbonate syringes) have been observed.
MEDI3506 and placebo do not contain preservatives and any unused portion must be 
discarded. Preparation of study  intervent ion is to be perform ed asept ically. Total in use 
storage time from needle puncture of the study  intervent ion vial to start of administration 
shoul d not exceed 4 hours at room temperature or 24 hours at 2°C to 8°C (36°F to 46°F). If 
storage time exceeds these limits, a new dose m ust be prepared fro m new vials assigned by  the 
RTSM.
A vial should be used only one t ime to prepare a single dose.
To prepare the participant’s dose, the unblinded study  intervent ion manager will select study  
intervent ion for administration acco rding to the kit identificat ion numbers assigned. A 
summary of the study  intervent ion volumes requi red and sy ringes to prepare for SC dose 
administration in each treatment group is provided ( Table 6).
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 52of 134Table 6 Study Intervention Dose Preparation
Contents of 
Vial(s)Number of KitsVolume 
RequiredSyringes to 
PrepareSize of 
SyringeTotal Volume of 
Study 
Intervention
mg MEDI3506 Treatment Group 
MEDI3506
mg MEDI3506 Treatment Group a
MEDI3506
Placebo
Placebo Treatment Group
Placebo
aDo not mix MEDI3506 and placebo in the same syringe.
The dose preparation steps are, as fo llows:
1Prepare the assigned MEDI3506 and/or placebo vials for the particular treatment group as 
per Table 6.
2Withdraw the required vo lume of MEDI3506 or placebo from each vial using a separate, 
appropriately  sized sy ringe and a separate 18 to20-gauge 1 to1.5inch needle, 
respectively .
3Remove the 18 -20-gauge needle. Replace wit h a capped 27 -gauge 0.5 inch needle unt il 
administration.
6.2.2.1 Treatment Administration
The first day  of dosing is considered Day 1 (SV4).
Female participants of childbearing potential, must have a negat ive urine pregnancy test prior 
to receiving ea ch dose of study  intervent ion.
MEDI3506 and placebo are not ident ical in appearance or viscosit y. The sy ringes shoul d be 
kept out of sight of all blinded persons, including the participant, to maintain the blind. Study  
intervent ion will be administered SC by unblinded site personnel via a 27 gauge 0.5 inch 
needle to the abdo men, back of the arms, or thigh. The 2 inject ions should be approximately 
1inch (2.5 cm) apart in the same anatomical regio n. The unblinded site personnel 
administering the dose will wi pe the skin surface of the administration sites with alcohol and 
allow the skin surface to air dry . The skin will be pinched to iso late the SC tissue fro m the 
muscle. The needle will be fully inserted at a 45 degree angle into the SC tissue. The study 
intervention will be slowly injected (at least 5 seconds’ duration is recommended). The area 
shoul d not be m assaged after inject ion.
CC
I
C
C
CCI
CCI
CCI
CCI
CCI
C
C
CCI
CCI
CCI
C
C
CCI
CCI
CCI
CCI
C
C
CCI
CCI
CCI
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 53of 134It is advised that the site of inject ion be rotated so that the participant receives inject ions of 
study  interventi on in differ ent anatomical regions from one visit to the next. In cases when 
rotati on of  the inject ion site is not feasible and/or the participant prefers not to rotate inject ion 
sites, the reason for not rotating the inject ion site should be documented in the source 
docum ents.
At each administration the time of the first injection and anatomical regio n used for both 
inject ions must be documented in the source documents.
6.2.2.2 Monitoring Dose Administration
After the administration of study  interventi on, vi tal si gns will  be assessed according to the 
SOA, and SC inject ion sites will be assessed for inject ion site reactions (Section 8.2.2 ) by the 
blinded study  team . Parti cipants should be monitored for a minimum o f one to 2 hours after 
administration of study  intervent ion (see Section 8.2.3 ).
As wi th any biologic product, allergic react ions to dose administration are possible. Therefore, 
appropriate drugs and medical equipment to treat acute anaphylact ic react ions must be 
immediately  available, and study  personnel must be trained to recognise a nd treat anaphylaxis 
(Appen dixH).
6.2.3 Accountability 
The site’s designated unblinded study  interventi on manager is requi red to m aintain accurate 
study  interventi on accountabilit y records. Upon complet ion of the study , copies of study  
intervent ion accountabilit y records will be returned to AstraZeneca. All unused study  
intervent ion will be disposed of fo llowing si te procedures and upon authorizat ion by 
AstraZeneca, or will be returned to an AstraZeneca -authori sed depot if a site is unable to 
dispose of unused study  intervent ion.
6.3 Measures to Minimise Bias: Randomisation and Blinding
6.3.1 Methods for Assigning Treatment Groups
All participants will be centrally a ssigned to randomised study  interventi on using an RTSM. 
The rando misat ion will  be stratified according to sub -study  parti cipat ion. Before each site is 
initiated, the log in informat ion and di rections for the RTSM will be provided. The RTSM will 
provi de to the investigator(s) or pharmacists the kit identificat ion numbers to be allocated to 
the participant at the dispensing visit. Routines for this will be described in the RTSM user 
manual that will be provided to each centre.
Study  intervent ion will be dispe nsed at the study  visits summarised in SOA or per SOC after 
data cut off.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 54of 1346.3.2 Methods to Ensure Blinding
This is a double -blinded study  in which MEDI3506 and placebo are not ident ical in 
appearance or viscosit y. Neither the parti cipant nor any  of the invest igator or sponsor staff 
who are invo lved in the treatment or clinical evaluation of the participants will be aware of the 
treatm ent received (ICH E9). Since MEDI3506 and placebo are not ident ical, study  
intervent ion will be handled by an unblinded study inter vention manager at the site and will be 
administered by  an unblinded study  team  member who will not be invo lved in the 
management of study  participants. An independent study  intervent ion monitor will  also be 
unblinded to perform study  intervent ion accounta bility. In the event that the treatment 
allocat ion for a parti cipant beco mes known to the investigator or other study staff invo lved in 
the management of study  parti cipants, AstraZeneca must be notified immediately . If the 
treatm ent allocation for a partic ipant needs to be known to treat an individual part icipant for 
an AE (Secti on6.3.3 ), the investigator must notify AstraZeneca immediately . The si te will 
maintain a written plan detailing which staff members are blinded/unblinded and the process 
of study  intervent ion preparation and administration used to maintain the blind.
MEDI3506 could reduce eosinophil counts in blood over time. As a precaution, eo sinophil, 
basophil, and monocy te data from  the haematol ogy laboratory  tests ( Table 7) will  not be 
communicated to blinded sponsor or site personnel durin g the treatm ent and follow -up 
periods.
To facilitate the in -stream  analysis of PK and ADA samples, the randomisat ion schedule may 
be provided to limited personnel who have responsibilit y for analysing the samples. These 
unblinded sample analysts will not h ave any other invo lvement with the conduct of the study .
6.3.3 Methods for Unblinding
The rando misat ion code should not be broken except in medical emergencies when the 
appropriate management of the participant requires knowledge of the treatment randomisation. 
The invest igator documents and reports the action to AstraZeneca, without revealing the 
treatm ent given to participant to the AstraZeneca staff.
AstraZeneca retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to a study  interventi on and that potentially require expedited 
reporting to regulatory  authori ties. Randomisat ion codes will not be broken for the planned 
analyses o f data until all decisio ns on the evaluabilit y of the data from  each individual 
participant have been made and documented.
The RTSM will be programmed wit h blind -breaking instructions. In case of an emergency, in 
which the knowledge of the specific blinded study  treatm ent will affect the immediate 
management of the participant’s condit ion(eg, antidote available), the invest igator has the 
sole responsibilit y for determining if unblinding of a participants’ intervent ion assignment is 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 55of 134warranted. Participant safet y must al ways be the first considerat ion in making such a 
determinat ion. If a pa rticipant’s intervent ion assignment is unblinded, the sponsor must be 
notified wit hin 24 hours after breaking the blind. The invest igator documents and reports the 
action to AstraZeneca, wi thout revealing the treatment given to participant to the AstraZene ca 
staff.
If unblinding is required by the DSMB (Appendix A 4), details o f the methods for unblinding 
(sponsor will remain blinded) will be provided i n a separate DSMB charter.
The primary  analysis (Secti on9.1) will be performed after all part icipants have co mpleted the 
SV10 (Week 16) assessments or have withdrawn from the study . The sponsor staff will be 
fully unblinded fo llowing the Primary  Analysis Clinical Data Lock. 
Invest igators, participants and site st aff will not be made aware of unblinded treatment 
assignments for individual part icipants who are in the fo llow-up peri od until these participants 
have co mpleted the study .
6.4 Study Intervention Compliance
When the individual dose for a participant is prepare d fro m a bulk supply, the preparation of 
the dose will be confirmed by  a second m ember of the unblinded study  site staff. 
Parti cipants will receive study  intervent ion from unblinded study  site personnel , under 
medical supervisio n. The date, and time if ap plicable, of each dose administered (first 
inject ion) in the clinic will be recorded in the source documents and recorded in the eCRF.
6.5 Concomitant Therapy
The invest igator must be informed as soon as possible about any medicat ion taken from the 
time of scr eening until the final study  visit. Any conco mitant m edicat ion(s), including herbal 
preparati ons, taken during the study  will be recorded in the eCRF, along wit h:
Reason for use.
Dates of administration including start and end dates.
Dosage information inc luding dose and frequency.
The m edical  monitor shoul d be contacted if there are any  questi ons regarding concomitant or 
prior therapy .
Parti cipants are prohibi ted from receiving certain concomitant medicat ions (described in 
Secti on6.5.4 ) unless clinically indicated as determined by a physician.
Other than the permitted medicat ions described in the current section, use of conco mitant 
medicat ions or ther apies from screening through to the early  discontinuat ion visit/end o f study  
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 56of 134is discouraged (except where medically necessary). Medicat ions or therapies that are not 
prohibited and neit her compro mise participant safety nor affect study data, as judged by t he 
investigator, will be permitted and recorded in the appropriate sections of the eCRF.
6.5.1 Rescue Medicine
Systemic corti costeroi d therapy  may be used in the case of asthma exacerbat ion during the 
study . Although the use of rescue medicat ions is allowable atany t ime during the study , the 
use of rescue medicat ions should be delayed, if possible, for at least 2 hours following the 
administration of study  intervent ion. The date and time of rescue medicat ion administration as 
well as the name and dosage regimen of the rescue medicat ion must be recorded.
6.5.2 Required Medications
Parti cipants shoul d continue to use the following medicat ions at stable dose and regimen 
throughout the study , with the except ion of medication withho ld periods described in 
Secti on6.5.3 :
Medium -to-high dose ICS.
LABA.
Any addit ional asthma controller therapies in use at time of screening eg, LAMA, LTRA, 
theophylline.
6.5.3 Medication Withhold Periods
Prior to Scheduled Spirometry, AO, and FeNO Measurement
Parti cipants shoul d withhol d the foll owing m edicatio ns for the specified times prior to 
scheduled spiro metry, AO, and FeNO measurement at site:
SABAs and short -acting muscarinic antagonists for at least 6 hours. In the case of 
spirometry and AO post administration of study  intervent ion, SABA should be withheld 
following post -BD spiro metry.
Twice daily LABA and/or LAMA -containing therapies for at least 12 hours.
Once daily  LABA and/or LAMA -containing therapi es for at l east 24 hours.
LTRA for at least 24 hours.
Twice daily theophylline for at least 12 hours.
Once daily  theophylline for at l east 24 hours.
Note: for visits where in- clinic spiro metry is performed post -administration of study 
intervention, the medicat ions shoul d be wi thheld unt il all spirometry assessments are 
complete.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 57of 134Addit ionally , partici pants shoul d withhol d all BD medicat ions for 4 hours prior to at -home 
spirometry assessments, where possible.
6.5.4 Prohibited Medications
The inclusi on and exclusio n criteria secti ons of  the protocol  define conco mitant medicat ions 
that, if taken in the period prior to randomisat ion, woul d lead to parti cipant screen failure.
In addit ion, unless clinically indicated as determined by  a physician , parti cipants are not 
permitted to receive any o f the following (for the time periods stated):
Any immunosuppressive or immuno modulator therapi es (other than corticosteroids): not 
allowed 12 weeks prior to randomisat ion, during screening and unt il at least Week 16,
unless there is a medical need as judged by  the investi gator.
Any immunotherapy  including allergen immunotherapy : not all owed 12 weeks pri or to 
rando misat ion, during screening and unt il at least Week 16, unl ess there i s a medical need 
as judged by  the inv estigator.
Immunoglobulin therapy  including (IFN -γ) or blood products: not allowed 30 days prior 
to SV1, during screening and unt il at least Week 16, unl ess there i s a m edical  need as 
judged by  the invest igator.
Live or attenuated vaccines: not allowed 30 days pri or to the date of rando misat ion, and 
during the study  including the fo llow-up peri od. (Note: Vaccines with adenoviral vectors 
that are unable to replicate, eg, ChAdOx1, are not considered live attenuated).
Vaccinat ion against COVID -19 (either first or subsequent dose) within 30 days before 
rando misat ion or wi thin 7 days before or after any  dose of study  intervent ion.
Study  intervent ions other than MEDI3506 or placebo are not allowed in the screening 
period to f ollow -up peri od incl usive.
Marketed bio logics are not allowed in the screening period to follow- up period inclusive.
Long -acting beta -agoni sts as a reliever (eg, Symbicort Maintenance and Reliever 
Treatment): not allowed 15 days prior to SV1, during screening and unt il at least 
Week 16, unl ess there is a medical need as judged by  the investi gator.
Suplatast tosilate (T2 cy tokine inhibitor): not allo wed wi thin 15 days prior to SV1, during 
screening and until at least Week 16, unless there is a medical need as judged by  the 
investigator.
The acti vity of cy tochrom e P450 (CYP450) enzymes can be altered by increased levels o f 
certain cy tokines (eg, IL -1, IL -6, IL -10, TNFα, IFN) during chronic inflammat ion 
(Huang et al 2010 ). Thus, MEDI3506, through its downstream mechanism o f action, has the 
potenti al to normalise the form ation of CYP450 enzymes indirect ly, through the alteration of 
local and systemic cy tokine l evels. However, a rol e for IL -33 in th e regulation o f CYP450 
enzymes has not been reported. As a precaution, upon init iation or di scont inuat ion of 
MEDI3506, in patients who are receiving conco mitant drugs that have a narrow therapeutic 
Clinical Study Pro tocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 58of 134index and are CYP450 substrates (eg, warfarin), the invest igator should consider whether 
(increased) monitoring is indicated.
6.5.5 COVID-19 Vaccination
If and when a participant receives a COVID -19 vaccinat ion, the fo llowing informat ion (if 
available) should be recorded in the patient’s notes:
Brand name (or alternat ively name of manufacturer)
Date of administration
Whether dose was first or second dose
Anatomical site/regio n of administration (eg, left deltoid)
Lot number
Details o f how thi s informat ion should be entered into the eCRF will be provided in sep arate 
guidelines.
Any AEs suspected to be due to the vaccinat ion shoul d be captured in the AE form including 
the causalit y assessment related to COVID -19 vaccine.
6.6 Dose Modification
Not applicable.
6.7 Intervention after the End of the Study
Not applicable.
7 DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL
7.1 Discontinuation of Study Intervention
It may be necessary  for a parti cipant to perm anent ly discont inue (definit ive discontinuation) 
study  interventi on. Note that di scont inuat ion from study  interventi on is NOT the sam e thing 
as a wi thdrawal  from the study .
An individual participant will not receive any further study  intervent ion if any o f the 
following occur in the participant in question:
1Withdrawal o f consent to further treatm ent wi th study  intervent ion.
2Lost to follow -up.
3Any anaphylact ic react ion to study  intervent ion requiring epinephrine administration.
4Any SAE of ≥ Grade 4 severit y (see Appendix B2).
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 59of 1345Any SAE that is in the Cardiac Disorders system organ class.
6Confirmed diagnosis of new onset of heart failure and/or progression o f heart failure 
during the study , regardless of severit y. For a partici pant wi th a suspected new onset of 
heart failure and/or progression of heart failure, the participant will discont inue and 
shoul d not be administered study  intervent ion unle ss and unt il agreed by the investigator 
and medical mo nitor that study  intervent ion may continue to be administered unt il the 
diagnosis is confirmed or refuted.
7Any other AE that, in the opinio n of the invest igator or the sponsor, warrants 
discontinuat ion of further dosing of study  interventio n.
8Pregnancy.
9Following rando misat ion, the participant meets ≥1 of the exclusio ncriteria (Secti on5.2) 
or fails to meet all o f the inclusio n criteria (Secti on5.1) for study participation, unless the 
PI and m edical mo nitor agree the participant may  continue receiving study  intervent ion.
10The parti cipant misses consecut ive doses.
11Following rando misat ion, receipt of prohibite d medi cation (Section 6.5.4 ).
If study  intervent ion is permanently discont inued, the participant will remain in the study  to be 
evaluated for assessments at end of t reatment and during follow-up, including fo llow-up of  
any AEs unless consent is wit hdrawn from further study participation, the participant is lost to 
follow-up, or the participant is enro lled in another clinical study .
See the SOA ( Table 2) for data to be collected at the time of E/D and follow -up, and for any  
further evaluat ions that need to be completed.
7.1.1 Missed doses
A participant not attending for a scheduled dose can continue study  intervent ion at the next 
scheduled visit.  Refer to Section 2.3.1.2 for informat ion on dealing with missed doses as a 
resul t of the COVID -19 pandemic.
7.2 Participant Withdrawal from the Study
A participant may withdraw fro m the study  at any  time at hi s/her own request, or may  be 
withdrawn at any  time at the di screti on of  the investi gator for safet y, behavioural, 
compliance , or administrative reasons. This is expected to be unco mmo n.
A participant who considers wit hdrawing fro m the study  must be informed by  the 
investigator about modified fo llow-up opti ons (eg, telephone contact, a contact with a 
relative or treating physici an, or information fro m medical records).
At the time of withdrawal fro m the study , if possible, an E/D visit should be conducted, as 
shown in the SOA (Table 2). See SOA for data to be co llected at the time of study  
withdrawal  and follow-up and for any  further evaluati ons that need to be completed.
C
C
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 60of 134The parti cipant will discont inue the study  interventio n and be wit hdrawn from the 
study  at that time.
If the participant wi thdraws consent for disclosure of future informat ion, the sponsor may  
retain and cont inue to use any data collected before such a withdrawal o f consent.
If a participant withdraws fro m the study , it shoul d be confirmed if he/she st ill agrees for 
exist ing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any samples taken and not tested should be 
carried in line wit h what was stated in the ICF and local regulation. The invest igator must 
docum ent the decisio n on use of exist ing samples in the site study records and inform the 
Global Study  Team .
7.3 Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and i s unable to be contacted by  the study  site.
The fo llowing acti ons m ust be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance o f maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study .
Before a participant is deemed lost to fo llow-up, the invest igator or desi gnee must make 
every effort to regain contact with the participant (where possible, 3 telephone calls and, 
if necessary , a certified l etter to the parti cipant’s last known mailing address or local 
equivalent m ethods). These contact attempts shou ld be documented in the participant’s 
medical record.
8 STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures and their timing are summarised in the SOA ( Table 1and Table 2). 
Protocol waivers or exempt ions are not allowed.
Immediate safet y concerns should be discussed wit h the sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in the SOA, is 
essent ial and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential 
participants m eet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all participants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 61of 134Procedures conducted as part of the participant’s routine clinical management (eg, 
methacho line challenge results) and obtained before signing of the ICF may be utilised 
for screening or baseline purposes provided the proc edures met the protocol -specified 
criteria and were performed within the t ime frame defined in the SOA. This excludes all 
central  laboratory  assessments, eosinophil counts and NT -proBNP, which need to be 
perform ed centrally .
8.1 Efficacy Assessments
8.1.1 In-clinic Spirometry
8.1.1.1 General requirements
Lung funct ion parameters including, but not limited to, FEV 1 and FVC, will be measured by 
spirometry using equipment provided by  a central  vendor. Spi rometry will be performed by  
the Invest igator or authorised delegate acco rding to ATS/ERS guidelines ( Miller et al 2005 ).
The vendor providing central spiro metry is responsible for assuring that the spiro meter meets 
ATS/ERS re commendations and that the study site personnel who will be performing the 
testing are properly  certified. Spi rometry calibrat ion will be detailed in a separate vendor 
manual.
Parti cipants shoul d follow the rel evant m edicat ion and other restrict ions before hand 
(Secti ons6.5.3 and5.3). If any o f the specified restrict ions are not met, and the assessment 
cannot be sufficient ly delayed on the day , the assessment should be rescheduled wit hin the 
allowed visit window.
Time of day for scheduled in- clinic spirometry
Spirometry will be performed at specifi ed visi ts as detailed in the SOA ( Table 1and Table 2). 
For all participants, spirometry  testing m ust be ini tiated between 6:00 AM and 11:00 AM 
during the screening or re -screening period, and rando misat ion visit (SV4).
If possible, all post -randomisat ion spirometry  assessments should be performed within 
±1.5hours of the time that the randomisat ion spirometry  was performed. For example, if the 
rando misat ion spirometry  was started at 8:00 AM, then all subsequent spiro metry testing 
needs to be init iated between 6:30AM and 9:30 AM.
Spirometry techniq ue
Detailed procedure for performing spiro metry will be described in a separate spirometry  
procedures manual. Details regarding assessment of the qualit y of spirometry and the BTR 
process will also be detailed in the manual.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 63of 134The highest technically acceptable pre- and post -BD FEV 1will be used to determine 
reversibilit y.
Reversibilit y is calculated as fo llows:
FEV 1% Reversibility = (post -BD FEV 1-pre-BD FEV 1)/pre- BD FEV 1× 100
Full details will be included in the vendor manual.
Record keeping
A signed and dated copy  of the pre -and post -BD printout must be kept at study  sites for 
source data verificat ion. The printout must be marked with the study  code, enrolment code, 
date and time of measurement, visit number. If a printout cannot be printed, the mean value o f 
the measurements will be recorded in the participant’s charts. 
8.1.2 At-home Spirometry
During the study  period, parti cipants will be required to monitor lung funct ion at hom e twice 
daily  using an at -home spiro metry device. Parti cipants shoul d follow the rel evant m edicat ion 
and other restrict ions beforehand (Section 5.3.2 and Secti on6.5.3 ). Further details will be 
provi ded in a separate instruction manual.
8.1.3 Airwave Oscillometry
Airwave oscillo metry  will be perform ed at specified visits as detailed in the SOA ( Table 1and 
Table 2). Airwave oscillo metry  is a non -invasive lung funct ion test i ncluded in this study  to 
evaluate treatment effect on small airway physio logy. By measuring participant’s airflow and 
response to sound waves, frequency -dependent resistance and reactance will be calculated by  
the AO system so ftware.
A calibrated sy stem  will be used for AO measurements (equipment to be provided by vendor). 
Detailed procedures for performing, recording and analysing AO data will be described in a 
separate manual. Details regarding assessment of the qualit y of AO and the BTR process will 
also be detailed in the manual and in the Monitoring plan. Prior to scheduling an d performing 
AO assessments, the following should be observed:
Parti cipants shoul d perform  AO pri or to pre -BD spirometry assessments if both tests are 
to be performed on the same visit.
Parti cipants shoul d observe the rel evant lifest yle restrict ions (see S ection5.3) prior to AO 
assessments.
Parti cipants shoul d observe the m edicat ion withhold peri ods (see Secti on6.5.3 ) prior to 
AO assessments.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 64of 134If any o f the above restri ctions are not met, and the assessment cannot be sufficient ly delayed 
on the day , the asses sment shoul d be rescheduled within the allowed visit window ( Table 2).
A signed and dated copy  of the resul ts printout from  the equipment m ust be kept at the study  
site for source data verificat ion. The printout must be marked with the study  code, SID, date 
and time o f measurement, and visit number. A number of parameters including (but not 
limited to) R5, R20 and AX for each assessment will be recorded an d analysed. The AO 
assessment at SV6, SV7, SV8, SV9, and SV10 will be performed only  if the baseline visit AO 
is performed successfully, as judged by  the invest igator.
8.1.4 Fractional Exhaled Nitric Oxide
Airway  inflammat ion will be evaluated using a standardis ed single -breath FeNO test in 
accordance with the SOA ( Table 1and Table 2).A single exhalat ion technique reco mmended 
by the m anufacturer will be fo llowed ( Allakhverdi etal2007 ; Alving etal2017 ).
The FeNO test will be performed prior to AO and spiro metry. Parti cipants shoul d follow the 
relevant medicat ion and other restrict ions beforehand (Sections 6.5.3 and 5.3). If any of the 
above restri ctions are not met, and the assessment cannot be sufficient ly delayed on the day  
the assessment should be rescheduled wit hin the allowed visit window.
The NIOX VERO® Airway Inflammat ion Monitor will be used to measure FeNO . 
Instructi ons for use of this monitor will be provided in a separate user’s manual.
NIOX VERO® sensors will be replaced as recommended by the manufacturer. The vendor 
supplying the equipment will be responsible for ensuring that the equipment and procedures 
for the m easurement of FeNO are validated prior to the start of the study . 
If possible, all post -randomisat ion FeNO assessments should be performed within ± 1.5 hours 
of the time that the randomisat ion FeNO was perform ed.
8.1.5 Asthma Exacerbations
Definition of Asthma Exacerbation
During the study , an asthma exacerbat ion will be defined as a change in the participant’s usual 
asthma symptoms that leads to any  of the fo llowing:
a.A tem porary  bolus/burst of systemic corticosteroids (or a temporary  increase in stable 
OCS back ground dose) for at least 3 consecut ive days to treat symptoms o f asthma 
worsening; a single depo -injectable dose of corticosteroids will be considered equivalent 
to a 3 -day bo lus/burst of systemic corticosteroids.
b.An emergency  room  or urgent care visit (d efined as evaluat ion and treatment for 
< 24 hours in an emergency department or urgent care centre) due to asthma that required 
systemic corticosteroids (as per the above).
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 65of 134c.An in-patient hospi talisati on (defined as admissio n to an inpatient facilit y and/or
evaluat ion and treatment in a healt hcare facilit y for ≥ 24 hours).
A hospi talised asthma exacerbation is defined as any  worsening of asthma that l eads to ( c.) 
above .
Note: for each exacerbat ion, the criterion/criteria met to confirm exacerbat ion status should be 
docum ented.
Assessment and Documentation of an Asthma Exacerbation
The list below defines what is acceptable documentation for historical exacerbat ions.
Discharge summaries from a hospital, emergency room, or an urgent care facilit y 
indicat ing that a participant was hospitalised/treated with systemic corticosteroids for an 
asthma exacerbation.
Signed and dated notes from a referring physicia n, including information regarding 
diagnosis and treatm ent of an exacerbation with systemic corticosteroids.
Evidence of prescriptions for sy stemic corti costeroids used during an exacerbat ion.
A docum ented conversat ion between the Invest igator (or delegate ) and a parti cipant who 
is already  on an OCS act ion plan, including the inform ation necessary  to assess Inclusio n 
Criterion 19 . 
A docum ented conversat ion between th e treating/referral physician or nurse/nurse 
practi tioner certifying that a participant was treated for an exacerbation wit h 
corticosteroi ds at thei r clinic or under their supervision. The dates (month/year) of the 
exacerbations and verbal confirmat ion tha t appropriate prescriptions were provided is 
necessary . This opti on shoul d be used only if reasonable attempts to procure participant 
records have been unsuccessful.
The gui dance below defines assessment of asthma exacerbations.
The start of an exacerbat ion is defined as the earliest of the fo llowing:
Start date of systemic corticosteroids or temporary  increase in a stable OCS 
background dose.
Date of emergency room or urgent care visits requiring systemic corticosteroids.
Date of hospital admiss ion due to asthma.
The end date of an exacerbat ion is defined as the latest of the fo llowing:
Last date of systemic corticosteroids or temporary  increase in a stable OCS 
background dose.
Date of discharge from emergency room or urgent care visit.
Date of h ospital discharge.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 66of 134If less than 7 days have elapsed since the end date of an asthma exacerbation and the start 
date of a new asthma exacerbat ion, the second event will be considered a relapse of the 
prior asthm a exacerbat ion in the statist ical analysis.
All asthma exacerbat ions that occur during the treatment period and fo llow-up, m ust be 
recorded in the exacerbat ion eCRF. See Section 8.3.6 for addi tional information on 
recording asthma exacerbat ions as an AE/SAE during the study.
eDiary data and Exacerbations
Any sustained increase in asthma symptoms as reported via the eDiary  (that do not m eet the 
definit ion of criteria of an asthma exacerbation) will be graded as a worsening of asthma. 
Specifically: 
An increase in rescue medicat ion use of 4 or more puffs on at least 2 consecut ive days 
compared wi th the average use during baseline or use of 12 puffs/day  on any  one day , 
and/or
An addit ional nebulised β 2 agonist use on at least 2 consecutive days co mpared wit h the 
average use during baseline, and/or 
An increase of 2 or more nights with awakenings due to asthma requiring rescue 
medicat ion over a 7 -day period compared wit h the average during baseline, and /or
≥6 out of previous 7 nights with awakenings due to asthma requiring rescue medicat ion
Alerts to study  site will  be triggered for parti cipants who experience a drop in PEF ≥ 30% on 
2consecutive days.
If an asthma exacerbat ion event is not associated with at least one of the above eDiary  data 
deteri oration cri teria, the investi gator will have to justify  the decisi on for defining the event as 
an exacerbat ion and record it in the eCRF. Events that are not supported by  any objective 
assessment will be de emed not to be a protocol -defined exacerbat ion.
Parti cipants will be requi red to keep a record of their asthma symptoms in the eDiary  as per 
the SOA ( Table 1and Table 2). The data captured in the eDiary  will also be used to determine 
individuals Co mpEx events.
8.1.6 CompEx
Com pEx is a combinat ion of exacerbat ions of asthma and diary events (ie, combinat ion of 
eDiary vari ables). Com pEx is a composite surrogate endpo int for exacerbations of asthma, 
recent ly developed by AstraZeneca (it is not yet a regulatory- approved clinical endpo int). 
Diary events are defined by the thresho ld and slope criteria using the fo llowing 
morning/evening (AM/PM) diary  variables:
PEF
Symptom  score (0 –3)
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 67of 134Use of rescue medicat ion
Com pEx can predi ct treatm ent efficacy  on exacerbati ons in early develo pment before running 
traditional long-term exacerbat ion trials. Com pEx can be used broadly in the assessment of 
new therapeut ic intervent ions for asthm a (Fuhlbrigge et al 2017 ; note: the referenced 
publicat ion used the term ‘severe exacerbation’ but used the same definit ion as used for 
‘exacerbat ion’ in this protocol; therefore, the term ‘exacerbat ion’ has been used in this sect ion 
for internal  consistenc y of the protocol.)
8.1.7 VitaloJAK Cough Mo nitor ( Expl oratory Cough Sub -study Only )
Object ive cough frequency over 24 hours will be measured using an ACM (VitaloJAK™; 
Vitalograph, Buckinghamshire, UK) which will be fitted and worn by  the parti cipants for 
approx imately 24 hours after the visit s detailed in the SOA.
The sites will receive training to ensure the ACM is correctly  fitted and activated by  site staff, 
and the site staff will be given instructions to provide to the participants on how the ACM 
shoul d be worn during the 24 hour period to ensure data is recorded correctly.
The di gitally recorded data recorded on the ACM will be sent to Vitalograph who will 
undertake cough counting for all part icipants using a standardised process. Details on the 
process to follow will  be provi ded to the si tes as part of the ACM training.
Parti cipants will be m onitored f or 24 hours following SV2 and SV10, and set up of the cough 
monitors shoul d be perform ed as the final assessment at each of these visits.
Detailed procedures for set up of device, recording and analysing objective cough data will be 
described in a separate manual provided to each site. Details regarding assessment of the 
qualit y of object ive cough monitoring undertaken by the vendor will also be detailed in the
manual.
8.1.8 Participant Reported Outcome Questionnaires
Parti cipants will com plete the PRO questionnaires on an electronic device (Section 8.1.8.1 ) 
supplied to the site according to the SOA ( Table 1and Table 2). PRO questi onnai res to be 
completed at the si te visi ts must be com pleted pri or to treatm ent administrati on and ideally  
before any discussio ns of health status or other study  procedures, such as collect ion of 
laboratory  samples to avoi d biasing the parti cipant’ s responses to the questions. All 
within-window PRO assessments for the morning and evening assessments at home should be 
completed wi thin this set time window programmed into the device and will notify  the 
participant when i t is time to respond to the questions.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 68of 1348.1.8.1 Daily eDiary
During the study  period, parti cipants will be required to take their asthma controller therapy  
regul arly and co mplete an eDiary twice daily. 
At SV1, participants will receive a handheld eDiary device to complete twice -daily, daily and 
non-daily  PRO assessments during the study . Partici pants will  be provi ded training on the use 
of the handheld device. Daily  assessments will include night -time and day time asthma 
symptoms (m orning and evening diary , respect ively), use of inhaled rescue medicat ion in 
response to worsening symptoms, nights with awakenings due to asthma symptoms (morning 
diary only) and background medicat ion use. The PEF data (obtained fro m the home peak flow 
meter) will be captured at the conclusio n of the morning and evening eDiary  entry .
Daytime is defined as the time period between the morning lung funct ion assessment (upon 
rising in the morning) and the evening lung funct ion assessment. Night -time is defined as the 
time period between the evening lung funct ion assessment (at bedtime) and the morning lung 
funct ion assessment.
The number of doses of rescue medicat ion (1 dose unit = 1 puff on inhaler) taken will be 
recorded by  the parti cipan t in the eDiary twice daily. The number of inhalations taken 
between the morning and evening lung funct ion assessments will be recorded in the evening. 
The number of inhalations taken between the evening and morning lung funct ion assessments 
will be record ed in the morning.
Nocturnal  awakenings due to asthma symptoms will be recorded by  the parti cipant in the daily  
eDiary each m orning by answering the quest ion whether he/she woke up during the night due 
to asthm a symptom s by a “yes” or “no” response.
Backgr ound (inhaled ICS/LABA) medicat ion administrati on use will be recorded once daily 
in the daily  eDiary  as “yes” or “no” response. 
The eDiary  quest ions support the analysis of a novel endpo int called Co mpE x (Section 8.1.6 ).
8.1.8.2 Cough Visual Analogue S cale (Explo ratory Cough Sub -study Only)
Parti cipants will be asked to complete a cough severit y visual analogue scale (VAS; 100 mm 
linear scale marked with a h orizontal  line by  the parti cipant, wi th 0mm represent ing ‘‘no 
cough’’ and 100 mm representing “worst cough”) measuring subject ive assessment by the 
participant of the pri or 24 hours for severit y of cough symptom s (Smithetal2006 ).
8.1.8.3 Asthma Control Questionnaire -6
The ACQ ( Juniper et al 1999 ) was develop ed to measure asthma control and has been fully 
validated for use in adults and children 6 to 17 y ears of  age. International guidelines for the 
treatm ent of asthma have ident ified that the primary clinical goal of asthma management is to 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 69of 134optimise asthma co ntrol (minimisation o f symptoms, activit y limitat ion, bronchoconstrict ion, 
and rescue BD use) and thus reduce the risk of life -threatening exacerbations and long -term 
morbidity. The ACQ was developed to meet these criteria by measuring both the adequacy  of
asthma control and change in asthma control, which occur either spontaneously or as a result 
of treatm ent.
In the ACQ- 6, parti cipants are asked to recall how their asthma has been during the previous 
week by responding to one BD use question and 5 symptom quest ions. Quest ions are 
weighted equally  and scored from 0 (totally  controlled) to 6 (severely uncontrolled). The 
mean ACQ -6 score is the m ean of the responses. Mean scores of ≤0.75 indicate 
well-controlled asthma, scores between 0.75 and ≤1.5 indicate partly controlled asthma, and 
scores > 1.5 indicate not well -controlled asthma ( Juniper et al 2006 ). Individual changes of at 
least 0.5 are considered clinically  meaningful .
The quest ionnaire will be co mpleted using the eDiary  in accordance wit h the SOA ( Table 1
and Table 2).
8.1.8.4 St George’s Respiratory Questionnaire
The SGRQ is a 50- item PRO instrum ent devel oped to m easure the healt h status of patients 
with airway obstructi on diseases ( Jones etal1991 ). The questi onnai re is divided into two 
parts: part one consists of 8 items pertaining to the severit y of respiratory  symptom s in the 
preceding 4 weeks; p art 2 consists of 42 items related to the daily  activity and psychosocial 
impacts of the individual’s respiratory  condi tion. The SGRQ yields a total score and three 
domain scores (symptom s, activit y, and impacts). The total score indicates the impact of 
disease on overall healt h status. This total score is expressed as a percentage of overall 
impairment, in which 100 represents the worst possible healt h status and 0 indicates the best 
possible healt h status. Likewise, the domain scores range from 0 to 100, with higher scores 
indicat ive of greater impairment.
Specific details on the scoring algorithms are provided by the developer in a user manual 
(Jones and Forde 2009 ). The SGRQ will be co mpleted using the eDiary  in accordance with 
the SOA, and a 4 -week recall versio n will be used.
8.1.8.5 Sino -nasal Outcome Test -22
The SNOT -22 is a condi tion-specific healt h-related quali ty of life assessment, which captures 
participant-reported physical problems, funct ional limitations, and emotional consequences of 
sinonasal condit ions (Hopkins etal2009 ; Piccirillo et al 2002 ). The SNOT -22 contains a list 
of 22 symptom s and soci al/em otional consequences of a parti cipant’s nasal  disorder, and 
measures how severe each symptom is and the social/emot ional consequences of symptoms 
over a 2 -week period on a scale fro m 0 (no problem) to 5 (problem as bad as it can be). The 
total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate 
poorer outcomes).
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 70of 134The SNOT -22 will be administered to participants who have co morbid chroni c inflammatory  
condi tions of the nasal mucosa and/or paranasal sinuses (CRS) on the eDiary  according to the 
SOA (Table 1and Table 2).
8.1.8.6 Patient Global Impression of Benefit/Risk 
The patient global impressio n of benefit/risk is a 5 -item questi onnai re assessing the 
participant’s perception of the overall benefits and risks o f treatm ent. The 5 items assess: 
overall tri al experi ence, efficacy , side effects, convenience and overall assessment of the 
benefits and har ms of treatment. Items are rated on  5-or 6-point verbal rat ing scales.
8.1.8.7 Study Participant Feedback Questionnaire
This study  will include an opti on for parti cipants to complete an anonymised questionnaire, 
‘Study  Parti cipant Feedback Questionnaire’ for part icipants to provide feedback on their 
clinical trial experience. Individual part icipant level responses will not be reviewed by 
inves tigators. Responses will be used by the sponsor to understand where improvements can 
be made in the clinical trial process. This quest ionnaire does not collect data about the 
participant’s disease, symptoms, treatment effect or adverse events and therefore would not be 
study  data.
8.2 Safety Assessments
Planned time po ints for all safet y assessments are provided in the SOA ( Table 1and Table 2).
8.2.1 Medical, Surgical, and Asthma Hi story
Com plete m edical and surgical history  will include history  of COVID -19, pri or and current 
medical condit ions, past or current cardiovascular disorders, respiratory , gastrointestinal, 
renal, hepat ic, neuro logical, endocrine, lymphat ic, haematologic, i mmuno logic, psychiatri c, 
genitourinary , drug and surgi cal history  (including COVID -19 vaccinat ion), or any  other 
diseases, di sorders, or surgical procedures.
The parti cipant’s asthma history  will also be collected and will include quest ions related to the 
participant’s asthma history , durati on of  asthma, and asthma medicat ions (both past and 
current).
8.2.2 Physical Exa minations, Weight, and Height
Com plete and bri ef physical examinat ions will be performed by  a licensed heal thcare 
provi der (eg, phy sician, physici an’s assistant, or licensed nurse practit ioner).
A co mplete physical examinat ion will include, but will not be limited to, assessment of 
general appearance, head, ears, eyes, nose, throat, neck, skin, as well as cardiovascular, 
respi ratory , abdo minal, and nervous systems.
A brief physical examinat ion will include, at a minimum, assessments of cardiovascular, 
respi ratory , and nervous systems. Each clinically  significant abnorm al finding will be 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 71of 134recorded in the medical history , and each treatment emergent abn ormality, incl uding 
inject ion site reactions ident ified by assessing SC inject ion sites, will be recorded as an 
AE.
Physical examinat ions, weight and height will be recorded at timepo ints specified in the 
SOA ( Table 1and Table 2).
8.2.3 Vital Signs
The no minal timing of vital signs, ECGs, and blood draws is described in the SOA ( Table 1
and Table 2). The participant should be in a rest ing supine posit ion for at least 10 minutes 
prior to the collect ion of vital signs, as fo llows:
Oral or tympanic tem perature.
DBP.
SBP.
Heart (pulse) rate.
Respiratory  rate.
For the first  doses of study  intervent ion, participants are to rem ain at the si te for ≥2 hours or 
until stable, whichever is later. In addit ion, vital signs will be taken before and immediately 
after administrati on of  study  intervent ion, and at 30, 60, and 120 minutes (± 5 minutes) 
thereafter or u ntil stable, whichever is later. For the final doses of study  interventi on, 
participants are to remain at the site for ≥ 1 hour or until stable, whichever is later. In addit ion, 
vital signs will be taken before and immediately after administration of stu dy intervent ion, and 
at 30 and 60 minutes (± 5 minutes) thereafter. Following the observation period, participant 
discharge will be at the discretion of the invest igator.
8.2.4 Electrocardiograms
The no minal timing of vital signs, ECGs, and blood draws is descri bed in the SOA ( Table 1
and Table 2). The parti cipant should be in a rest ing supine posit ion for at least 10 minutes 
prior to the collect ion of ECGs. At baseline, pre- dose of study  intervent ion at SV4 
(randomisat ion), tri plicate ECGs will be performed (all 3 ECGs within a 5-minute time period, 
at least 1 minute apart). The mean value of each parameter from the triplicate will be used as 
the baseline value. ECGs taken at all other times will be single assessments.
Electrocardiograms will be recorded with 12 -lead di gital ECG devices at a speed of 
25mm/second wi th ampli tude recording of 10 mm/m V. Where possible the same make and 
model ECG device shoul d be used for recording all ECGs for a particular participant. At least 
3 full complexes must be recorded. Date and time settings should be checked regularly a nd 
following t ime changes for daylight savings time. Skin preparation should be thorough and 
electrode posi tions shoul d be according to standard 12 -lead ECG placements.
C
C
C
C
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 72of 134Electrocardiogram device so ftware will be used to assess ECG parameters. All ECGs must be 
reviewed by  the PI or a qualified designee before the participant is permitted to leave the 
clinic. Abnormalit ies and obvious changes in ECG parameters from baseline will be assessed 
by the PI for clinical significance.
Electrocardiogram variables will be collected as follows:
Heart (pulse) rate.
RR interval.
QRS interval.
PR interval.
QT interval.
8.2.5 Echocardiograms
A transthoracic echocardiogram to assess left ventricular eject ion fraction will be performed 
and read locally according to the SOA ( Table 1and Table 2).
8.2.6 SARS-Co V-2 Serology Testing
Parti cipants’ serum  will be tested for the presence of ant ibodies to the SARS -CoV -2 virus 
from blood drawn at the visits indicated in the SOA (Section 1.3).
8.2.7 Clinical Safety Laboratory Assessments
The no minal timing of vital signs, ECGs, and blood draws is described in the SOA ( Table 1
and Table 2). A l aboratory  manual will  be provi ded to the si tes that specifies the procedures 
for collect ion, processing, storage, and shipment of samples, as well as laboratory  contact 
inform ation, specific to this clinical research study. Clinical laboratory  safet y tests will be 
perform ed in a central  clinical laboratory  (note: during the screening period, for any  clinical  
laboratory  test where the result i s not avai lable from central laboratories prior to 
rando misat ion, a result from a local laboratory  may be an acceptable al ternat ive but the 
medical mo nitor must be consulted first). 
Urine pregnancy  tests m ay be perform ed at the si te using a licensed test (dipst ick). Clinically  
significant abnorm al laboratory  resul ts shoul d be repeated as soon as possible (preferably  
within 24 to 48 hours). 
All local laboratory  resul ts will  be recorded/filed in the source notes.
The l aboratory  variables listed in Table 7will be measured in this study .
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 73of 134Table 7 Laboratory Safety Variables
Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma)
WBC count with differential Potassium
RBC count Sodium
Haematocrit AST
Platelet count ALT
Haemoglobin ALP
Coagulation parameters (PT, INR, and aPTT) TBL (if result is > 1.5ULN, indirect and direct 
bilirubin will be measured)
GGT
Urinalysis (dipstick) Creatinine
Colour and appearance Blood urea nitrogen
Specific gravity Albumin
pH Total protein
Protein Uric acid
Microscopy including WBCs, RBCs, and casts.
Glucose
Ketones
Blood
Bilirubin
Leukocytes
Note for haematology : blinding procedures for eosinophil, basophil, and monocyte data are described in 
Section 6.3.2 .
Note for serum chemistry: Tests for AST, ALT, ALP, and TBL must be conducted concurrently and assessed 
concurrently.
ALP =alkaline phosphatase; ALT =alanine transaminase; aPTT =activated partial thromboplastin time; 
AST =aspartate transaminase; GGT =gamma glutamyl transferase; Ig =immunoglo bulin; INR =international 
normalised ratio; PT =prothrombin time; RBC =red blood cell; TBL =total bilirubin; ULN =upper limit of 
normal; WBC =white blood cell.
Note: In case a participant shows an AST orALT ≥ 3 × ULN together with TBL ≥ 2 × ULN 
please refer to Appendix E: ‘Act ions required in cases of increases in liver biochemistry  and 
evaluat ion of Hy’s Law’, for further instructions.
Pregnanc y Test
Serum  beta -human chorionic gonadotropin.
Urine human chorionic gonadotropin.
Other Safety Tests
FSH (if needed to confirm post -menopausal status in female participants aged < 50 years 
and not on HRT).
HbA1c.
Hepati tis B (HbsAg, ant i-HBs, and anti -HBc) and C ant ibodies.
HIV-1 and HIV -2 antibodies.
IGRA (TB test). See Exclusion Criterion 4.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 74of 134Serum  tryptase will only  be taken in the event of suspected anaphylaxis ( Appendix Gand 
Appendix H).
NT-proBNP.
SARS -CoV -2 PCR test.
8.3 Adverse Events and Serious Adverse Events
The PI is responsible for ensuring that all staff involved in the study  are f amiliar with the 
content of this sect ion.
The definit ions of an AE or SAE can be found in Appendix B.
Adverse events wil l be reported by  the parti cipant (or, when appropri ate, by  a caregiver, 
surrogate, or the participant's legally authorised representative).
The invest igator and any designees are responsible for detecting, document ing, and recording 
events that meet the de finition of an AE.
8.3.1 Time Period and Frequency for Collecting AE and SAE Information
Adverse events will be collected from signing of ICF throughout the treatment period and 
including the follow -up peri od. SAEs will be recorded fro m the time of signing of IC F.
If the invest igator becomes aware of an SAE with a suspected causal relat ionship to the study  
intervent ion that occurs after the end of the clinical study  in a parti cipant treated by  him or 
her, the invest igator shall report the SAE to the sponsor within 24 hours.
8.3.2 Follow- up of AEs and SAEs
Any AEs that are unresolved at SV12 in the study  are f ollowed up by the invest igator for as 
long as medically  indicated, but wi thout further recording in the eCRF. AstraZeneca retains 
the right to request addi tional information for any  parti cipant wi th ongoing AE(s)/SAE(s) at 
the end of the study , if judged necessary .
Adverse event variables
The fo llowing variables will be collected for each AE:
AE (verbat im).
The date and time when the AE started and stopped.
Severit y grade.
Whether the AE is serious or not.
Invest igator causalit y rating against the study  intervent ion (yes or no).
Action taken with regard to study  intervent ion.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 75of 134AE caused participant’s withdrawal fro m study  (yes or no).
Outcom e.
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for seri ous AE.
Date invest igator became aware of serious AE.
AE is seri ous due to.
Date of hospitalisat ion.
Date of discharge.
Probable cause of death.
Date of death.
Autopsy  performed.
Causalit y assessment in relat ion to study  procedure(s).
Causalit y assessment to other medicat ion.
8.3.3 Causality Collection
The invest igator should assess causal relationship between study intervention and each AE, 
andanswer ‘yes’ or ‘no’ to the question ‘Do you consi der that there is a reasonable possibilit y 
that the event may have been caused by  the study  intervent ion?’
For SAEs, causal relat ionship should also be assessed for other medicat ion and study  
procedures. Note that for SAEs that could be associated with any study  procedure the causal 
relationship is implied as ‘yes’.
A guide to the interpretation of the causalit y quest ion is found in Appendix B.
8.3.4 Disease Under study
The invest igator should report clinically significant worsening of asthma symptoms, including 
exacerbations, as an AE. Signs and symptoms consistent with a participant’s baseline asthma 
status will not be reported as an AE.
8.3.5 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by  the parti cipant or reported in response to the open question 
from the study  site staff: ‘Have y ou had any heal th probl ems since y ou were l ast asked?’ or 
revealed by  observati on will be co llected and recorded in the eCRF. When collecting AEs, the 
recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms. 
However, if a diagnosis is known and there are other signs or symptoms that are not generally 
part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately .
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 76of 1348.3.6 Adverse Events Based on Examinations and Tests
The results from the protocol -mandated laboratory tests and vital signs will be summarised in 
the CSR. Deterioration as compar ed to baseline in protocol -mandated laboratory  values, 
spirometry values and vital signs should therefore only  be reported as AEs if:
They  fulfil any  of the SAE cri teria, or
Are the reason for discont inuat ion of treatment with the study  interventi on, or
Are considered to be clinically  relevant as j udged by  the investi gator (whi ch may  include 
but not limited to considerat ion as to whether treatment or non -planned visit s were 
requi red or other acti on was taken with the study  treatm ent, eg, dose adj ustment or drug 
interrupti on).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting invest igator 
uses the clinical, rather than the laboratory  term  (eg, anaemia versus low haemoglo bin value). 
In the absence of clinical signs or symptoms, clinically relevant deteriorations in 
non-mandated parame ters shoul d be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE unless unequivocally 
related to the disease under study .
8.3.7 Adver se Events of Special Interest
Adverse events of special interest are events of scient ific and medical interest specific to 
understanding of MEDI3506 and may require close monitoring and rapid communicat ion by 
the invest igator to AstraZeneca. An AESI may be serious or non -serious. The rapi d reporting 
of AESIs allows ongoing surveillance of these events in order to characterise and understand 
them in associ ation with the use of MEDI3506.
The fo llowing AESIs will be particularly  monitored in this study :
Hepati c funct ion abnormalit y meet ing the definit ion of Hy’s Law as described in 
Secti on8.3.8 .
Serious hy persensi tivity (including Ty pe 1 to 4 hypersensit ivity react ions), for example 
anaphylaxis and severe allergic reactions, and immune co mplex disease.
Inject ion site reactions.
Cardi ac events (including angina or my ocardial  infarcti on, congestive heart failure, 
symptom atic atherosclerotic vascular disease, cor pulmo nale, or arrhy thmia).
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 77of 134Serious infect ions (including opportunist ic infect ions and viral react ivations), for example 
herpes simplex virus/varicella zoster virus, Epstein Barr virus/cyto megalo virus, TB, 
SARS -CoV -2 and all other opportunistic infect ions listed in the Guidelines for the 
Prevent ion and Treatment of Opportunist ic Infect ions in Adult s and Ado lescents with 
HIV ( NIH 2019 ).
Gastroin testinal  adverse events.
Malignancy .
8.3.8 Hy’s Law
Cases where a participant shows elevations in liver biochemistry  may requi re further 
evaluat ion and occurrences of AST or ALT ≥ 3×ULN together with total bilirubin 
≥ 2 × ULN may need to be reported as SAEs. Please refer to Appendix Efor further 
instructi on on cases of increases in liver biochemistry  and evaluat ion of HL.
8.3.9 Reporting of Serious Adverse Eve nts
All SAEs have to be reported, whether or not considered causally related to the study  
intervent ion, or to the study  procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study , then investi gators or other si te pers onnel inform 
the appropriate AstraZeneca representatives within one day  ie, immediately  but no later than 
24 hours of when he or she beco mes aware of it.
The designated AstraZeneca representative works with the invest igator to ensure that all the 
necessary informat ion is provided to the AstraZeneca Patient Safet y data entry  site within 
1calendar day of initial receipt for fatal and life -threatening events and within 5 calendar
days of initial receipt for all other SAEs.
For fatal  or life -threatening AEs wh ere important or relevant informat ion is missing, active 
follow-up is undertaken immediately . Invest igators or other site personnel inform AstraZeneca 
representatives of any  follow-up inform ation on a previously reported SAE within one 
calendar day  ie, imm ediately but no later than 24 hours of when he or she becom es aware of 
it.
For further guidance on the definit ion of an SAE, see Appendix B.
The re ference document for definit ion of expectedness/listedness for MEDI3506 is the IB. 
8.3.10 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca except if the 
pregnancy is discovered before the study  parti cipant has received any study  interventi on.
Clinic al Study  Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 78of 1348.3.10.1 Maternal Exposure
If a participant beco mes pregnant during the course of the study , study  intervent ion shoul d be 
discontinued immediately .
Pregnancy itself is not regarded as an AE unless there is a suspicio n that the study  intervent ion
may have interfered with the effect iveness of a contraceptive medicat ion. Congenital 
abnorm alities/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs. Elective abortions wit hout complicat ions should not be handled as AEs. Th e outcom e 
of all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy, normal 
birth or congenital ano maly) should be fo llowed up and docum ented even if the participant 
was discont inued from the study.
If any pregnancy  occurs in the course of the study , then the investigator or other site personnel 
informs the appropriate AstraZeneca representatives within one day  ie, immediately  but no 
later than 24 hours of when he or she becom es aware of i t.
The designated AstraZeneca representati ve works with the invest igator to ensure that all 
relevant informat ion is provided to the AstraZeneca Patient Safet y data entry  site wi thin one 
or 5 cal endar days for SAEs (see Section 8.3.9 ) and within 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
The PREGREP module in the eCRF is used to report the pregnancy.
8.3.10.2 Paternal Exposure 
Male parti cipants shoul d refrain from  fathering a child or donating sperm during the study  and 
for 12 weeks fo llowing the l ast dose of study  intervent ion.
Pregnancy of the participant’s partners is not considered to be an AE. However, the outcome 
of all pregnancies (spontan eous miscarri age, elect ive terminat ion, ectopic pregnancy, normal 
birth or congenital ano maly), occurring fro m the date of the first dose until the end of the
follow-up period (SV11 [Week 16]) or date of last contact should, if possible, be fo llowed up 
and docum ented in the Pregnancy Report Form. Consent from the partner must be obtained 
before the Pregnancy  Report Form  is completed.
8.3.11 Medication Error
If a medicat ion error occurs in the course of the study , then the investigator or other site 
personnel info rms the appropri ate AstraZeneca representatives within one day  ie, immediately 
but no l ater than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the invest igator to ensure that all 
relevant informat ion is completed wi thin one (Init ial Fatal/Life -Threatening or fo llow-up 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 79of 134Fatal /Life -Threatening) or 5 (other serious init ial and fo llow-up) cal endar days if there is an 
SAE associated with the medicat ion error and within 30 days for all other medicat ion errors.
The definit ion of a medicat ion error can be found in Appendix B. 
8.4 Overdose
An overdose is defined as a participant receiving a dose of study  intervention in excess of that 
specified in the IB, unless otherwise specified in this protocol.
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated symptoms is only reported on the Overdose eCRF 
module.
If an overdose on an AstraZeneca study  drug occurs in the course of the study , the invest igator 
or other si te personnel will inform appropriate AstraZeneca representatives immediately, but 
no later than 24 hours of when he or she beco mes aware of it.
The designated AstraZeneca representative works with the invest igator to ensure that all 
relevant informat ion is provided to the AstraZeneca Patient Safet y data entry  site wi thin 1 or 
5calendar days for overdoses associated with an SAE (see Section 8.3.9 ) and within 30 days 
for all other overdoses.
The designated sponsor representative wo rks with the invest igator to ensure that all relevant 
inform ation is provided to the sponsor's Patient Safet y data entry  site.
8.5 Human  Biological Sample Biomarkers
8.5.1 Human Biological Samples
Instructi ons for the collect ion and handling of bio logical samples will be provided in the study  
specific laboratory  manual. Sam ples shoul d be stored in a secure storage space with adequate 
measures to protect confident iality. For further details on handli ng of  human bi ological 
samples see Appendix C.
Samples will  be stored for a m aximum  of 15 y earsafter the end of the study in line wit h 
consent and local requi rements, after which they  will be destroy ed/repatri ated.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 80of 134PK samples will be disposed of after the Bioanaly tical Report finalizat ion or six months 
after issuance of the draft Bioanaly tical Report (whichever is earlier), unless consented 
for future analyses. 
PK samples may be disposed of or anonymised by pooling. Addit ional analyses may 
be conducted on the anonymised, pooled PK samples to further evaluate and validate 
the analy tical method. Any results from such analyses may  be reported separately
from the CSR.
Remaining ADA sample aliquots will be retained at AstraZeneca or its designee for a 
maximum o f 15 years after the end of the stud y. Addi tional use includes but i s not limited 
to further characteri sation of  any ADAs, confirmatio n and/or requa lificat ion of the assay  
as well as addit ional assay  devel opment work. The resul ts from future analysis will not be 
reported in the CSR.
8.5.2 Pharmacokinetics
Serum  samples will be co llected for measurement of serum concentrations of MEDI3506 
as specified in th e SOA ( Table 1and Table 2).
Samples may  be colle cted at addi tional time points during the study  if warranted and 
agreed upon between the invest igator and the sponsor eg, for safet y reasons. The timing 
of sampling may be altered during the course of the study  based on newly  available data 
(eg, to obtain data cl oser to the time of peak or trough matrix concentrations) to ensure 
appropriate monitoring. 
Samples will  be collected, l abelled, stored, and shipped as detailed in the laboratory  
manual.
Samples fro m participants who receive placebo may  be analysed at minimum selected 
time points to confirm no dosing with MEDI3506 took place.
8.5.2.1 Determination of Drug Concentration
The no minal timing of vital signs, ECGs, and blood draws is described in the SOA ( Table 1
and Table 2). The time of the first SC inject ion will be recorded for each participant as the 
timings will be required for analysing the PK data.
Serum  will be collected to evaluate the PK of MEDI3506 according to the SOA. MEDI3506 
concentration in serum will be measured utilizing a validated assay  method.
Instructi ons for sam ple collect ion, processing , storage, and shipment can be found in a 
separate laboratory  manual provi ded to si tes.
8.5.3 Immunogenicity Assessments
Blood sam ples f or determinat ion of ADA in serum will be assayed by bioanalyt ical test sites 
operated by  or on behalf o f AstraZeneca, using an appropriately  validated bi oanaly tical 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 81of 134method. Tiered analyses will be performed to include screening, confirmatory , and t itre assay  
components. Full details of the methods used will be described in a separate report.
ADA samples may also be further tested for characterisat ion of the ADA response, including 
possible assessment of neutralising ant ibody .
Samples will  be collected, l abelled, stored, and shipped as detailed in the laboratory  manual .
8.5.4 Pharmacodynamics
There are no established PD measures for MEDI 3506. For exploratory bio markers that may 
indicate a PD effect, see Section 8.5.5 .
8.5.5 Collection of Mandatory Samples for Biomarker Analysis
Samples for biomarker research are required and will be co llected fro m all part icipants in 
this study  as specified in the SOA ( Table 1and Table 2).
Samples include the following:
Nasal mucosal sampling. Nasal mucosa (for mRNA) is collected using a sterile, 
disposable nasal mucosal co llection device to curette a sam ple of nasal mucosa for 
analysis.
Nasal mucosal lining fluid. Nasal mucosal lining fluid is collected using the 
Nasosorpti on™ FX·i  device, which i s gent ly applied to the nasal mucosa to absorb 
mucosal lining fluid from mucosal surfaces.
Who le blood for RNA PAXgene. RNA PAXgene will be used for the collect ion, 
transport, and storage of who le blood, and the stabilizat ion of intracellular RNA. 
RNA transcript profiling analyses will be performed on RNA PAXgene samples.
Note: If nasal mucosal sampling for mRNA at SV4 (randomisat ion) is deemed by the 
investigator to have been challenging for individual participant tolerabilit y (eg, due to nasal 
polyps), subsequent nasal sampling may  be omi tted at the invest igator’s discretion.
Biological samples will be collected at specified visits as detailed in the SOA ( Table 1and 
Table 2):
Total  IgE (serum).
Allergen -specific IgE (serum).
EDN (pl asma).
sST2 (serum).
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 83of 134drawn at SV4, it may be taken at any  visit until  the last study  visit. Only one sample should be 
collected per participant for genetic s during the study .
For storage and destruction of genetic samples, see Appendix D.
8.7 Health Economics
Not applicable.
8.8 Impact of COVID -19 Pandemic
To assess the impact of the COVID -19 pandemic on the study , sites will  be asked to com plete 
the pandemic impact form at each study  visit, according to the SOA ( Table 1and Table 2).
9 STATISTICAL CONSIDER ATIONS
9.1 Statistical Hypotheses
Theprimary  efficacy  endpoint i s the change from baseline in pre -BD FEV 1at Week 16. A 
treatm ent policy est imand will be applied whereby all available data are included in the 
analysis, irrespect ive of whether a participant discontinued study  intervent ion or received 
rescue therapy .
The null hypothesis is that the change fro m baseline in FEV 1at Week 16 for participants 
dosed with MEDI3506 is equal to the change fro m baseline in FEV 1at Week 16 for 
participants dosed with placebo. The alternat ive hypothesis is that the change from baseline in 
FEV 1at Week 16 for participants dosed with MEDI3506 is greater than the change fro m 
baseline in FEV 1at Week 16 for participants dosed with placebo, ie:
H0: Change fro m Baseline in FEV 1at Week 16 (MEDI3506 -placebo) = 0.
H1: Change fro m Baseline in FEV 1at Week 16 (MEDI3506 -placebo) > 0. 
Hypothesis testing will be performed at the one -sided 10% l evel. If the p -value is < 0.1, reject 
H0 and accept H1. A hierarchical testing strategy will be used to preserve the type I error for 
the com parisons of each o f the 2 dose levels of MEDI3506 versus pl acebo, as fo llows:
Step 1: Test MEDI3506 600 mg versus placebo in regard to H0
Step 2: If previous step rejects: test MEDI3506 300 mg versus placebo in regard to H0
9.2 Sample Size Determination
A sample size o f 216 participants (72 participants per treatment group), randomised 1:1:1 to 
MEDI3 506 mg: MEDI3506  mg: placebo, will provide at least 80% power to detect a 
statist ically significant difference in change from baseline to Week 16 in pre -BD FEV 1, 
CCI
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 84of 134assuming a difference of 150 mL between placebo and MEDI3506, a between -participant SD 
of 420mL and a one -sided-10% al pha l evel. To all ow for 5% parti cipants being ineligible for 
the primary  analysis, a total of approximately 228 participants will be rando mised 
(approximately 76/arm).
Up to 60participant sareintended to be included in the cough sub -study  (ie, approximately 
20participants per treatment group). However, given the exploratory  nature of the sub -study  
and that it may not be activated in all countries, rando misat ion of participants not includ ed in 
the sub -study  will not be restri cted,therefore, sub-study  recrui tment m ay not be achieved. 
Since limited data are available on cough monitoring in this population, the sub -study  is 
considered exploratory  and no formal  power cal culati ons have been pe rformed.
9.3 Populations for Analyses
The fo llowing popul ations are defined:
Table 8 Populations for Analysis
Population/Analysis set Description
ITT population Participants who are randomised and receive any study intervention. 
Parti cipants will be analysed according to their randomised treatment group.
As-treated Population Participants who are randomised and receive any study intervention. 
Participants will be analysed according to the treatment they actually 
receive.
PK population Participants who received at least one dose of MEDI3506 and had at least 
one detectable serum concentration measurement post first dose of study 
interventio n. Participants will be analysed according to the treatment they 
actually  receive.
ITT=Intent -to-treat; PK =pharmacokinetic(s).
The ITT population will be used to summarise all demographic and baseline characterist ics, 
concomitant medicat ions, and efficacy measures. The As -treated popul ation will be used to 
summarise all safet y measures ( AEs, laboratory  tests, ECG, and vital signs). The PK 
popul ation will be used to summarise PK measures.
9.4 Statistical Analyses
All personnel invo lved wit h the analysis o f the study  will remain blinded unt il Primary 
clinical data lock and until Clinical Study  Protocol deviat ions are ident ified.
Analyses will be performed by AstraZeneca or its representatives. A comprehensive SAP will 
be developed and finalised before Primary clinical data lock and will describe the participant 
popul ations to be included in the analyses, and procedures for accoun ting for missing, unused, 
and spurious data. 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 85of 134This sect ion is a summary of the planned statist ical analyses of the primary and secondary 
endpo ints. Any deviat ions from this pl an will  be reported in the CSR.
9.4.1 General Consid erations
Efficacy analyses will be performed using the ITT populat ion. 
The primary  estimand is a ‘Treatment Policy’ estimand, as follows: The difference in mean 
change from baseline in FEV 1at Week 16 (MEDI3506 –placebo) will be est imated using a 
repeated m easures mixed effects analysis o f covariance model, for the ITT population. This 
will include all available data from all visit s up to and including Week 16, irrespect ive of 
whether the p articipant discont inued study  intervent ion or received rescue therapy .
Dem ography  and baseline characterist ics will be summarised by treatment group for the ITT 
popul ation.
9.4.2 Efficacy 
9.4.2.1 Primary Endpoint
The difference in mean change fro m baseline in FEV 1at Week 16 (MEDI3506 –placebo) will 
be est imated using a repeated measures mixed effects analysis of covariance model, for the 
ITT populat ion. The model will include all available data fro m all visits up to and including 
Week 16, irrespect ive of whether the parti cipant discontinued study  interventi on or received 
rescue therapy . No im putati on will  be made for missing data, as a repeated measures model is 
being applied. The model will include fixed effects for baseline, visit, treatment and the 
baseline by visit and treatment by  visit interacti ons. 
The significance of the treatment effect will be tested at a 10% one -sided level of significance 
as described in Sect ion 9.1.
9.4.2.2 Secondary and Exploratory Endpoints
Change from baseline in ACQ -6, SGRQ and AO parameters will be analysed using a repeated 
measures analysis o f covari ance m odel, similar to that described for the primary  efficacy  
analysis (Section  9.4.2.1 ). PRO responder endpoints at Week 16 will be analysed using a 
chi-squared test. 
Object ive cough measurements will be analysed using analysis of covari ance, and m ay be 
log-transform ed pri or to analysis. Estimates of the least square mean change fro m baseline for 
each treatment, and the difference between them, together with 80% confidence interval and 
one-sided p -values, will be obtained fro m the model for each visi t.
Time to first CompEx event and time to first asthma exacerbat ion will be analysed using a 
Cox proportional hazard model, with treatment fitted as a covariate. The data will also be 
displayed in a Kaplan -Meier pl ot. The Com pEx event rate will be analysed using negative 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 86of 134binomial regressio n, wi th the l og(follow-up time) included as an offset term. The dependent 
variable will be the number of Co mpEx events through Week 16, and the m odel will incl ude 
treatm ent group as a fixed effect. Al l available data fro m participants through to Week 16 will 
be included, irrespect ive of whether they discont inued study  intervent ion.
Change from baseline to Week 16 in concentration of FeNO will be analysed using a repeated 
measures analysis o f covari ance model, similar to that described for the primary  efficacy  
analysis (Section 9.4.2.1 ). Where appropriate, endpoints may be log -transform ed pri or to 
analysis. Estimates of the least square mean change fro m baseline for each treatment, and the 
difference between them, together with 80% confidence interval and one -sided p- values, will  
be obtained from the model for each visit.
The difference in mean chan ge from baseline in post -BD FEV 1, and the change in FEV 1% 
reversibilit y at Weeks 8 and 16 will be est imated using a repeated measures mixed effects 
analysis of covariance model, similar to that described for the primary  efficacy  analysis 
(Secti on 9.4.2.1 ).
The composite est imand will be the difference between MEDI3506 and placebo response rate 
at Week 16 in the ITT populat ion. Parti cipants wi th missing data at Week 16 will be 
considered non -responders. For each MEDI3506 group compared wit h placebo, the odds rati o 
and 80%, and one- sided p -values will be reported.
9.4.3 Subgroup Analyses
Subgroup analyses may  be perf ormed and will be described in the SAP. 
9.4.4 Safety
The occurrence of AEs and SAE will be described by System Organ Class, Preferred Term, 
severit y, and relat ionship to the study  intervent ion. Participants will be counted only once for 
each preferred term, once for each system organ class, and by  the highest severit y of an event. 
Number of participants with elevated liver function tests that meet the HL definit ion will be 
evaluated. Laboratory  evaluati ons will be summarised with descript ive statist ics at each visit 
and change fro m baseline summarised f or each post -baseline visit. Laboratory measurements 
will also be summarised based on the number and percentage of participants above or below a 
pre-specified threshold for each test. The number of part icipants wi th clinically significant 
abnorm al ECG resu lts based on invest igators’ judgments will be summarised at each visit. 
Change from baseline in vital signs will be summarised by  visit.
9.4.5 Other Analyses
9.4.5.1 Immunogenicity and PK
Positive ant ibodies to MEDI3506 will be reported by treatment group. If there is a high 
incidence of ADA, the associat ion of ADA with MEDI3506 concentration will be assessed. In 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 87of 134addition, the rel ationship between ADA and bio markers, efficacy, and safet y may be 
evaluated. MEDI3506 serum concentrations will be tabulated along wit h descrip tive stati stics. 
Mean and individual serum MEDI3506 concentration -time profiles will be plotted. Populat ion 
PK m odelling may  be perform ed if data allow, but will not be reported in the CSR. The 
potenti al correl ation between PK exposure and biomarkers, and efficacy/safet y response may  
be evaluated.
9.4.5.2 Exploratory Biomarker Outcomes
Change from baseline in blood eosinophils, EDN, total IgE and blood neutrophils will be 
analysed using a repeated measures analysis of covariance model, similar to that described for
the primary  efficacy analysis, in Sect ion9.4.2.1 . Where appropriate, endpoints may be 
log-transform ed pri or to analysis. Estimates of the least sq uare mean change fro m baseline for 
each treatment, and the difference between them, together with 80% confidence interval and 
one-sided p -values, will be obtained fro m the model for each visi t.
Full details o f all other exploratory  biomarker outcom es will  be provided in the SAP.
9.4.5.3 Exploratory Analyses
Full details o f all other exploratory  analyses will be provided in the SAP.
9.5 Interim Analyses 
No formal interim analyses are pl anned for thi s study . 
The primary  analysis will occur once all participants have ei ther com pleted the SV10 
(Week 16) assessments or have wit hdrawn from the study . The sponsor staff will be fully  
unblinded fo llowing the Primary  Analysis Clinical Data Lock. Invest igators, participants and 
site staff will not be made aware of unblinded trea tment assignments for individual 
participants who are in the fo llow-up peri od until these parti cipants have co mpleted the study . 
The final analysis will occur when all part icipants have co mpleted the fo llow-up peri od at 
SV12 (Week 24) or have withdrawn fro m the study.
9.6 Data Monitoring Committee
An independent unblinded DSMB will perform evaluat ions of safety  data, from  this study  and 
Studi es D9180C00002 (in participants with COPD), D9182C00001 (in participants with AD) 
and D9183C00001 (in participants with DKD). Details of the composit ion of the DSMB, the 
data to be reviewed, and the frequency of the meetings can be found in the DSMB Charter . 
The DSMB will make any  necessary  recommendati ons to the sponsor regarding further 
conduct of the studies based on the ir evaluat ions of emerging data.
For details on the DSMB, refer to Appendix A 4.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 88of 13410 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATI ONS
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 89of 134Appendix ARegulatory, Ethical, and Study Oversight Considerations
A 1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol, and wit h the following:
Consensus ethical principles derived from international guidelines inclu ding the 
Declaration of Helsinki and Council o f Internat ional Organisat ions of Medical 
Sciences Internat ional Ethical Guidelines.
Applicable ICH GCP Guidelines.
Applicable laws and regulations.
The protocol, protocol amendments, ICF, IB, and other relevant docum ents (eg, 
advert isements) must be submitted to an IRB/IEC by the investigator and reviewed and 
approved by  the IRB/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC and applicable Regulatory  
Authori ty approval  before implementati on of  changes m ade to the study  design, except 
for changes necessary  to eliminate an immediate hazard to study  parti cipants.
AstraZeneca will be responsible for obtaining the required authorisations to conduct the 
study  from the concerned R egulatory  Authori ty. This responsibilit y may be delegated to a 
CRO but the accountabilit y remains wi th AstraZeneca.
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
oblig ations and ethical responsibilit ies towards the safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, IRB/IEC, and invest igators.
For all studies (excep t those using m edical  devices), invest igator safet y reports must be 
prepared for Suspected Unexpected Serious Adverse React ions according to local 
regul atory  requi rements and sponsor policy and forwarded to invest igators as necessary.
An invest igator who r eceives an invest igator safety report describing a SAE or other 
specific safet y informat ion (eg, summary or list ing of SAEs) fro m the sponsor will review 
and then file it along with the IB and will notify the IRB/IEC, if appropriate according to 
local requ irements.
A 2 Informed Consent Process
The invest igator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorised representative and answer all quest ions regarding 
the study .
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 90of 134Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary and they  are f ree to 
refuse to participate and may wit hdraw their consent at any  time and for any  reason 
during the study . Partici pants will be requi red to sign a statement of informed consent that 
meets the requiremen ts of 21 CFR 50, l ocal regul ations, ICH gui delines, HIPAA 
requi rements, where applicable, and the IRB/IEC or study  centre.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participant was enrolled in the stu dy and the date the written consent was 
obtained. The authorised person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current version of the ICF(s) during their 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  
authori sed representative.
Parti cipants who are rescreened are required to sign a new ICF.
The ICF will contain a separate section that addresses and documents the collect ion and use of 
any mandatory  and/or opti onal human bio logical  sam ples. The invest igator or authorised 
designee will explain to each participant the objectives of the analysis to be done on the 
samples and any potential future use. Participants will be told that th ey are free to refuse to 
participate in any optional samples or the future use and may wit hdraw their consent at any  
time and for any  reason during the retention period. 
A 3 Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any participant records or 
datasets that are transferred to the sponsor will contain the ident ifier only; part icipant 
names or any  information which would make the participant ident ifiable will not be 
transferred.
The parti cipant must be inform ed that hi s/her personal study -related data will  be used by  
the sponsor i n accordance with local data protection law. The level of disclo sure and use 
of their data m ust al so be explained to the participant in the informed consent 
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by 
Clinical Qualit y Assurance auditors or other authorised personnel appo inted by  the 
sponsor, by  appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
A 4 Committee’s Structure
An independent DSMB w ill be formed to eval uate safet y data fro m concurrent ly conducted 
MEDI3506 Phase II clinical studies in other indications. 
Unblinded review of safet y data will be required for indicat ions where the potential risks of 
MEDI3506 are high due to the disease u nder study and the commo n comorbidit ies of 
particular parti cipant popul ations. Safet y data fro m this study  will be provi ded to the DSMB 
Clinical St udy Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 91of 134for oversi ght of all safet y data. Details o f the com position of  the DSMB, the data to be 
reviewed, and the frequency of the meet ings can be found in the DSMB Charter.
A 5 Dissemination of Clinical Study Data
A descript ion of this clinical study  will be available on http://astrazenecaclinicaltrials.com and 
http://www.clinicaltrials.gov, as will the summary of the study  resul ts when they  are available. 
The clinical study  and/or summary  of study  resul ts may  also be available on other websites 
according to the regulat ions of the countries in which the study  is conducted.
A 6 Data Quality Assurance
All participant data relat ing to the st udy will be recorded on eCRF unless transmitted to 
the sponsor or designee electronically (eg, laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  physically  or 
electroni cally signing the eCRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect access to source data documents.
Moni toring details describing strategy  (eg, risk -based init iatives in operations and qualit y 
such as Risk Management and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, includ ing handling of 
nonco mpliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the Moni toring Plan .
The sponsor or designee is responsible for the data management of this study  including 
qualit y checking of the data .
The sponsor assumes accountabilit y for acti ons delegated to other individuals (eg, CROs).
Study  monitors will perform  ongoing source data verification to confirm that data entered 
into the eCRF by authorised site personnel are accurate, complete, and ver ifiable fro m 
source documents; that the safet y and ri ghts of  participants are being protected; and that 
the study  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by the invest igato r for 25 years after study  com pletion unless local 
regul ations or inst itutional policies requi re a l onger retenti on peri od. No records may be 
destroy ed during the retention period without the written approval of the sponsor. No 
records m ay be transferred to another location or party  without wri tten notificat ion to the 
sponsor.
A 7 Source Documents
Source documents provide eviden ce for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the invest igator’s site.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 92of 134Data reported on the eCRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent wi th the source documents or the discrepancies must be 
explained. The invest igator may need to request previous medical records or transfer 
records, depending on the study . Also, current m edical records must be available.
Definit ion of what cons titutes source data can be found in the source data verificat ion 
plan.
A 8 Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
The sponsor designee reserves the right to c lose the study  site or terminate the study  at any  
time for any  reason at the sole discret ion of the sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines.
Inadequate re cruitment of parti cipants by  the investi gator.
Discontinuati on of  further study  intervent ion developm ent.
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investigators, the IECs/IRBs, the regulatory  authorit ies, and any contract research 
organi sation(s) used in the study  of the reason for terminat ion or suspensio n, as specified by 
the applicable regulatory  requi rements. The invest igator shall pro mptly inform the participant 
and should assure appropriate participan t therapy  and/or foll ow-up.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 93of 134Appendix BAdverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
B 1 Definition of Adverse Events
An adverse event is the development of any untoward medical occurrence in a participant or 
clinical study  parti cipant administered a medicinal product and which does not necessarily 
have a causal relat ionship with this treatment. An AE can therefore be any unfavourable and 
unintended sign (eg, an abnormal laboratory  finding), symptom (for example nausea, chest 
pain), or disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product. 
The term  AEis used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence. An AE may  occur at any  time, including 
run-in or washout periods, even if no Study treatment has been administered.
B 2 Definition of Ser ious Adverse Events
An SAE is an AE occurring during any study  phase (i e, run -in, treatment, washout, 
follow-up), that fulfils one or more of the following criteria:
Results in death
Is immediately life -threatening
Requi res in -partici pant hospi talisat ion or prolongatio n of exist ing hospitalisat ion 
Results in persistent or significant disabilit y or incapaci ty. 
Is a congenital ano maly or bi rth defect
Is an important medical event that may jeopardise the participant or may require medical 
treatm ent to preven t one of the outcom es listed above.
AEs for malignant tumours reported during a study  shoul d generally be assessed as serious 
AEs. If no other seriousness criteria apply, the ‘Important Medical Event’ criterion should be 
used. In certain situations, howev er, m edical judgement on an individual event basis should be 
applied to clarify that the malignant tumour event should be assessed and reported as a 
non-serious AE. For example, if the tumour is included as medical history and progression 
occurs duri ng the study , but the progression does not change treatment and/or prognosis of the 
malignant tumour, the AE may  not fulfil the attributes for being assessed as serious, although 
reporting of the progression of the malignant tumour as an AE is valid and should o ccur. Al so, 
some ty pes of  malignant tum ours, which do not spread remotely after a routine treatment that 
does not require hospitalizat ion, may be assessed as non -serious; examples in adult s include 
Stage 1 basal cell carcino ma and S tage 1A1 cervical cancer removed via cone biopsy .
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 94of 134Life threatening
‘Life -threatening’ means that the participant was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
participant’s death. ‘Life -threatening’ does not m ean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatit is that resolved wit hout hepatic failure).
Hospitalisation
Outpati ent treatm ent in an emergency room is not in itself a serious AE, althou gh the reasons 
for it may be (eg, bronchospasm, laryngeal oedema). Hospital admissions and/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illness or disease 
existed before the participant was enrolled in the study , provi ded that i t did not deteri orate in 
an unexpected way  during the study .
Important medical event or medical treatment
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important m edical events m ay not be immediately life threatening or result in 
death, hospi talisat ion, disabili ty or incapaci ty but may jeopardise the participant or may  
requi re medical treatm ent to prevent one or more outcomes listed in the definit ion of seri ous. 
These should usual ly be considered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used.
Angioedema not severe enough to require intubation but requiring IV hydrocortisone 
treatm ent.
Hepatotoxicit y caused by paracetamo l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine.
Intensive treatment in an emergency room or at home for allergic bronchospasm.
Blood dy scrasias (eg, neutropenia or anaemia requiring blood transfusion, etc.) or 
conv ulsions that do not resul t in hospi talisat ion.
Development of drug dependency or drug abuse.
Severity rating scale
The determinat ion of severit y shoul d be made by  the invest igator based upon medical 
judgment and the severit y categories of Grade 1to5 (ba sed on the CTCAE criteria, 
NCI 2017 ) as defined below.
Grade 1 An event of mild intensit y that is usually transient and may  require only 
minimal treatment or therapeuti c intervent ion. The event does not generally 
interfere wi th usual  activi ties of  daily living.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 95of 134Grade 2 An event of moderate intensit y that i s usually alleviated with addit ional 
specific therapeut ic intervent ion. The event interferes with usual activit ies of
daily  living, causing discomfort but poses no significant or permanent risk of 
harm to the subject.
Grade 3 A severe event that requires intensive therapeutic intervent ion. The event 
interrupts usual  activit ies of daily living, or significant ly affects th e clinical 
status of the subject.
Grade 4 An event, and/or its immediate sequelae, that is associated with an imminent 
risk of death.
Grade 5 Death as a result of an event.
It is important to dist inguish between serious and severe AEs. Severit y is a measure of 
intensity whereas seri ousness is defined by the criteria in Appendix B2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it meets the criteria 
shown in Appendix B 2. On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Appendix B2.
B 3 A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the foll owing f actors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by the drug.
Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience. Did the AE resolve or improve on stopping or reducing the dose 
of the suspect drug?
No al ternative cause. The AE cannot be reasonably explained by another aetio logy such 
as the underlying disease, other drugs, other host or environmental factors.
Re-challenge experi ence. Di d the AE reoccur if the suspected drug was reintroduced after 
having been stopped? AstraZeneca would not normally reco mmend or support a re-
challenge .
Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship .
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 96of 134In difficult cases, other factors could be considered such as:
Is this a recogni sedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related’ is m ade if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case. The expressio n 
‘reasonable possibilit y’ of acausal relationship is meant to convey, in general, that there are 
facts (evidence) or argum ents to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an informed judgment. With no available facts or arguments to suggest a 
causal relat ionship, the event(s) will be assessed as ‘not related’.
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
B 4 Medication Error
For the purposes of this clinical study  a medicat ion error is a n unintended failure or mistake in 
the treatment process for an AstraZeneca study  drug that ei ther causes harm to the participant 
or has the potential to cause harm to the participant. 
A medicat ion error is not lack of efficacy o f the drug, but rather a human or process related 
failure while the drug is in control of the study  site staff or parti cipant.
Medicat ion error includes situat ions where an error:
Occurred.
Was i dentified and intercepted before the participant received the drug.
Did not occur, but circumstances were recognised that could have led to an error.
Examples of events to be reported in clinical studies as medication errors:
Drug name confusio n.
Dispensing error eg, medication prepared incorrectly , even if i t was not actually  given to 
theparticipant.
Drug not administered as indicated, for example, wrong route or wrong site of 
administration.
Drug not taken as indicated eg, tablet disso lved in water when it should be taken as a 
solid tablet.
Drug not stored as instructed eg, kept in the f ridge when i t shoul d be at room  temperature 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI350 6 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 97of 134Wrong participant received the medicat ion (excluding RTSM errors)
Wrong drug administered to participant (excluding RTSM errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m RTSM -including those which lead to one of the above 
listed events that would otherwise have been a medicat ion error.
Parti cipant acci dentally  missed drug dos e(s) eg, forgot to take medication.
Accidental  overdose (will be captured as an overdose).
Parti cipant f ailed to return unused medicat ion or empt y packaging.
Errors related to background and rescue medicat ion, or SOC medicat ion in open label 
studi es, even if an AstraZeneca product.
Medication errors are not regarded as AEs but AEs may occur as a consequence of the 
medication error.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 98of 134Appendix CHandling of Human Biological Samples
C 1 Chain of Custody
A full chain o f custody  is maintained for all samples throughout their l ifecycle.
The invest igator at each centre keeps full traceability of co llected bio logical sam ples f rom the 
participants while in storage at the centre until shipment or disposal (where appropriate) and 
records relevant processing information related to the samples whilst at site.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
AstraZeneca or d elegated representatives will keep oversight of the ent ire life cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders
Samples retained for further use will be stored in the AstraZeneca- assigned biobanks or other 
sample archive facilit ies and will be tracked by  the appropri ate AstraZeneca Team during for 
the rem ainder of the sam ple life cycle.
If required, AstraZeneca will ensure that remaining bio logical samples are returned to the site 
according to local regulations or at the end of the retention period, whichever is the sooner.
C 2 Withdrawal of Informed Consent for Donated Biological Samples 
If a participant withdraws consent to the use of donated bio logical  sam ples, the samples will 
be disposed of/destroy ed/repatriated, and the action documented. If samples are already  
analysed ,AstraZeneca is not obliged to destroy  the resul ts of this research.
Following wi thdrawal  of consent for bio logical samples, further stu dy participation should be 
considered in relat ion to the wi thdrawal  processes outlined in the informed consent.
The invest igator:
Ensures participant’s withdrawal of informed consent to the use of donated samples is 
highlighted immediately to AstraZeneca o r delegate.
Ensures that relevant human bio logical samples from  that parti cipant, if stored at the 
study  site, are immediately  identified, disposed of as appropriate, and the action 
docum ented
Ensures that the participant and AstraZeneca are informed about the sample di sposal .
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 99of 134AstraZeneca ensures the organisat ion(s) ho lding the sam ples is/are inform ed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as appropriate, 
and the action documented and study  site notified.
C 3 International Airline Transportation Association 6.2 Guidance 
Document
LABELLING AND SHIPMENT OF BIOHAZARD SAMPLES
International Airline Transportation Associat ion (IATA) 
(https://www.iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: Category  A, Category B or Exempt
Category A infectious substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal  disease in 
otherwi sehealt hy humans or animals. 
Category A pathogens are eg, Ebola, Lassa fever virus. Infectious substances meet ing these 
criteria which cause disease in humans or both in humans and animals must be assigned to UN 
2814. Infectious substances which cause dise ase only  in animals must be assigned to UN 
2900:
Category B infectious substances are infect ious substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are eg, hepatit is A, C, D, and E viruses. They 
are assigned the fo llowing UN number and proper shipping name:
UN 3373 –Biological Substance, Category  B
are to be packed in accordance with UN3373 and IATA 650
Exempt -substances which do not contain infectious substances or substances which are 
unlikely  to cause disease i n humans or animals are not subject to these regulat ions unless they  
meet the criteria for inclusio n in another class.
Clinical study samples will fall into Category  B or exempt under IATA regulat ions.
Clinical study  samples will routinely  be packed and tr ansported at ambient temperature in 
IATA 650 compliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/DGR -60-EN-PI650.pdf).
Biological samples transported in dry  ice requi re addi tional dangerous goods specificat ion 
for the dry  ice content.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 100of 134Appendix DOptional Genomics Initiative Sample
D 1 Use/Analysis of DNA
AstraZeneca intends to collect and store DNA for genet ic research to explore how genetic 
variat ions may affect clinical parameters, risk and prognosis o f diseases, and the response 
to medicat ions. This genetic research may lead to better understanding of diseases, better 
diagnosis of diseases or other improvements in healt h care and to the discovery o f new 
diagnosti cs, treatm ents or m edicat ions. Therefore, where local regulat ions and IRB/IEC 
allow, a blo od sam ple will be collected for DNA analysis from consent ing participants.
This optional genet ic research may consist of the analysis o f the structure of the 
participant’s DNA, i e, the enti re genom e.
The results of genetic analyses may be reported in a sep arate study  summary .
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confident iality.
The sam ples will  be retained while research on MEDI3506 continues but no longer than 
15 years after the end of the stud y or other peri od as per l ocal requi rements.
D 2 Genetic Research Plan and Procedures
Selection of genetic research population
All participants will be asked to participate in this genet ic research. Participat ion in the 
geno mics init iative is vo luntary and if a parti cipant declines to participate there will be no 
penalt y or l oss of benefit. The participant will not be excluded fro m any aspect of the main 
study .
Inclusion criteria
For inclusio n in this genet ic research, participants must fulfil all of the inclu sion criteria 
described in the main body  of the CSP andprovide informed consent for the Geno mics 
Initiative sampling and analyses.
Exclusion criteria
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified in the 
main study or any  of the fo llowing:
Previous allogeneic bone marrow transplant.
Non-leukocyte depleted whole blood transfusio n wit hin 120 days of genet ic sample 
collect ion.
Healthy vol unteers and paediatric pat ient samples will  not be coll ected for the Genomics 
Initiative.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 101of 134Withdrawal of consent
Parti cipants may  withdraw from  this genet ic research at any t ime, independent of any decisio n 
concerning participat ion in other aspects of the main study . Vol untary  withdrawal  will not 
prejudice further treatment. Procedu res for withdrawal are outlined in Sect ion7.2.
Collection of samples for genetic research
The blood sample for this genetic research will be obtaine d from the parti cipants at SV4 
(randomisat ion). Although DNA is stable, early sample co llection is preferred to avoid 
introducing bias through excluding participants who may  withdraw due to an AE. If for any  
reason the sample is not drawn at SV4, it may be taken at any  visit until  the last study  visit. 
Only one sample should be co llected per participant for genetics during the study.
Coding and storage of DNA samples
The processes adopted for the coding and storage of samples for genet ic analysis are 
import ant to maintain participant confident iality. Sam ples will  be stored for a m aximum  
of 15years after the end of the study , after wh ich they will be destroy ed. DNA is a finite 
resource that is used up during analyses. Samples will be stored and used until no further 
analyses are possible or the maximum storage time has been reached.
An addit ional second code will be assigned to the sample eit her before or at the time of 
DNA extraction replacing the informat ion on the sample tube. Thereafter, the sample will 
be ident ifiable only by the second, unique number. This number is used to identify the 
sample and corresponding data at the AstraZeneca genet ics laboratori es, or at the 
designated organisation. No personal details ident ifying the individual will be availabl e to 
any person (AstraZeneca emplo yee or desi gnated organi sations working with the DNA).
The link between the participant enrolment/randomisat ion code and the second number 
will be maintained and stored in a secure environment, with restricted access at 
AstraZeneca or designated organisat ions. The link will be used to identify the relevant 
DNA samples for analysis, facilitate correlat ion of genoty pic resul ts wi th clinical data, 
allow regulatory  audi t, and permi t tracing of samples for destruction in the cas e of 
withdrawal  of consent.
Ethical and regulatory requirements
The principles for ethical and regulatory  requi rements for the study , incl uding this genet ics 
research component, are outlined in Appendix A.
Informed consent
The genetic component of this study  is opti onal and the parti cipant m ay part icipate in other 
components of the m ain study  without parti cipat ing in this genet ic co mponent. To particip ate 
in the genet ic co mponent of the study the participant must sign and date both the consent form 
for the m ain study  and the addendum for the Genomics Init iative co mponent of the study . 
Copi es of  both si gned and dated consent forms must be given to the pa rticipant and the 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 102of 134original  filed at the study  centre. The PI is responsible for ensuring that consent is given freely  
and that the participant understands that they  may freely  withdrawal  from the genet ic aspect of 
the study  at any  time.
Participant data protection
AstraZeneca will not provide individual genoty pe resul ts to parti cipants, any  insurance 
company, any emplo yer, thei r family members, and/or general physician unless required 
to do so by  law.
Extra precautions are taken to preserve confident iality and prevent genetic data being 
linked to the ident ity of the parti cipant. However, in except ional circumstances, certain 
individuals might see both the genet ic data and the personal ident ifiers of a participant. 
For example, in the case of a medical emerge ncy, an AstraZeneca Physician or an 
investigator might know a participant’s ident ity and al so have access to his or her genetic 
data. Regul atory  authori ties may requi re access to the rel evant files, though the 
participant’s m edical  information and the gene tic files woul d rem ain physically separate.
Data management
Any genet ic data generated in this study will be stored at a secure system at AstraZeneca 
and/or designated organizations to analyse the samples.
AstraZeneca and its designated organisat ions may share summary results (such as genet ic 
differences fro m groups of individuals with a disease) fro m this genetic research with 
other researchers, such as hospitals, academic organisations or healt h insurance 
companies. This can be done by placing the result s in scientific databases, where they  can 
be co mbined with the results of similar studies to learn even more about health and 
disease. The researchers can only  use thi s inform ation for heal th-related research 
purposes. Researchers may  see summary  resul ts but they  will not be able to see individual 
participant data or any  personal ident ifiers. 
Some or all  of the clinical datasets from the main study  may be merged wi th the genet ic 
data in a suitable secure environment separate from the clinical database.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 103of 134Appendix EActions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
E 1 Introduction
This Appendix describes the process to be fo llowed in order to ident ify and appropriately 
report PHL and HL cases. It is not intended to be a comprehensive guide to the management 
of elevated liver biochemistries. 
During the course of the study , the inves tigator will remain vigilant for increases in liver 
biochemistry . The invest igator is responsible for determining whether a participant meets PHL 
criteria at any  point during the study .
All sources of l aboratory  data are appropri ate for the determinat ion of PHL and HL events; 
this includes samples taken at scheduled study  visits and other vi sits including central  and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; for exam ple, PHL 
criteria coul d be m et by  an elevated ALT from a central  laboratory  and/or elevated TBL fro m 
a local laboratory . 
The invest igator will also review AE data (for example, for AEs that may indicate elevations 
in liver bio chemistry ) for possible PHL events.
The invest igator participates, together with AstraZeneca clinical project representatives, in 
review and assessment of cases meet ing PHL criteria to agree whether HL criteria are met. HL 
criteria are met if there is no alternat ive explanation for the elevat ions in liver biochemistry  
other than DILI c aused by  the IMP.
The invest igator is responsible for recording data pertaining to PHL/HL cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in line wit h 
standard safet y reporting processes.
E 2 Definitions
Potential Hy’ s Law
AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN at any po int during the study  
following the start of study  medicat ionirrespect ive of an increase in ALP.
Hy’s Law
AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN, where no other reason, other than 
the IMP, can be found to explain the co mbinat ion of increases, eg, elevated ALP indicating 
cholestasis, viral hepat itis, another drug. 
Clinical Stu dy Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 104of 134For PHL and HL the elevat ion in transaminases must precede or be coincident with (ie, on the 
same day ) the el evati on in TB L, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
E 3 Identification of Potential Hy’s Law Cases
In order to i dentify  cases of PHL i t is important to perform a comprehensive review of 
laboratory  data for an y participant who meets any of the fo llowing identificat ion criteria in 
isolation or in combinat ion:
ALT ≥ 3 × ULN.
AST ≥ 3 × ULN.
TBL ≥ 2 × ULN.
When a participant meets any of the PHL ident ification criteria, in iso lation or in co mbinat ion, 
the central  laboratory  will immediately send an alert to the investigator (also sent to 
AstraZeneca representative). 
The invest igator will also remain vigilant for any local laboratory reports where the PHL 
ident ificat ion criteria are met, where this is the case the invest igator will:
Notify  the AstraZeneca representative.
Request a repeat of the test (new blood draw) by  the central  laboratory without delay .
Com plete the appropri ate unscheduled laboratory  eCRF m odule(s) wi th the ori ginal  local 
laboratory  test resul t.
When the identificat ion criteria are m et from central  or local laboratory  resul ts the invest igator 
will wit hout del ay:
Determine whether the participant meets PHL criteria (see Appendix E 2for definit ion) 
by reviewing laboratory  reports from  all previ ous visi ts (including both central and local 
laboratory  resul ts).
E 4 Follow -up
E4.1 Potential Hy’s Law Criteria not met
If the participant does not meet PHL criteria the investigator will:
Inform  the AstraZeneca representative that the participant has not met PHL criteria.
Perform  follow-up on subsequent laboratory  resul ts according to the guidance provided in 
the CSP.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 105of 134E4.2 Potential Hy’s Law Criteria met
If the p articipant does m eet PHL cri teria the investigator will:
Notify  the AstraZeneca representative who will then inform the central study  team .
Within one day  of PHL cri teria being m et, the investi gator will report the case as an SAE 
of Potenti al Hy’s Law; ser ious cri teria ‘Important medical event’ and causalit y 
assessment ‘y es/related’ according to CSP process for SAE reporting.
For parti cipants that met PHL criteria prior to starting IMP, the invest igator is not 
requi red to submit a PHL SAE unless there is a significant change#in the participant’s 
condi tion.
The Study  Physician contacts the investigator, to provide guidance, discuss and agree an 
approach for the study  parti cipants’ fo llow-up (including any further laboratory  testing) 
and the continuous review of data.
Subsequent to this contact the invest igator will:
Moni tor the parti cipant until liver bio chemistry  param eters and appropri ate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Completes fo llow-up SAE form  as required.
Invest igate the aetiology o f the event and perform diagnostic investigat ions as 
discussed wi th the Study  Physician. This includes deciding which of the tests 
available in the Hy’s law lab kit should be used.
Com plete the three L iver eCRF Modules as information beco mes available.
#A ‘significant’ change in the participant’s conditio n refers to a clinically  relevant 
change in any  of the individual liver biochemistry  param eters (ALT, AST or TBL) in iso lation 
or in co mbination, or a clinically relevant change in associated symptoms. The determinat ion 
of whether there has been a significant change will be at the discretion o f the invest igator. 
This m ay be in consultation wit h the Study  Physician if there is any uncertaint y.
E 5 Review an d Assessment of Potential Hy’s Law Cases
The instructions in this sect ion shoul d be fo llowed for all  cases where PHL cri teria are m et.
As soon as possible after the biochemistry  abnormalit y was ini tially detected, the Study  
Physician contacts the invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ion for meeting PHL criteria other than DILI caused by the 
IMP, to ensure timely analysis and reporting to healt h authorit ies wit hin 15 calendar days 
from date PHL c riteria was met. The AstraZeneca Global Clinical Lead or equivalent and 
Global Safet y Physician will also be invo lved in this review together with other subject matter 
experts as appropriate. 
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 106of 134According to the outcome of the review and assessment, the inve stigator will fo llow the 
instructi ons bel ow.
Where there is an agreed alternative explanation for the ALT or AST and TBL elevations, 
a determination of whether the alternat ive explanatio n is an AE will be made and 
subsequent ly whether the AE meets the crit eria for a SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate eCRF
If the alternat ive explanat ion is an AE/SAE: update the previously submitted Potential 
Hy’s Law SAE and AE eCRFs accordingly wit h the new informat ion (reassessing event 
term; causalit y and seri ousness cri teria) fo llowing the AstraZeneca standard processes.
If it is agreed that there is no explanat ion that would explain the ALT or AST and TBL 
elevations other than the IMP:
Send updated S AE (report term ‘Hy’s Law’) according to AstraZeneca standard 
processes. 
 The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious 
criteria apply
 As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘relat ed’ should be assigned.
If there is an unavo idable delay o f over 15 cal endar days in obtaining the informat ion 
necessary  to assess whether or not the case meets the criteria for HL, then it is assumed that 
there is no alternat ive explanation unt il such ti me as an informed decisio n can be made:
Provi des any  further update to the previously submitted SAE of Potential Hy’s Law, 
(report term now ‘Hy’s Law case’) ensuring causalit y assessment i s related to IMP and 
seriousness cri teria is m edically important, ac cording to CSP process for SAE reporting.
Continue fo llow-up and review according to agreed plan. Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previous ly submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an alternat ive explanat ion for the liver biochemistry  
elevations is determined.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 107of 134E 6 Laboratory tests
Hy’s Law lab kit for central laboratories 
Additional standard chemistry and coagulation tests GGT
LDH
Prothrombin time
INR
Viral hepatitis IgM anti -HAV 
IgM and IgG anti -HBc
HBsAg
HBV DNAa
IgG anti -HCV
HCV RNA a
IgM anti -HEV
HEV RNA
Other viral infections IgM & IgG anti -CMV
IgM & IgG anti -HSV
IgM & IgG anti -EBV
Alcoholic hepatitis Carbohydrate deficient transferrin ( CD-transferrin) b
Autoimmune hepatitis Antinuclear antibody (ANA)
Anti-Liver/Kidney Microsomal Ab (Anti -LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases alpha -1-antitry psin
Ceruloplasmin
Iron
Ferritin
Transferrinb
Transferrin saturation
aHCV RNA; HCV DNA are only tested when IgG anti -HCV is positive or inconclusive.
CMV = cytomegalovirus; EBV = Epstein -Barr virus GGT =gamma glutamyl transferase; HAV = hepatitis A 
virus; HBV = hepatitis B virus; HCV  hepatitis C virus; HEV = hepatitis E virus; Ig =immunoglobulin; 
INR =international normalised ratio; LDH = lactate dehydrogenase.
E 7 References
1Aithal et al 2011, Clinical Pharmaco logy and Therapeutics 89(6):806 -815.
2FDA Guidance for Industry  (issued July  2009) ‘Drug -induced liver injury: Premarket ing 
clinical evaluat ion’. Available from; https://www.fda.gov/regulatory -informat ion/search -
fda-guidance -docum ents/drug -induced -liver-injury -premarketing -clinical -evaluat ion
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 108of 134Appendix FMaintenance Therapy Equivalence Table
Estimated daily doses for ICS.
Asthma TherapyTotal Daily Dose (μg/day)
Medium High
ICSa
Beclomethasone dipropionate (CFC) >500 to 1000 >1000
Beclomethasone dipropionate (HFA) >200 to 400 >400
Budesonide >400 to 800 >800
Ciclesonide >160 to 320 >320
Fluticasone furoate (eg, Arnuity®Ellipta®Breo®) N/A 200
Fluticasone propionate >250 to 500 >500
Fluticasone propionate (HFA) >250 to 500 >500
Mometasone furoate >220 to 440 >440
Triamcinolone acetonide >1000 to 2000 >2000
ICS in ICS/LABA combinationa
Beclomethasone dipropionate (eg, Fostair®) >200 to 400 >400
Fluticasone propionate (HFA; eg, Seretide®, Advair®) >250 to 500 >500
Fluticasone furoate (eg, Relvar®Ellipta®, Breo®Ellipta®) N/A 184 to 200
Budesonide, if as delivered dose (eg, Symbicort®) >400 to 640 >640
Mometasone Furoate (eg, Dulera®) >220 to 400 >400
aThe ICS doses were derived from GINA 2018 and the ICS/LABA combinations were derived from GINA 
2017 and 2018 and using prescribing information.
CFC =chlorofluorocarbon propellant; GINA = Global Initiative for Asthma; HFA =hydrofluoroalkane 
propellant; ICS =inhaled corticosteroid; LABA =long-acting beta-agonist; N/A =not applicable.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 109of 134Appendix GNational Institute of Allergy and Infectious Diseases and 
Food Allergy and Anaphylaxis Network Guidance for 
Anaphylaxis Diagnosis
National Inst itute of Allergy and Infectious Diseases and Food Allergy and Anaphylaxis 
Network define anaphylaxis as a serious allergic reaction that is rapid in onset and may cause 
death ( Sampson et al 2006 ). They  recognise 3 categories of anaphylaxis, with criteria 
designated to capture from 80% of cases (category 1) to > 95% of all cases of anaphylaxis (for 
all 3 categories). 
1Acute onset of an illness (minutes to several hours) with invo lvement of the skin, mucosal 
tissue, or both (eg, g eneralised hives, pruritus or flushing, swo llen lips -tongue -uvula) 
AND AT LEAST ONE OF THE FOLLOWING:
(a)Respiratory  com promise (eg, dyspnoea, wheeze- bronchospasm, stridor, reduced 
PEF, hy poxemia).
(b)Reduced BP or associated symptoms of end -organ dy sfunct ion (eg, hy potoni a 
[collapse], syncope, incont inence).
2Two or more of the fo llowing that occur rapidly after exposure to a likely allergen for that 
participant (minutes to several hours):
(a)Involvement of the skin -mucosal t issue (eg, generalised hives, itch -flush, swollen 
lips-tongue-uvula).
(b)Respiratory  com promise (eg, dyspnoea, wheeze- bronchospasm, stridor, reduced 
PEF, hy poxemia).
(c)Reduced BP or associated symptoms (eg, hy potonia [coll apse], syncope, 
incont inence)
(d)Persi stent gastrointestinal symptoms (eg, crampy  abdominal pain, vo miting).
3Reduced BP after exposure to known allergen for that participant (minutes to several 
hours):
(a)Adults: SBP of less than 90 mmHg or greater than 30% decrease fro m that 
participant’s baseline.
For the purpose of AE reporting, the abo ve criteria should be used to guide retrospective 
judgment as to whether an event was true anaphylaxis. Guidance on the recognit ion of 
possible anaphylaxis at the time of the event is provided ( Appendix H).
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 110of 134Appendix HSigns, Symptoms, and Management of Acute Anaphylaxis
Appropriate drugs, such as epinephrine, antihistamines, corticosteroids, etc, and medical 
equipment to treat anaphylact ic reactions must be immed iately available at study  sites, and 
study  personnel shoul d be trained to recognise and treat anaphylaxis. Local or national 
guidelines for the recognit ion and m anagement of acute anaphylaxis should be fo llowed 
where available. Where not available, guidanc e is provi ded below.
H 1 Signs and Symptoms of Acute Anaphylaxis
Anaphylaxis is an acute and potentially lethal mult i-system  allergic reacti on in which som e or 
all of the following si gns and symptoms occur:
Diffuse ery thema.
Pruri tus.
Urticaria and/or angioede ma.
Bronchospasm.
Laryngeal oedema.
Hypotensi on.
Cardi ac arrhy thmias.
Feeling of impending doom.
Unconsciousness.
Shock.
Other earlier or concomitant signs and symptoms can include:
Itchy  nose, ey es, pharynx, genitalia, palms, and so les.
Rhinorrhoea.
Change in voice.
Metallic taste.
Nausea, vo miting, di arrhoea, abdominal cramps, and blo ating.
Lightheadedness.
Headache.
Uterine cramps.
Generalised warmth.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 111of 134H 2 Management of Acute Anaphylaxis
H2.1 Immediate Intervention
1Assessment of airway , breathing, ci rculation, and adequacy  of mentati on.
2Administer epinephrine intramuscularly  every  5 to 15 minutes, in appropriate doses, as 
necessary , depending on the presenting signs and symptoms of anaphylaxis, to control 
signs and symptoms and prevent progression to more sev ere symptom s such as 
respi ratory  distress, hypotension, shock and unconsciousness.
H2.2 Possibly Appropriate, Subsequent Measures Depending on Response to 
Epinephrine
1Place participant in recumbent posit ion and elevate lower extremit ies.
2Establish and maintain airway .
3Administer oxy gen.
4Establish venous access.
5Norm al saline IV for fluid replacement.
H2.3 Specific Measures to Consider after Epinephrine Injections, Where 
Appropriate
1Consider epinephrine infusio n.
2Consider H1 and H2 ant ihistamines.
3Consider nebulised beta-2 agoni st [eg, albuterol (salbutamol)] for bronchospasm resistant 
to epinephrine.
4Consider systemic corticosteroids.
5Consider vasopressor (eg, dopamine).
6Consider glucagon for participant taking b -blocker.
7Consider atropine for symptomat ic bradycardi a.
8Consider transportation to an emergency  depart ment or an intensive care facilit y.
9For cardi opulm onary arrest during anaphylaxis, high -dose epinephrine and prolonged 
resuscitat ion efforts are encouraged, if necessary .
If a suspected anaphylact ic reactio n occurs during or within a 24 -hour peri od after 
administration of study  intervent ion, blood samples for serum try ptase shoul d be collected as 
soon as possible after the event, at 60 ± 30 minutes after the event, at discharge, and between 
2 and 4 weeks pos t discharge. Immediate care of the participant and treatment of the reaction 
must take priority  over collecting blood samples.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 112of 134Adapted from Kemp SF, Lockey  RF, Simo ns FE; Worl d Allergy  Organizati on ad hoc 
Committee on Epinephrine in Anaphylaxis. Epinephrin e: the drug of cho ice for anaphylaxis. 
A statement of the World Allergy Organizat ion. Allergy . 2008;63(8):1061 -70.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 113of 134Appendix IContraception Guide
Females are considered to be of childbearing potential unless they meet either of the criteria, 
as fo llows:
Surgically st erilised (including bilateral tubal ligation, bilateral oophorectomy, or 
hysterectomy), or
Post-menopausal.
For females aged < 50years, post -menopausal is defined as having both:
A history  of ≥ 12 months amenorrhea, without an alternat ive cause, fo llowing cessat ion of 
exogenous sex- horm onal treatment and,
A follicle -stimulat ing hormone level in the post -menopausal range.
For females aged ≥ 50 years, post -menopausal is defined as having a history  of ≥ 12 months 
amenorrhea, wi thout an al ternat ive cause, fo llowing cessat ion of exogenous sex -horm onal 
treatm ent.
A highly effect ive method of contraception is defined as one that results in a low failure rate 
(ie, less than 1% per y ear) when used consistent ly and correctly. The acceptable methods of 
contraception are described in Table I9.
Periodic abstinence, the rhythm method, and withdrawal are NOT acceptable methods of 
contraception.
Table I9 Highly Effective Methods of Contraception
Barrier Methods Hormonal Methods
• Intrauterine device
• Intrauterine hormone -releasing system (IUS) a
• Bilateral tubal occlusion
• Vasectomised partner b
• Sexual abstinence cCombined (estrogen and progestogen containing 
hormonal contraception)
 Oral (combined pill)
 Injectable
 Transdermal (patch)
Progestogen -only  hormonal contraception
 Desogestrel
aThis is also considered a hormonal met hod.
bWith appropriate post -vasectomy medical testing of surgical success (ie, absence of sperm in ejaculate).
cSexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of the study  and if it is the preferred and usual lifestyle of the 
participant.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 114of 134Appendix JAbbreviations
Abbreviation or special 
termExplanation
ACM Ambulatory cough monitoring
ACQ Asthma control questionnaire
AD Atopic dermatitis
ADA Anti-drug antibody(ies)
AE Adverse Event
AESI Adverse event of special interest
ALP Alkaline phosphatase
ALT Alanine transaminase
anti-HBc Antibody to hepatitis B core antigen 
anti-HBs Antibody to hepatitis B surface antigen
AO Airwave oscillometry
AST Aspartate transaminase
ATS American thoracic society
AUC Area under the concentration -time curve
BD Bronchodilator
BP Blood pressure
BTR Best test report
BMI Body mass index
CAP College of American Pathologists
CLIA Clinical Laboratory Improvement Amendments
Cmax Observed maximum concentration
CompEx Composite endpoint for severe exacerbations of asthma
COPD Chro nic obstructive pulmonary disease
COVID -19 Coronavirus disease 2019
CRO Contract Research Organisation
CRS Chro nic rhinosinusitis
CSP Clinical Study Protocol
CSR Clinical Study Report
CT Computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CYP450 Cytochrome P450
DBP Diastolic blood pressure
DKD Diabetic kidney disease
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 115of 134Abbreviation or special 
termExplanation
DSMB Data Safety Monitoring Board
ECG Electrocardiogram
eCRF Electronic case report form
E/D Early  study  intervention discontinuation
EDN Eosinophil derived neurotoxin
ERS European Respiratory Society
FDA Food and Drug Administration
FeNO Fractional exhaled nitric oxide
FEV 1 Forced expiratory volume in the first second
FVC Forced vital capacity
GCP Good clinical practice
GINA Global Initiative for Asthma
GGT Gamma -glutamyl transferase
GMP Good manufacturing practice
HbA1c Haemoglobin A1c
HBsAg Hepatitis B surface antigen
HIV Human immunodeficiency virus
HL Hy’s law
HRT Hormone replacement therapy
IATA International Airline Transportation Association
IB Investigator’s Brochure
ICF Informed consent form
ICH International Council for Harmonisation
ICS Inhaled corticosteroids
IEC/IRB Institutio nal Ethics Committee/Institutional Review Board
IFN Interferon
Ig Immunoglobulin
IGRA Interferon gamma release assay
IL Interleukin
ILC2s Type 2 innate ly mphoid cells
IMP Investigation medicinal product
ITT Intent -to-treat
LABA Long -acting beta agonist(s)
LAMA Long -acting muscarinic antagonist(s)
LTBI Latent tuberculosis infection
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 116of 134Abbreviation or special 
termExplanation
LTRA Leukotriene receptor antagonist(s)
LVEF Left ventricular ejection fraction
mAb Monoclonal antibody(ies)
mRNA Messenger RNA
NCI Natio nal Cancer Institute
NIMP Non-investigation medicinal product
NOAEL No observed adverse events level
NT-proBNP N-terminal prohormone of B -type natriuretic peptide
OCS Oral corticosteroid(s)
PC 20 Provocative concentration causing a 20% decline in FEV
PCR Polymerase chain reaction
PD Pharmacodynamic(s)
PEF Peak expiratory flow
PHL Potential Hy’s law
PI Principal Investigator 
PNV Predicted normal value(s)
PK Pharmacokinetic(s)
PRO Patient reported outcome
RTSM Randomisation and trial supply management
SABA Short -acting bronchodilator
SAE Serious Adverse Event 
SAP Statistical Analysis Plan
SARS -CoV -2 Severe acute respiratory syndrome coronavirus 2
SBP Systolic blood pressure
SC Subcutaneous
SD Standard deviation
SGRQ St George’s respiratory questionnaire 
SID Subject identification
SNOT -22 Sino-nasal outcome test
SNP Single nucleotide polymorphism
SOA Schedule of activities
SOC Standard of care
sST2 Soluble ST2
SV Study visit
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 117of 134Abbreviation or special 
termExplanation
TB Tuberculosis
TBL Total bilirubin
Th T-helper
TNF α Tumo r necrosis factor alpha
TSLP Thymic stromal ly mphopoietin
ULN Upper limit of normal
VAS Visual analogue scale
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 118of 134Appendix KProtocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.
Amendment 3.0 (25 May 2021)
Overall Rationale for the Amendment:
Changes from Global Protocol Amendment 2.0
The principal reason for this amendment is to amend the study  design to separate the m ain 
study  (Part A) from the airway hyperresponsiveness and remodelling study, Part B, which was 
previously a sub -study .
Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
Section 1.1 Synopsis, 
Section 3 Objectives and 
EndpointsTable o f objectives and endpoints 
divided into 3 separate tables to 
present those objectives specific 
to Part A, Part B, and both Part A 
and Part B, respectively.To add clarity to the 
presentation of study 
objectives and 
endpoints in the 
protocol.Non-substantia l
Section 1.1 Synopsis, 
Section 3 Objectives and 
EndpointsFor Part B endpoints: added new 
timepoint (Week 12 compared 
with baseline) for FEV 1% 
reversibility and post BD FEV 1
(L); specified timepoints of 
Week 16 compared with baseline 
for proportion of participants who 
achieve at least one doubling 
concentration improvement in 
methacholine PC 20and Week 12 
compared with baseline for 50% 
reductio n in post BD FEV 1
reversibility.To amend study 
endpoints as 
appropriate for the 
change to a 2-part study 
design.Non-substantial
Section 1.1 Synopsis, 
Section 4.1 Overall 
DesignAdded details of the design of 
Part B: approximately 
44evaluable participants to be 
randomised in a 1:1 rat io to 
receive  mg MEDI3506 or 
placebo  by SC injection for 
a total of doses. To amend the study 
design to divide it into 
2parts: Part A (main 
study) and Part B 
(airway 
hyperresponsiveness 
and remodelling study).Substantial
Section 1.1 Synopsis,
Section 9.1 Statistical 
Hypotheses, Section 9.2 
Sample Size 
Determination, Added details for Part B of 
sample size calculation and 
analy sis of primary  and secondary  
endpoints.To specify the 
statistical methods for 
Part B.Non-substantial
CC
CCI
C
C
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 119of 134Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
Section 9.4 Statistical 
Analy ses
Section 1.3 Schedule of 
Activities, Section 4.1 
Overall Design, 
Section 8.1.7 VitaloJAK 
Cough Mo nitor, 
Section 8.1.8.2 Cough 
Visual Analogue Scale, 
Section 8.1.9 
Methacholine Challenge 
Testing, Section 8.1.10 
Inspiratory/Expiratory 
Comput ed TomographyClarification added that the 
exploratory cough sub -study 
applies to Part A only, that Part B 
comprises the exploratory airway 
hyperresponsiveness and 
remodelling study, and that SV3 
only applies to Part B.To take into account the 
change to a 2-part study 
design.Non-substantial
Section 1.3 Schedule of 
Activities, Section 4.1 
Overall DesignSpecified that for Part A and 
Part B at SV1, post -BD 
spirometry  is to be performed if 
documented evidence of asthma 
is not already available. In Part A 
atSV2 it should be performed if 
documented evidence of asthma 
is not already available and in 
Part B at SV2 it is to be 
performed regardless of 
availability  of documented 
evidence.To take into account the 
change to a 2-part study 
design.Non-substantial
Section 1.3 Schedule of 
ActivitiesClarified that on days when 
investigational product is 
administered, all assessments 
should be performed pre -dose 
unless otherwise specified.For clarity. Non-substantial
Section 1.3 Schedule of 
ActivitiesFor Part B, spe cified that 
echocardiogram may be 
performed any time after signing 
informed consent.To ensure that results 
are available prior to 
methacholine challenge 
testing and CT scan.Non-substantial
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 120of 134Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
Section 1.3 Schedule of 
Activities, Section 5.1 
Inclusion Criteria, 
Section 6.2.2.1 Treatment 
AdministrationUpdated wording regarding 
pregnancy testing in female 
participants.To ensure clarity on 
pregnancy testing.Non-substantial
Section 1.3 Schedule of 
ActivitiesClarified provision for airwave 
oscillometry and in -clinic 
spirometry  to be performed 
4hours post -administration of 
study intervention at SV4 
(Randomisation).To add clarity for 
timing of pre -and post -
dose airwave 
oscillometry and 
in-clinic spirometry 
assessments.Non-substantial
Section 1.3 Sched ule of 
ActivitiesIn Part B, methacholine challenge 
testing and inspiratory/expiratory 
CT moved from SV9 to SV10. 
Added provision that in -clinic 
spirometry  post -BD for Part B is 
at SV9, and for Part A is at SV10.The creation of a 
separate study Part B 
(rather than a 
sub-study ) removed 
logistical constraints, 
meaning that 
methacholine challenge 
testing and 
inspiratory/expiratory 
CT can now occur at 
SV10.Non-substantial
Section 1.3 Schedule of 
ActivitiesSpecified that the mean value of 
each parameter from the triplicate 
ECG will be used as the baseline 
value.For clarity. Non-substantial
Section 1.3 Schedule of 
Activities, Section 2.3.1 
Risk AssessmentClarified that methacholine 
challenge testing and CT scans 
will only be performed in Part B. To specify potential 
risks of clinical 
significance that are 
applicable to Part B 
only.Non-substantial
Section 2.3.1.1 Study 
Conduct During 
COVID -19 PandemicSpecified that respiratory testing 
at locations other than the primary 
study site may be required in 
Part B of the study; consequently, 
participants in Part B could be at 
increased risk for exposure to 
individuals with COVID -19.To specify the impact 
of the COVID -19 
pandemic on Part B. 
AstraZeneca recognises 
that conduct of Part B is 
very challenging during 
the acute pandemic 
phase; therefore, it will 
be activated only when 
safe and feasible.Non-substantial
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 121of 134Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
Section 4.2.1 Rationale 
for EndpointsAdded rationale for the Part B 
primary  endpoint (change in 
methacholine PC 20). Clarified that 
objective cough monito ring will 
only be performed in the Part A 
exploratory cough sub -study.To add rationale for the 
Part B primary endpoint 
and clarify those 
exploratory endpoints 
that apply  only  to 
Part A. Non-substantial
Section 4.3 Justification 
for DoseClarified that the MEDI3506 dose 
of mg SC  will be used 
in Part A and Part B but the lower 
dose of mg  SC will 
only be used in Part A.To specify which part 
of the study each dose 
of MEDI3506 will be 
used.Non-substantial
Section 5 Study 
PopulationSection restructured to present 
inclusion and exclusion criteria in 
the following order: those 
applicable to both Part A and 
Part B, those applicable to Part A 
only, and those applicable to 
Part B only. As a consequence, 
some renumbering of inclusion 
criteria has occurred.To provide clarification 
and aid sites to apply 
study inclusion and 
exclusion criteria 
appropriately for Part A 
and Part B.Non-substantial
Section 5.2 Exclusion 
CriteriaClarification of a positive IGRA 
test in the context of treated latent 
TBinfectionTo avoid exclusion of 
participants who have 
been treated for latent 
TB infection but still 
have a positive IGRA 
testNon-substantial
Section 5.1.1, Criteria to 
be Assessed at SV1, 
Section 5.1.2, Criteria to 
be Assessed at SV2 and 
SV4 (Randomisation), 
Section 5.1.3 Criteria to 
be Assessed for 
Explo ratory  Airway  
Hyperresponsiveness and 
Rem odelling Sub study, 
Section 5.2.1 Criteria to 
be Assessed at SV1 and 
SV2, Section 5.2.2 
Criteria to be Assessed at 
SV1, SV2 and SV4 
(Randomisation)Section headings revised to 
reflect change in structure from 
specifying criteria at specific SVs 
to specifying criteria applicable to 
both Part A and Part B, Part A 
only, and Part B only.As a consequence of 
restructuring the study 
populatio n section.Non-substantial
CC
I
CCI
CCI
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 122of 134Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
Section 5.1.4 Criteria to 
be Assessed for 
Explo ratory  Cough 
Sub-study , Section 5.2.3 
Criteria to be Assessed 
for Explo ratory  Airway  
Hyperresponsiveness and 
Rem odelling Sub study at 
SV2 and SV3Sections removed and criteria 
moved to relevant restr uctured 
sections.As a consequence of 
restructuring the study 
populatio n section.Non-substantial
Section 5.1 Inclusion 
CriteriaInclusion criterion regarding 
documented history of ≥1asthma 
exacerbation in 12 months prior 
to SV1 to be applicable to Part A 
only.To avoid negatively 
affecting recruitment, 
as asthma in 
participants who meet 
this criterion may be 
too severe for 
methacholine challenge 
testing in Part B.Non-substantial
Section 5.1 Inclusion 
CriteriaFor Part B: clarified that inclusion 
criterion regarding morning 
pre-BD FEV 1is ≥ 60% predicted 
normal and > 1.5L at SV1 and 
SV2. Clarified that methacholine 
PC 20≤ 8 mg/mL at SV2 serves as 
documented evidence of asthma.As a consequence of the 
change to a 2-part study 
design and restructuri ng 
of the study population 
section.Non-substantial
Section 5.2 Exclusion 
CriteriaExclusion Criterion 23(i) updated 
to specify that systemic 
corticosteroids within 4 weeks of 
SV1 is allowed if use is as stable 
maintenance therapy for asthma.To correct a n erro r in 
protocol whereby stable 
maintenance therapy 
was permitted by 
Inclusion Criterion 5 
(now Inclusion 
Criterio n4) but 
prohibited by the 
original wording of 
Exclusion Criterion 23Non-substantial
Section 6.2.2.2 
Monitoring Dose 
AdministrationState d that assessment of 
injection site reactions after 
administration of study 
interventio n will be carried out by 
the blinded study team.To clarify that the 
personnel who perform 
the assessment will be 
blinded to study 
treatment.Non-substantial
Section 6.3.1 Methods for 
Assigning Treatment 
GroupsAdded details of stratification 
according to study part and 
sub-study  participation.To take into account the 
change to a 2-part study 
design.Non-substantial
Clinical Study Proto col–Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 123of 134Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
Section 6.3.3 Methods for 
Unblinding, Section 9.4 
Statistical Analyses, 
Section 9.5 Interim 
Analy sesSpecified, separately for Part A 
and Part B, timing of the primary 
analy sis, sponsor staff unblinding, 
and unblinding of all personnel 
involved with the study analysis.To take into account the 
change to a 2-part study 
design.Non-substantial
Section 6.5.3 Medication 
Withhold PeriodsUpdated list of medication 
withhold periods to be applied 
prior to scheduled spirometry, 
AO, and FeNO measurement and 
added list of medication withhold 
periods to be applied p rior to 
methacholine challenge testing.For clarity and to align 
medication withhold 
periods prior to 
methacholine challenge 
testing with ERS 2017 
MCT guidelines.Non-substantial
Section 6.5.5 COVID -19 
Vaccinatio nUpdated the list of information to 
be recorded (if available) if and 
when a participant receives a 
COVID -19 vaccination.To ensure collection of 
all data that may be 
needed to assess 
potential interaction 
between COVID -19 
vaccine and 
MEDI3506.Non-substantial
Section 8.3.10.1 Maternal 
Exposur e, 
Section 8.3.10.2 Paternal 
Exposure, Appendix B2 
Definitio n of Serious 
Adverse EventsChanged “congenital 
abnormality” to “congenital 
anomaly ”.To align with the latest 
AstraZeneca Clinical 
Study Protocol 
template, in which this 
change was made to 
align with regulatory 
requirements.Non-substantial
Section 8.5.2 
PharmacokineticsSpecified that samples from 
participants who receive placebo 
may be analy sed to confirm no 
dosing with MEDI3506.For clarification. Non-substantial
Section 8.5.3 
Immunogenicity
AssessmentsSpecified that ADA samples may 
be tested for neutralising 
antibody.For clarification. Non-substantial
Section 9.4.5.2 
Explo ratory  Biomarker 
OutcomesSpecified that change from 
baseline in EDN and total IgE 
will be analysed for Part A only.Measurement in Part A 
only is considered 
sufficient.Non-substantial
Section 9.6 Data 
Monitoring CommitteeReference to 
Study D9180C00001 changed to 
Study D9180C00002.To correct an error Non-substantial
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 124of 134Section # and Name Description of Change Brief RationaleSubstantial/
Non-substantial
ThroughoutMinor editorial and document 
formatting revisions.Minor, therefore have 
not been summarised.Non-substantial
ADA =anti-drug antibody(ies); AO =airwave oscillometry; BD =bronchodilator; COVID -19 = coronavirus 
disease 2019; CT =computed tomography; ECG =electrocardiogram; EDN =eosinophil d erived neurotoxin; 
ERS =European Respiratory Society; FeNO =fractio nal exhaled nitric oxide; FEV 1=forced expiratory volume 
in the first second; Ig =immunoglobulin; IGRA =interferon gamma release assay; L =litre(s); 
MCT =methacholine challenge testi ng; PC 20=provocative concentration causing a 20% decline in FEV; 
 SC=subcutaneous; SV=study visit; TB =tuberculosis.
Amendment 2.0 (23 February 2021)
Overall Rationale for the Amendment:
Changes fro m Global Protocol  Amendment 1. 0
The principal reason for this amendment is to respond to the recent regulatory 
authori sations/approvals of vaccines against COVID -19 and ensure the protocol is clear with 
respect to them.
Section # and Name Description of Change Brief Rationale Substantial/Non -substantial
Section 1.3 Schedule 
of Activities, 
Section 8.1.1 In -clinic 
SpirometryAdded that the timing of 
in-clinic spirometry at 
randomisation visit (SV4) 
should be initiated between 
6:00 AM and 11:00 AM.To correct a text 
omission in p revious 
version of protocol; 
no change to actual 
conduct of the 
spirometry  assessmentNon-substantial
Section 1.3 Schedule 
of Activities, Section 
5 Study  Populatio n, 
Section 8.2.7 Clinical 
Safety Laboratory 
AssessmentsAdded provision that 
during the scre ening 
period, in the event that 
clinical laboratory test 
results are not available 
from central laboratories, 
local laboratories can be 
used following 
consultation with medical 
monitor.To increase flexibility 
for clinical laboratory 
testing due to 
practical limitations in 
receiving test results.Non-substantial
Section 1.3 Schedule 
of Activities, 
Section 2.3.1.2 
COVID -19 
Mitigations, 
Section 5.2.1 Criteria 
to be Assessed at SV1 
and SV2Added provision that 
participants are permitted 
to continue scr eening if the 
result from the 
SARS -CoV -2 PCR test 
performed at SV1 has not 
been returned by SV2 or 
SV3, and that the test may 
be performed at either SV2 
or SV3 o r any time on or To increase flex ibility  
for COVID -19 PCR 
testing due to 
practical limitations in 
receiving test results.Non-substantial
CCI
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 125of 134Section # and Name Description of Change Brief Rationale Substantial/Non -substantial
after Day -7 such that the 
results are available prior 
to SV4.
Section 1.3 Schedule 
of Activities, 
Section 5.1.1 Criteria 
to be Assessed at SV1, 
Section 5.1.2 Criteria 
to be Assessed at SV2 
and SV4 
(Randomisation)Clarification that all 
female participants should 
have a pregnancy test. To ensure clarity on 
testing all females for 
pregnancy.Non-substantial
Section 1.3 Schedule 
of Activities, 
Section 5.2.1 Criteria 
to be Assessed at SV1 
and SV2, 
Section 8.2.7 Clin ical 
Safety Laboratory 
AssessmentsAdded provision for 
retesting of IGRA.To permit retesting of 
participants with a 
positive IGRA test 
result, following 
investigator feedback. 
A negative IGRA test 
result is still required 
for eligibility.Non-substantial
Section 2.3.1.3 
Vaccinatio n Against 
COVID -19New section added to 
inform investigators of the 
sponsor’s approach to 
COVID -19 vaccination in 
Study D9181C00001.Provide clarification 
to investigators and to 
help ensure 
interpretability of 
safety data.Non-substantial
Section 5.2.1 Criteria 
to be Assessed at SV1 
and SV2Added provision for 
retesting of NT -proBNP.To permit retesting of 
participants with a 
NT-proBNP result 
greater than the upper 
limit of the laboratory 
reference range if this 
is clinical ly 
unexpected. An 
acceptable NT -
proBNP result is still 
required.Non-substantial
Section 5.1.2 Criteria 
to be Assessed at SV2 
and SV4 
(Randomisation)Adjustment to the periods 
to which the adherence 
criteria apply.To remove a 
discrepancy between 
the crit eria and the 
periods used to 
calculate certain 
relevant baseline 
values.Non-substantial
Section 6.3.2 Methods 
to Ensure BlindingAdded allowance that 
limited personnel that have 
responsibility for analysing To facilitate in -stream 
analy sis of PK and 
ADA samples. Non-substantial
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 126of 134Section # and Name Description of Change Brief Rationale Substantial/Non -substantial
PK and ADA samples can 
have access to the 
rando misatio n schedule. 
Section 5.2.2 Criteria 
to be Assessed at SV1, 
SV2 and SV4 
(Randomisation), 
Section 6.5.4 
Prohibited 
MedicationsClarification that 
adenoviral vector vaccines 
are not considered live 
attenuated.
Addition of certain 
restrictions on when 
vaccines against 
COVID -19 may  be 
administered.Provide clarification 
to investigators and to 
help ensure 
interpretability of 
safety data.Non-substantial
Section 6.5.5 
COVID -19 
Vaccinatio n, 
Section 8.2.1 Medical, 
Surgical, and Asthma 
Histor yNew text added on 
recording COVID -19 
vaccinationTo clarify the need for 
recording of receipt of 
COVID -19 
vaccination.Non-substantial
COVID -19 = coronavirus disease 2019; IGRA =interferon gamma release assay; NT -proBNP =N terminal 
prohormone of B type natriuretic peptide; PCR =polymerase chain reaction; SV =study visit.
Amendment 1.0 (19 October 2020)
Overall Rationale for the Amendment:
Changes fro m Original  Global Protocol
The principal  reasons for this amendment are to provide a harmonised global protocol by  
incorporating the changes fro m local amendments USA -1.0 and GER -1.0, to rem ove the 
interim analysis based on FeNO data, and clarify and correct some wording issues. 
The FDA reque sted changes to the protocol to reflect that all AEs that occur during the study  
shoul d, in relati on to study  stopping criteria, be treated as related to study  drug, unl ess clearly  
unrelated. The FDA requested addit ional inform ation on study stopping crite ria and a 
standardised toxicit y grading scale to be incorporated in the individual and study  stopping 
criteria.
The Paul -Ehrlich -Institut requested a change to the protocol to clearly  state that the use of 
prohibited medicat ions will lead to discont inuat ion and to add this po int to the list of the 
discontinuat ion criteria.
Section # and Name Description of Change Brief Rationale Substantial/Non -substantial
Section 1.1 Synopsis, 
Section 6.3.3.1 
Unblinding for interim Rem oval of references to 
the interim analysis for 
the study .Changes in pipeline 
and clinical 
development timing Non-substantial
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 127of 134Section # and Name Description of Change Brief Rationale Substantial/Non -substantial
analy sis, Section 9.4 
Statistical Analyses, 
Section 9.5 Interim 
Analy sesmade interim 
analy sis 
unnecessary.
Section 3 Objectives and 
EndpointsRem oval of airway
volume and airway 
resistance CT scan 
measures from airway 
remodelling endpoint.Airway  volume and 
airway resistance 
are not provided by 
the vendor 
providing the CT 
scan data.Non-substantial
Section 4.4.1 Study 
Stopping CriteriaNew section added.The FD A requested 
the addition of 
study stopping 
criteria.Non-substantial
Section 6.2 
Preparation/Handling/
Storage/Accountability of 
InterventionsAddition of list item #1 to 
the section.To confirm that 
dispensation and 
dosing should 
happen o n the same 
day of study  
interventio n 
allocatio n in the 
RTSM system.Non-substantial
Section 6.2.2 Dose 
Preparation StepsAddition of ‘respectively’ 
to step 2 of the dose 
preparation steps.Clarification to 
instructio ns as use 
of word ‘separate’ 
in the instructions is 
to prevent 
MEDI3506 and 
placebo being 
mixed in one 
syringe, not to 
prevent 2 vials of 
MEDI3506 being 
mixed in one 
syringe.Non-substantial
Section 7.1 
Discontinuation of Study 
InterventionReference to relatedness 
of SAEs as a reason to 
discontinue participants 
from the study removed 
and ‘any  SAE of 
≥Grade4 severity’ 
added.To address the 
comment from the 
FDA regarding 
concerns on the 
attribution of 
causality of AEs to 
a study drug.Non-substantial
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 128of 134Section # and Name Description of Change Brief Rationale Substantial/Non -substantial
Section 7.1 
Discontinuation of Study 
InterventionNew discontinuation 
criterion added.The PEI required 
the addition of this 
discontinuation 
criterion.Non-substantial
Appendix B2 Definition 
of Serious Adverse 
EventsSeverity rating scale 
updated from 
‘mild/moderate/severe’ to 
a Grade 1 to5 scale based 
on CTCAE criteria.In order to align 
with the 
standardised 
toxicity grading 
used to assess 
individual study 
interventio n 
discontinuation 
criteria.Non-substantial
ThroughoutMinor editorial and 
document formatting 
revisionsMinor, therefore 
have not been 
summarisedNon-substantial
AE=adverse event; CT =computerised tomography; CTCAE =Common Terminology Criteria for Adverse 
Events; FDA =Food and Drug Administration; PEI =Paul-Ehrlich -Institut; RTSM =randomisation and trial 
supply management; SAE =serious adverse event.
Changes from local protocol amendment USA- 1.0 (04 August 2020)
Section # and NameDescription of 
ChangeBrief Rationale Substantial/Non -substantial
Section 1.1 Synopsis, 
Section 6.3.3.1 Unblinding 
for interim analysis, Section 
9.4 Statistical Analyses, 
Section 9.5 Interim 
Analy sesRem oval of 
references to the 
interim analysis for 
the study .Changes in pipeline and 
clinical development 
timing made interim 
analy sis unnecessary.Non-substantial
Section 3 Objectives and 
EndpointsRem oval of airway 
volume and airway 
resistance CT scan 
measures from 
airway remodelling 
endpoint.Airway  volume and 
airway resistance are 
not provided by the 
vendor providing the 
CT scan data.Non-substantial
Section 6.2 
Preparation/Handling/
Stora ge/Accountability of 
InterventionsAddition of list 
item #1 to the 
section.To confirm that 
dispensation and dosing 
should happen on the 
same day of study 
interventio n allocation 
in the RTSM system.Non-substantial
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 129of 134Section # and NameDescription of 
ChangeBrief Rationale Substantial/Non -substantial
Section 6.2.2 Dose 
Preparation StepsAddition of 
‘respectively’ to 
step 2 of the dose 
preparation steps.Clarification to 
instructio ns as use of 
word ‘separate’ in the 
instructio ns is to prevent 
MEDI3506 and placebo 
being mixed in one 
syringe, not to prevent 2 
vials of MEDI3506 
being mixed in on e 
syringe.Non-substantial
Section 7.1 Discontinuation 
of Study InterventionNew 
discontinuation 
criterion added.The PEI required the 
addition of this 
discontinuation 
criterion.Non-substantial
ThroughoutMinor editorial and 
document 
formatting 
revisionsMinor, therefore have 
not been summarisedNon-substantial
AE=adverse event; CT =computerised tomography; CTCAE =Common Terminology Criteria for Adverse 
Events; FDA =Food and Drug Administration; PEI =Paul-Ehrlich -Institut; RTSM =randomisa tion and trial 
supply management.
Changes from local protocol amendment GER- 1.0 (01 October 2020)
Section # and Name Description of Change Brief Rationale Substantial/Non -substantial
Section 1.1 Synopsis, 
Section 6.3.3.1 
Unblinding for interim 
analy sis, Section 9.4 
Statistical Analyses, 
Section 9.5 Interim 
Analy sesRem oval of references to 
the interim analysis for 
the study .Changes in pipeline 
and clinical 
development timing 
made interim 
analy sis 
unnecessary.Non-substantial
Section 3 Objectives and 
EndpointsRem oval of airway 
volume and airway 
resistance CT scan 
measures from airway 
remodelling endpoint.Airway  volume and 
airway resistance 
are not provided by 
the vendor 
providing the CT 
scan data.Non-substantial
Section 4.4.1 Study 
Stopping CriteriaNew section added.The FDA requested 
the addition of 
study stopping 
criteria.Non-substantial
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 130of 134Section # and Name Description of Change Brief Rationale Substantial/Non -substantial
Section 6.2 
Preparation/Handling/
Storage/Accountability of 
InterventionsAddition of list item #1 to 
the section.To confirm that 
dispensation and 
dosing should
happen o n the same 
day of study  
interventio n 
allocatio n in the 
RTSM system.Non-substantial
Section 6.2.2 Dose 
Preparation StepsAddition of ‘respectively’ 
to step 2 of the dose 
preparation steps.Clarification to 
instructio ns as use 
of word ‘separate’ 
in the instructions is 
to prevent 
MEDI3506 and 
placebo being 
mixed in one 
syringe, not to 
prevent 2 vials of 
MEDI3506 being 
mixed in one 
syringe.Non-substantial
Section 7.1 
Discontinuation of Study 
InterventionReference to relatedness 
of SAEs as a reason to 
discontinue participants 
from the study removed 
and ‘any  SAE of 
≥Grade4 severity’ 
added.To address the 
comment from the 
FDA regarding 
concerns on the 
attribution of 
causality of AEs to 
a study drug.Non-substantial
Appendix B2 Definition 
of Seriou s Adverse 
EventsSeverity rating scale 
updated from 
‘mild/moderate/severe’ to 
a Grade 1 to5 scale based 
on CTCAE criteria.In order to align 
with the 
standardised 
toxicity grading 
used to assess 
individual study 
interventio n 
discontinuation 
criteria.Non-substantial
ThroughoutMinor editorial and 
document formatting 
revisionsMinor, therefore 
have not been 
summarisedNon-substantial
AE=adverse event; CT =computerised tomography; CTCAE =Common Terminology Criteria for Adverse 
Events; FDA =Food and Dr ug Administration; RTSM =randomisation and trial supply management; 
SAE =serious adverse event.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 131of 13411 REFERENCES
Allakhverdi etal 2007
Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S et al. Thymic 
strom al lymphopoi etin is released by human epit helial cells in response to microbes, trauma, 
or inflammation and potently  activates mast cells. J Exp Med. 2007;204(2):253 -8.
Alving etal 2017
Alving K AR, Crater G, LaForce C F, Rickard K. Validat ion of a new portable exhaled nitric 
oxide anal yzer, NIOX VERO: randomized studies in asthma. Pulm Ther. 2017;3(1):207 -18.
Bonnelykke etal 2014
Bonnelykke K, Sleiman P, Nielsen K, Kreiner -Moller E, Mercader JM, Belgrave D et al. A 
geno me-wide associ ation study  identifies CDHR3 as a suscept ibilit y locus for early  childhood 
asthma with severe exacerbat ions. Nat Genet. 2014;46(1):51 -5.
Cayrol and Girard 2018
Cayrol C, Gi rard JP. Interleukin -33 (IL -33): A nuclear cy tokine f rom the IL -1 family. 
Immunol Rev. 2018;281(1):154-68.
Fuhlbrigge etal 2017
Fuhlbrig ge AL, Bengtsson T, Peterson S, Jauhiainen A, Eriksson G, Da Silva CA et al. A 
novel endpo int for exacerbat ions in asthma to accelerate clinical development: a post -hoc 
analysis of randomised controlled trials. The Lancet Respiratory  medicine. 2017;5(7):577-90.
GINA 2020
GINA. Gl obal Strategy  for Asthma Management and Prevent ion https://ginasthma.org/wp -
content/uploads/2020/04/GINA -2020 -full-report_ -final-_wms.pdf [3 April2020].  Accessed 
on: 14 May  2020.
Gorbacheva etal 2018
Gorbacheva AM, Korneev KV, Kuprash DV, Mitkin NA. The Risk G Allele of the Single -
Nucl eotide Polymorphism rs928413 Creates a CREB1 -Binding Site That Activates IL33 
Prom oter i n Lung Epi thelial Cells. Int J Mol Sci. 2018;19(10).
Gudbjartsson etal 2009
Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM et al. 
Sequence variants affecting eosinophil numbers associate with asthma and myo cardi al 
infarction. Nat Genet. 2009;41(3):342 -7.
Hirota etal 2011
Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Doi S et al. Geno me-wide associ ation 
study  identifies three new suscept ibility loci for adul t asthm a in the Japanese population. Nat 
Genet. 2011; 43(9):893 -6.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 132of 134Hodzic etal 2017
Hodzi c Z, Schill EM, Bol ock AM, Good M. IL -33 and the intestine: The good, the bad, and 
the inflammatory . Cytokine. 2017;1001 -10.
Hopkins etal 2009
Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psy chometric validit y of the 22-item 
Sinonasal Outcome Test. Clin Otolaryngo l. 2009;34(5):447 -54.
Huang etal 2010
Huang SM, Zhao H, Lee JI, Reyno lds K, Zhang L, Temple R et al. Therapeut ic protein -drug 
interact ions and implicat ions for drug development. Clin Pharmacol Ther. 2010; 87(4):497 -
503.
Jones etal 1991 
Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory  Quest ionnaire. Respir 
Med. 1991;85 Suppl B25 -31; discussio n 3-7.
Jones and Forde 2009
Jones PW, Forde Y. St George's Respiratory  Questi onnaire Manual .  2009;Ver sion 2.3.
Juniper etal 1999
Juniper EF, O'By rne PM, Guy att GH, Ferri e PJ, King DR. Development and validation of a 
questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902 -7.
Juniper etal 2006
Juniper EF, Bousquet J, Abetz L, Bateman ED, Committee G. Identifying 'well -controlled' 
and 'not well -controlled' asthma using the Asthma Control Quest ionnaire. Respir Med. 
2006;100(4):616 -21.
Kearley etal 2015
Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N et al. Cigarette smoke silences
innate lympho id cell funct ion and facilitates an exacerbated ty pe I interl eukin-33- dependent 
response to infection. Immunit y. 2015;42(3):566 -79.
Martin andMartin 2016
Martin NT, Martin MU. Interleukin 33 is a guardian of barriers and a local alarmin. Nat
Immunol. 2016;17(2):122 -31.
Miller etal 2005
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Standardisat ion 
of spirometry. Eur Respi r J. 2005;26(2):319 -38.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 133of 134Moffat etal 2010
Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S et al. A large -scale, 
consorti um-based geno mewide associat ion study  of asthma. N Engl J Med. 
2010;363(13):1211 -21.
Mousas etal 2017
Mousas A, Ntritsos G, Chen MH, Song C, Huffman JE, Tzoulaki I et al. Rare coding variants 
pinpo int genes that c ontrol  human hematol ogical traits. PLoS Genet. 2017;13(8):e1006925.
NCI 2017
NCI. Commo n Termino logy Criteria for Adverse Events (CTCAE) v5.0. 
https://ctep.cancer.gov/protocolDevelopment/electronic_applicat ions/docs/CTCAE_v5_Quick
_Reference_5x7.pdf. Publis hed 2017. Accessed 17Jul2020.
NIH 2019
NIH. Gui delines for the prevent ion and treatment of opportunist ic infect ions in adults and 
adolescents wi th HIV. https://aidsinfo.nih.gov/content files/lvguidelines/adult_o i.pdf. 
Published 2019. Accessed 14 May 2020.
Piccirillo etal 2002
Piccirillo JF, Merritt MG, Jr., Richards ML. Psychometric and clinimetric validit y of the 20 -
Item Sino -Nasal Outcome Test (SNOT -20). Otolaryngo l Head Neck Surg. 2002;126(1):41 -7.
Sampson etal 2006
Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A et al. 
Second symposium on the definit ion and m anagement of anaphylaxis: summary  report --
Second National Inst itute of Allergy  and Infect ious Di sease/Food Allergy  and Anaphylaxis 
Network symposium. J Allergy  Clin Imm unol. 2006;117(2):391-7.
Scott etal 2018
Scott IC, Rees DG, Cohen ES. New perspectives on IL -33 and IL -1 family cy tokines as innate 
environmental sensors. Biochem Soc Trans. 2018;46(5):1345- 53.
Shrine etal 2019
Shrine N, Portelli MA, John C, Soler Artiga s M, Bennett N, Hall R et al. Moderate -to-severe 
asthma in individuals o f European ancestry : a genome -wide associat ion study . The Lancet 
Respiratory  medicine. 2019;7(1):20-34.
Smith etal 2017
Smith D, Hel gason H, Sul em P, Bj ornsdotti r US, Lim AC, Sveinbjo rnsson G et al . A rare 
IL33 l oss-of-function mutation reduces blood eosinophil counts and protects from asthma. 
PLoS Genet. 2017;13(3):e1006659.
Clinical Study Protocol –Amendment 4.0 AstraZeneca
MEDI3506 -D9181C00001
CONFIDENTIAL AND PROPRIETARY 134of 134Smith etal 2006
Smith J, Owen E, Jones A, Dodd M, Webb A, Woodcock A. Object ive measurement of cough 
during pu lmonary exacerbati ons in adul ts wi th cysti c fibrosi s. Thorax. 2006;61(5):425-9.
Sorkness etal 2008
Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF et al. Lung 
funct ion in adults with stable but severe asthma: air trapping and inco mpletereversal o f 
obstructi on wi th bronchodilati on. J Appl Physio l (1985). 2008;104(2):394 -403.
Torgerson etal 2011
Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE et al. 
Meta -analysis o f geno me-wide associ ation studies of asthma in et hnically diverse North 
American populations. Nat Genet. 2011;43(9):887 -92.
Vandenberk etal 2016
Vandenberk B, Vandael E, Robyns T, Vandenberghe J, Garweg C, Foulon V et al. Which QT 
Correcti on Form ulae to Use for QT Monitoring? Journal of the American Hea rt Associ ation. 
2016;5(6).
Wan etal 2012
Wan YI, Shrine NR, Soler Art igas M, Wain LV, Blakey JD, Moffatt MF et al. Geno me-wide 
associ ation study  to identify genet ic determinants of severe asthma. Thorax. 
2012;67(9):762 -8.
Weng etal 2018
Weng CM, Wang CH, Lee MJ, He JR, Huang HY, Chao MW et al. Aryl hydrocarbon receptor 
activat ion by diesel exhaust particles mediates epithelium -derived cy tokines expressi on in 
severe allergic asthma. Allergy. 2018;73(11):2192-204.
SIGNATURE PAGE
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
Document Name: d9181c00001-csp-amendment-4
Document Title: D9181C00001 Clinical Study Protocol Amendment 4
Document ID: Doc ID-003946841
Version Label: 5.0 CURRENT LATEST APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by Meaning of Signature
10-Mar-2022 15:12 UTC Fred Reid Author Approval
10-Mar-2022 12:11 UTC Helen Lundblad Content Approval
10-Mar-2022 14:27 UTC Hitesh Pandya Author Approval
10-Mar-2022 15:34 UTC Swathi Ramesh Content Approval
10-Mar-2022 12:08 UTC Wenjing Xin Content Approval
Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.